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ABSTRACT
OBJECTIVES: The objectives of this thesis were to review the use of outcome
measures systematically across amyotrophic lateral sclerosis (ALS) clinical trials, and
evaluate the utility of decomposition-enhanced spike-triggered averaging (DE-STA)
motor unit number estimation (MUNE) as an outcome measure, with a particular focus
on its application to the upper trapezius (UT).
METHODS: First, a systematic review quantified the frequency of use of outcome
measures in ALS randomized controlled trials (Chapter 2). Next, the intra- and interrater reliability of DE-STA MUNE was evaluated in the UT of control subjects (Chapter
3), followed by the intra-rater reliability of the technique in the UT and biceps brachii of
subjects with ALS (Chapter 4). To assess validity, the results of the technique in the UT
were compared between subjects with ALS and control subjects (Chapter 4). The
sensitivity to change of DE-STA MUNE in the UT was compared with that of various
clinical outcome measures in a longitudinal study of subjects with ALS (Chapter 5).
Finally, the influence of needle electrode depth on the results of the technique in the UT
was evaluated in control subjects (Chapter 6).
RESULTS: The heterogeneity in the use of outcome measures across ALS randomized
controlled trials was demonstrated, in addition to the infrequent use of MUNE. MUNE
results demonstrated moderate intra- and inter-rater reliability for control subjects in the
UT, although less favorable results were found overall for inter-rater reliability.
Application of DE-STA MUNE to the UT in subjects with ALS demonstrated
consistently high intra-rater reliability, the ability to detect the underlying
pathophysiology of the disease, and a moderate degree of sensitivity to change for
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MUNE results. Further evaluation found needle electrode depth to significantly influence
the results of the technique, with suggestions made for improved standardization of the
protocol.
SIGNIFICANCE: These studies were novel in their evaluation of MUNE in the
proximal, potentially clinically relevant UT. The studies mark the first evaluations of the
reliability and sensitivity to change of DE-STA MUNE in subjects with ALS, finding
application to the UT to be practical and promising for use as an outcome measure.
Implementation of proposed improvements to the protocol may aid in further establishing
DE-STA MUNE for use as an outcome measure in studies of ALS.

KEYWORDS: amyotrophic lateral sclerosis (ALS), decomposition-enhanced spiketriggered averaging (DE-STA), electromyography (EMG), motor unit number estimation
(MUNE), outcome measure, upper trapezius.
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CHAPTER 1
GENERAL INTRODUCTION AND OVERVIEW
1.0 GENERAL INTRODUCTION
1.0.1 The motor unit
A motor unit (MU) is defined as a single motor neuron (located in the brain stem
or spinal cord), its peripheral axon and the muscle fibers innervated by that axon.1, 2
Responsible for the production of force via reflex and voluntary contractions of skeletal
muscle, MUs are considered the elementary functional component of the motor system.3
Losses of MUs occur in aging, many peripheral neuropathies, and motor neuron diseases
such as amyotrophic lateral sclerosis (ALS).4
1.0.2 Amyotrophic lateral sclerosis
ALS is a progressive neurodegenerative disease characterized by the selective
death of upper and lower motor neurons.5 The disease has a population incidence of 1.5
to 2.5 per 100 000 persons per year and a gender ratio of roughly 2:1 male to female,
although there have been reports of a trend towards unity.6 While 5 to 10% of ALS cases
are familial, 90 to 95% of cases are considered sporadic, characterized by an absence of
family history.5 Cases are classified by region of symptom onset, with limb onset as the
most common presentation (e.g. foot drop), followed by bulbar onset (e.g. dysphagia,
dysarthria), and the relatively uncommon respiratory onset ALS (e.g. orthopnea).7
Degeneration of LMNs (and a corresponding decline in the number of functioning
MUs) results in denervation of skeletal muscle fibers and progressive muscle atrophy and
weakness.5 The progression of the disease is highly variable from patient to patient, and
while a small proportion of patients survive much longer, ALS is typically fatal within
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3-5 years of symptom onset.5, 8 In general, death occurs as a result of respiratory failure.9
Many unknowns remain with regard to the etiology and pathogenesis of ALS. However,
a common overarching hypothesis for the etiology of ALS is that it involves the coupling
of exposure to a risk factor (proposed risk factors include strenuous physical activity,
exposure to heavy metals, and trauma with skeletal fracture) with genetic susceptibility to
the disease.10, 11 Many potentially convergent hypotheses exist as to the underlying
causes of motor neuron degeneration, including oxidative damage, glutamate
excitotoxicity, and aberrant RNA metabolism.12 With the exception of the drug riluzole
(which has been shown to prolong survival modestly),13 the interventions tested in
clinical trials thus far have not been found to modify the progression of the disease.14
1.0.3 Motor unit number estimation
Highly relevant for application to this disease population, motor unit number
estimation (MUNE) was developed by McComas et al. (1971)15 as a quantitative,
electrophysiological method for estimating the number of functioning MUs within a
muscle or group of muscles. This quantification may be useful to evaluate the severity
and natural history of the disease. Furthermore, it may be especially useful as an
outcome measure in ALS clinical trials to assess the efficacy of interventions by
monitoring disease progression.16
MUNE uses electromyography (EMG), which detects and records the electrical
activity of active MUs using surface and/or intramuscular electrodes. The action
potentials propagated along the individual muscle fibers of a MU following the discharge
of the associated motor neuron correspond with waveforms termed muscle fiber action
potentials.17 The summation of these individual waveforms yields the expression of a
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waveform termed a motor unit potential (MUP) that is unique for each MU.17 Certain
parameters associated with a surface-detected motor unit potential (S-MUP) or
intramuscularly-detected MUP (hereafter simply referred to as a MUP) are related to the
morphological and physiological characteristics of the underlying MU. For example, the
amplitude or area of an S-MUP is representative of the number of muscle fibers within
the MU (i.e. the innervation ratio, or size of the MU).3, 15, 17
Based on these principles, a MUNE is calculated through the division of a size
parameter of the maximum compound muscle action potential (CMAP), representative of
the activation of all of the motor axons in the nerve in response to supramaximal
electrical stimulation, by the same size parameter of the mean S-MUP, representative of
the average single MU size (Equation 1).1, 18
1.0.3.1 Equation 1
MUNE = maximum CMAP size
mean S-MUP size
Where MUNE, motor unit number estimate; CMAP, compound muscle action potential;
S-MUP, surface-detected motor unit potential.
1.0.4 Outcome measures and collateral reinnervation
The selection of primary and secondary outcome measures (also termed
endpoints) for use in ALS clinical trials to determine the efficacy of interventions has
been highly heterogeneous. However, a quantitative review of ALS clinical trials has yet
to be conducted to identify the most commonly used and underutilized measures.
In general terms, ALS clinical trials commonly employ outcome measures that
assess function and muscle strength.19, 20 However, these outcome measures are
influenced by the compensatory process of collateral reinnervation which takes place in
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chronic denervating disorders such as ALS, whereby new nerve sprouts grow out from
surviving nerve axons to supply denervated muscle fibers (Figure 1.1). This process, by
maintaining muscle mass and strength, may allow these measures to remain relatively
stable until MU loss has surpassed a critical threshold.21
In contrast to these clinical outcome measures, MUNE takes into account the
effects of collateral reinnervation, as mean S-MUP size is incorporated into its
calculation. Its subsequent ability to monitor the underlying progression of the disease
(MU loss as well as collateral reinnervation) makes MUNE a valuable addition as an
outcome measure for use in ALS clinical trials.16, 22
1.0.5 Motor unit number estimation techniques
Various types of MUNE have been developed and modified since its introduction
over 40 years ago, with manual incremental stimulation,15 multiple point stimulation,23, 24
the statistical method,1 spike-triggered averaging (STA),25, 26 and decompositionenhanced spike-triggered averaging (DE-STA)18, 27 used most commonly.16, 22 While the
basic principles are the same for all techniques, they differ in their underlying
assumptions, as well as their inherent benefits and limitations.
A key difference among the techniques is the way in which the mean S-MUP is
obtained, which influences the range of muscle groups to which the protocol can be
applied. Manual incremental stimulation, multiple point stimulation, and the statistical
method (along with modifications to these techniques) employ percutaneous electrical
stimulation of the motor nerve in order to collect a sample of S-MUPs, whereas STA and
DE-STA utilize voluntary contractions. MUNE techniques utilizing electrical stimulation
to collect a sample of S-MUPs are generally limited to application to relatively distal
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muscles with easily accessible nerve supplies, and in the case of multiple point
stimulation, a certain length of the motor nerve available for stimulation. In contrast, the
use of voluntary contractions to collect a sample of S-MUPs allows for STA and DESTA MUNE to be applied to any muscle from which a maximum CMAP can be elicited.
Thus, these techniques can be applied to not only distal, but proximal muscles.16, 18, 22
1.0.6 Quantitative electromyography
A further advantage of STA and DE-STA MUNE stems from the introduction of
a needle electrode, which allows for an intramuscular EMG signal to be collected
simultaneously with the surface EMG signal during each voluntary contraction (Figure
1.2).16, 18, 22 The subsequent application of quantitative electromyography (QEMG)
techniques allows for quantitative MUP analysis in addition to the results yielded through
MUNE. QEMG techniques allow for the isolation of the activity of individual MUP
trains, representative of the repetitive firing of single MUs over a given period of time,28
and subsequent determination of the prototypical MUP associated with each MUP train.
Quantification of the distributions of various parameters characterizing the sizes, shapes,
and firing patterns of a representative sample of MUPs from a given muscle allows for
the evaluation of corresponding morphological and physiological features of the
associated MU pool. As such, quantitative MUP analysis is able to yield information
complementary to MUNE corresponding with the severity and progression of processes
affecting the neuromuscular system such as ALS.29, 30
QEMG facilitates the process of MUNE, with STA and DE-STA utilizing
different techniques. The process of STA involves the application of a level or windowbased discriminator to the intramuscularly-detected EMG signal in order to isolate the
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activity of an individual, voluntarily activated MUP train. Each MUP firing that meets or
falls within the limits of the discriminator acts as a trigger to isolate the time-locked SMUP for that specific MUP (Figure 1.2). Next, the S-MUPs associated with each MUP
firing for a given MUP train are ensemble-averaged to derive the S-MUP template
associated with a given MU.25, 26 First described as a method of MUNE by Boe et al.
(2004),27 DE-STA improves upon conventional STA MUNE by incorporating a series of
computer-based algorithms for intramuscular EMG signal decomposition, termed
decomposition-based quantitative electromyography (DQEMG).18, 28, 31
1.0.7 Decomposition-based quantitative electromyography
While STA is limited to the collection of one MUP train from each low-level
voluntary contraction, the addition of DQEMG allows for the resolution of composite
EMG signals produced from stronger voluntary contractions into their constituent MUP
trains. The individual MUP firings from each MUP train then serve as triggers to be used
in STA, resulting in the collection of S-MUP templates for numerous MUs from a single
contraction. By collecting more than one MUP train at a time from stronger voluntary
contractions, DE-STA MUNE both eases the level of focus required of the subject, and
allows for more efficient collection of a sample of S-MUPs. Furthermore, in line with
the “size principle” of MU recruitment,32 the use of stronger voluntary contractions
allows DE-STA MUNE to include not only low-threshold, generally smaller MUs but
also higher-threshold, larger MUs. This may allow for the determination of a more
representative mean S-MUP from which to calculate a MUNE.18, 31
The DQEMG algorithms involve MUP detection, clustering, and supervised
classification, and are applied sequentially and iteratively to the composite intramuscular
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EMG signal. The composite signal is first bandpass filtered using a first-order difference
filter. Subsequently, the MUPs exceeding a certain threshold are detected and considered
to represent a significant MUP occurrence. Next, a shape- and temporal-based clustering
algorithm is applied to the detected MUPs from an interval of the EMG signal in order to
elucidate the number of contributing MUs, and the prototypical MUP shape for each MU.
Supervised classification involves the assignment of each MUP detected initially to its
corresponding MUP train. Assignments are made based on shape and firing pattern
information and utilize a certainty algorithm, with only classifications that exceed a
specific threshold of assignment certainty being made. Lastly, algorithms that examine
the temporal relationships between MUP trains allow for the splitting and merging of
MUP trains.28, 33
EMG signal decomposition and subsequent STA yields a decomposition summary
for each voluntary contraction, as depicted in Figure 1.3. Quantitative MUP analysis
involves the calculation of various parameters characterizing the MUP template, MUP
shimmer plot, S-MUP template, and firing pattern associated with each MUP train using
standard algorithms. Finally, descriptive statistics are calculated automatically for each
parameter based on the entire sample of accepted MUPs, S-MUPs, and MUP trains from
the muscle under study.28, 33
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Figure 1.1 Collateral reinnervation. Two functioning MUs are depicted with their motor
neurons located in the anterior horn of a cross-section of the spinal cord and their
peripheral axons innervating respective groups of muscle fibers. The muscle fibers
innervated by the MU on the left are represented as shaded circles in the inset (A).
Degeneration of one of the MUs occurs, resulting in the denervation of its associated
skeletal muscle fibers (B). Collateral reinnervation is depicted, with new nerve sprouts
from the axon of the surviving MU reinnervating many of the orphaned muscle fibers.
The inset depicts the subsequent increase in the innervation ratio of the surviving MU
(C). (Modified from Stålberg E, Falck B. The role of electromyography in neurology.
Electroencephalogr Clin Neurophysiol 1997; 103:579-598).34
Abbreviation: MU, motor unit.
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Figure 1.2 Spike-triggered averaging. An example of the simultaneous collection of an
intramuscular EMG signal (top panel) and surface EMG signal (bottom panel) from a
voluntary contraction, as occurs in STA and DE-STA MUNE techniques (A). Following
the isolation of the activity of an individual MUP train from the intramuscular EMG
signal using QEMG, individual MUP firings act as triggers to isolate time-locked SMUPs. An S-MUP (thin line) is shown superimposed on its corresponding MUP firing
(thick line) (B). ([B] Modified from Doherty T, Simmons Z, O'Connell B, Felice KJ,
Conwit R, Chan KM, et al. Methods for estimating the numbers of motor units in human
muscles. J Clin Neurophysiol 1995; 12:565-584).18
Abbreviations: DE-STA, decomposition-enhanced spike-triggered averaging; EMG,
electromyography; MUNE, motor unit number estimation; MUP, motor unit potential; SMUP, surface-detected motor unit potential; STA, spike-triggered averaging; QEMG,
quantitative electromyography.
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Figure 1.3 Decomposition summary depicting the results of DQEMG from a single
voluntary contraction. Each row represents one MUP train. The first column depicts a
MUP template and the number of isolated MUPs used for its estimation. The second
column presents a MUP shimmer plot of the isolated MUPs making up the MUP train.
The third column depicts an S-MUP template and the number of firings used for its
estimation. The fourth column displays an interdischarge interval histogram, as well as
the mean interdischarge interval, and standard deviation and coefficient of variation of
the interdischarge interval. The fifth column depicts a firing graph, with vertical lines
representing MU firing times and the top tracing representing the instantaneous firing rate
plot. (Modified from Stashuk D. EMG signal decomposition: How can it be
accomplished and used? J Electromyogr Kinesiol 2001; 11:151-173).33
Abbreviations: DQEMG, decomposition-based quantitative electromyography; MU,
motor unit; MUP, motor unit potential; S-MUP, surface-detected motor unit potential.
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1.0.8 Upper trapezius muscle
Thus far, the use of MUNE as an outcome measure in ALS clinical trials has been
limited. Taking into consideration the many advantages associated with DE-STA
MUNE, this technique may be very useful in such a role.
In evaluating the potential utility of DE-STA MUNE as an outcome measure, the
role of the muscle under study becomes an important consideration. As previously
mentioned, respiratory failure is generally the cause of death in ALS.9 Thus, it would be
clinically relevant to study muscles of respiration in this population. While the principal
muscles of respiration (i.e. diaphragm, intercostal muscles) are not feasible to study using
MUNE, the upper trapezius (UT) muscle is an accessory muscle of respiration9 that
would be practical to assess, given its superficial position and easily accessible nerve
supply.
The UT (descending fibers), together with the middle (transverse fibers) and
lower (ascending fibers) trapezii, compose the trapezius muscle. The UT originates from
the external occipital protuberance, the medial third of the superior nuchal line, and the
ligamentum nuchae, and inserts into the posterior border of the lateral third of the
clavicle. This muscle acts with the levator scapulae to perform scapular elevation.35 The
primary source of motor innervation for the UT is the spinal accessory nerve, which is the
spinal branch of cranial nerve XI, termed the accessory nerve.35-38 The spinal accessory
nerve is a motor nerve that supplies both the trapezius and sternocleidomastoid muscles,
and originates from motor neurons lying in the lateral portion of the gray matter of the
upper cervical spinal cord (C1-C6). Rootlets exit the lateral aspect of the spinal cord,
forming a trunk which ascends through the foramen magnum, exiting the skull soon after

12
through the jugular foramen. The spinal accessory nerve then travels inferiorly,
innervating the SCM, and on through the posterior triangle of the neck to innervate the
UT (Figure 1.4).35, 36
As an accessory muscle of respiration, the UT aids with inspiration in the
presence of impaired diaphragmatic function, as occurs with progressive denervation in
ALS.9 Quantification of the number and characteristics of MUs associated with a muscle
related to respiratory function may offer insight into the severity and progression of the
disease, as well as the potential efficacy of interventions. Additionally, as a proximal
muscle, examination of the UT would be novel, as the majority of previous studies using
MUNE have utilized techniques that limited their evaluations to distal muscles.
A preliminary study by Lewis (2009)39 examined the application of DE-STA
MUNE to the UT in a small sample that included three control subjects and one subject
with ALS. Their results suggest that the application of DE-STA MUNE to this proximal
muscle is feasible and warrants further study.
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Figure 1.4 Innervation of the upper trapezius by the spinal accessory nerve. (Modified
from Mosby’s medical dictionary. Mosby/Elsevier: St. Louis; 2009. 2056 p.).40
Abbreviation: CN, cranial nerve.
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1.0.9 Evaluation of decomposition-enhanced spike-triggered averaging MUNE
In order to assess the utility of DE-STA MUNE as an outcome measure, its
reliability, validity, and sensitivity to change must be evaluated.41, 42 With respect to
reliability, the results of any useful measurement technique must be reproducible, both in
the hands of the same evaluator at two or more points in time (intra-rater reliability) and
of different evaluators (inter-rater reliability).43 Previous studies have established the
intra-27, 44 and inter-rater reliability45 of DE-STA MUNE in various muscle groups in
control subjects, in addition to the intra-rater reliability of subsets of data collected using
DQEMG46, and the intra- and inter-rater reliability46, 47 of the analysis of this data.
However, the reliability of DE-STA MUNE as applied to the UT in control subjects
remains to be assessed. Additionally, the reliability of DE-STA MUNE has yet to be
studied in any muscle group in subjects with ALS.
In addition to reliability, a critical property of any outcome measure is its validity.
That is, its ability to measure what it purports to measure in an accurate fashion.43 We
currently lack a gold standard technique to quantify the number of MUs in a given
muscle group in a living subject, and normative anatomical data for many muscle groups
with which to compare the results of DE-STA MUNE. A single previous study
compared the results of DE-STA MUNE between subjects with ALS and control
subjects, demonstrating the ability of the technique to detect the underlying
pathophysiology of the disease in the biceps brachii (BB) and first dorsal interosseous.48
However, such an evaluation of the validity of the technique in the UT has yet to be
conducted.
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Finally, an important property of any outcome measure is sensitivity to change,
which is the ability of an instrument to detect minimal change over time, and thus
monitor the potential efficacy of an intervention.43 A cross-sectional study by Boe et al.
(2009)49 compared DE-STA MUNE in the first dorsal interosseous and BB alongside
several clinical outcome measures in subjects with ALS to normative results for the same
measures. The study demonstrated the ability of DE-STA MUNE to detect underlying
pathophysiological features of the disease despite better-preserved functional
performance. However, a longitudinal study comparing the sensitivity to change between
DE-STA MUNE and clinical outcome measures in subjects with ALS has yet to be
conducted.
Sources of error associated with a measurement technique may negatively
influence its reliability, validity, and sensitivity to change.43 Thus, investigation into
potential sources of error associated with DE-STA MUNE may lead to improvements in
these properties of the technique that are essential to its utility as an outcome measure. It
is well established that the position of the detecting electrode relative to the muscle fibers
of a MU influences the characteristics of the corresponding EMG signal.17 Thus, the
influence of the depth of the needle electrode on the results of DE-STA MUNE may be
important to assess. This component of the technique’s data collection protocol has not
been evaluated systematically.
It is the overall objective of this thesis to review the use of outcome measures
systematically across ALS clinical trials, and to evaluate the utility of DE-STA MUNE as
an outcome measure, with a particular focus on its application to the UT.
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1.1 OVERVIEW OF THESIS CHAPTERS
The objectives of this thesis were addressed through the conduct of a series of five
studies. First, a review of the frequency of use of outcome measures across ALS clinical
trials, in addition to the advantages and disadvantages of select measures was conducted
(Chapter 2). In order to assess the utility of DE-STA MUNE as an outcome measure, the
reliability (Chapters 3 and 4), validity (Chapter 4), and sensitivity to change (Chapter 5)
of the technique was evaluated. The findings from the study reported in Chapter 5
indicated the need for further study regarding potential sources of error associated with
the technique. Thus, continuing the assessment of the utility of DE-STA MUNE as an
outcome measure, the influence of the depth of the needle electrode on the results of the
technique was evaluated (Chapter 6).
1.1.1 Chapter 2 study objectives


To conduct a systematic review quantifying the frequency of use of outcome
measures as primary and secondary endpoints in ALS randomized controlled
trials published since 1990, classifying these outcome measures according to
common categories from the ALS literature.



To briefly review the advantages and disadvantages associated with select
outcome measures identified by the review.

1.1.2 Chapter 3 study objective


To assess the intra- and inter-rater reliability of DE-STA MUNE and quantitative
MUP analysis in the UT of control subjects.
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1.1.3 Chapter 4 study objectives


To assess the intra-rater reliability of DE-STA MUNE and quantitative MUP
analysis in the UT and BB of subjects with ALS.



To compare the results of DE-STA MUNE and quantitative MUP analysis in the
UT of subjects with ALS to data obtained previously (study 2) in control subjects
in the same muscle.

1.1.4 Chapter 5 study objective


To compare the sensitivity to change of DE-STA MUNE and quantitative MUP
analysis in the UT to that of various clinical outcome measures in subjects with
ALS. More specifically, to make comparisons with manual muscle testing in five
upper extremity muscle groups, scapular elevation and elbow flexion peak force
measured using hand-held dynamometry, forced vital capacity, sniff nasal
inspiratory pressure, and the Revised Amyotrophic Lateral Sclerosis Functional
Rating Scale.

1.1.5 Chapter 6 study objective


To evaluate the influence of needle electrode depth on the results of DE-STA
MUNE and quantitative MUP analysis in the UT of control subjects by comparing
the results obtained across superficial, intermediate, and deep needle electrode
depths.
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CHAPTER 2
USE OF OUTCOME MEASURES IN ALS RANDOMIZED CONTROLLED
TRIALS: A SYSTEMATIC REVIEW
2.0 INTRODUCTION
Clinical trials aimed at identifying interventions to modify the progression of
amyotrophic lateral sclerosis (ALS) are underway constantly. To date, only one drug
(riluzole) has been shown to prolong survival modestly.1 The process of drug
development typically begins with basic science investigations, followed by sequential
phases of human clinical trials. Early phase trials (phase I and II) focus on examination
of pharmacokinetic characteristics, the clinical safety and toxicity profile, feasibility, and
dosing of the pharmacologic agent, with some phase II trials opting to include a
preliminary assessment of efficacy.2
If the results of these early phase trials show promise for treatment efficacy, a
potential intervention would then be studied in a phase III clinical trial. A phase III
clinical trial is conducted in a large sample of patients, and the primary aim of these trials
is to assess the efficacy and safety of an intervention. A randomized controlled trial
(RCT) is the gold standard design for a phase III clinical trial. These trials are typically
randomized, double-blind, and placebo-controlled in order to promote high levels of
internal validity.3
As previously stated, the vast majority of interventions studied in RCTs for ALS
thus far have not been shown to alter the course of the disease significantly. This may be
due to their genuine ineffectiveness or, alternatively, to the design or conduct of the
RCTs themselves. A critical component of trial design is the selection of outcome
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measures, which are the variables used to monitor the efficacy of an intervention.
Outcome measures are also termed ‘endpoints’ and are designated as either the primary
or secondary outcomes in clinical trials. While more than one may occasionally be
selected, trials typically employ a single primary outcome measure, which is used in the
power calculation to determine the required sample size and whether the end result of the
trial is ‘positive’ or ‘negative’. Secondary outcome measures are considered to be less
clinically important than the primary outcome measure for a particular trial.2
The power of a clinical trial may be impacted by the chosen primary outcome
measure. Calculation of the sample size required in order for a trial to reach a desired
level of statistical power is dependent in large part on the sensitivity to change and
variability of the chosen primary endpoint. In addition, the degree of complexity and
burden added to study visits by the primary and secondary measures may influence the
amount of missing data and subject dropouts. Missing data may also result if the measure
becomes more difficult to assess with progression of the disease; an important issue in
ALS trials. The selected primary outcome measure also impacts the required duration of
the trial, thus acting as a critical determinant in the cost and time required for a single
study. These are particularly important issues when studying a relatively rare disease for
which resources (subjects and money) are often limited. The amount of time spent on
individual trials is also of key importance given the sense of urgency accompanying the
fatal nature of the disease, and considering the large number of potential agents waiting
to be tested.4, 5
While survival is obviously a clinically meaningful outcome for a fatal disease, its
use as a primary endpoint typically necessitates long trials with large sample sizes in
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order for studies to reach statistical power.4 The additional consideration of other
disadvantages associated with the use of survival (as will be discussed in detail) has led
to the utilization of other outcome measures in ALS clinical trials. These outcome
measures fall under categories of muscle strength, pulmonary function, functional rating
scales/timed functional tests, electrophysiological indices, biomarkers, imaging and
quality of life (QoL).2, 6
Assessment of muscle strength is a highly relevant outcome measure given that
muscle wasting and weakness are core features of disease progression. The strength of a
muscle or group of muscles during a voluntary contraction can be assessed quantitatively
with a strain-gauge, determining maximal voluntary isometric contraction (MVIC) or
with hand-held dynamometry, as well as by manual muscle testing (MMT) using the
Medical Research Council scale.7
Given that respiratory failure as a result of progressive respiratory muscle
weakness is generally the cause of death in ALS, clinical trials also commonly employ
outcome measures of pulmonary function. As the diaphragm is the major muscle
responsible for inspiration, these measures largely aim to monitor changes in the strength
of this muscle over time, and include such measures as vital capacity and forced vital
capacity (FVC).8
Functional outcome measures such as timed functional tests and functional rating
scales (e.g. Revised Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRSR]) are measures of the impact of an intervention on activities of daily living and other
functional tasks which may be specifically affected by the disease process. These types
of measures are highly relevant, given that preservation of function is likely of great
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importance to the patient and their family.9 Functional rating scales can be generic or
disease-specific, and utilize the patient’s self-report or a clinician’s report.10
Unlike measures of muscle strength and function,11 electrophysiological indices
assess the underlying pathophysiology and progression of the disease, providing
quantitative information on the upper motor neuron (UMN) or lower motor neuron
(LMN) component. The quantitative techniques assessing the LMN rely on
electromyography (EMG) (e.g. motor unit number estimation [MUNE],
neurophysiological index, various needle EMG parameters) and those assessing the UMN
component of the disease currently utilize transcranial magnetic stimulation.12, 13
Biomarkers are objective laboratory measurements (e.g. cerebrospinal fluid levels
of prostaglandin E2, blood markers of oxidative damage) that function as potential
indicators of pathogenesis and biological response to pharmacologic intervention. These
markers may be highly sensitive to disease progression and early therapeutic effects as
outcome measures in clinical trials.14, 15 Although in their relatively early stages of use as
outcome measures, neuroimaging techniques such as magnetic resonance spectroscopy
may be highly valuable given their unique capacity to detect and monitor the UMN
component of the disease non-invasively and objectively.16
Incorporation of measures of QoL as outcome measures for an ALS clinical trial
allows for a more complete evaluation of the effect of an intervention, and may be
especially important to the patient given the fatal nature of the disease.2, 17 QoL
questionnaires can be generic, meaning that their items assess general health concepts not
specific to any age, disease, or treatment group18 (e.g. 36-item Short-Form survey [SF-
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36]), or specific, having been developed for the ALS patient population (e.g. Sickness
Impact Profile/ALS-19).19
Selection of primary and secondary endpoints to be used in a clinical trial may be
aided by the consensus guidelines on ALS trial design and execution published by the
World Federation of Neurology20 or by guidelines published by Leigh et al. (2004)9.
Although outdated, the World Federation of Neurology guidelines suggest the use of
change in muscle strength or survival as the primary outcome measure, and make a broad
recommendation for the inclusion of measures of muscle strength (recommending
quantitative myometry [i.e. MVIC]), pulmonary function (recommending FVC), bulbar
function and time to death in every trial. The guidelines by Leigh et al. (2004)9
recommend the use of either survival or, preferentially, the ALSFRS-R as the primary
outcome measure, with both sets of guidelines recommending the inclusion of a diseasespecific QoL measure alongside the SF-36 generic measure as secondary endpoints.
Heterogeneity in the use of outcome measures as a result of: a) the absence of an
unequivocal primary outcome measure selection; b) the presence of a multitude of
options available for secondary outcome measures; and c) limited guidelines for the use
of these measures, is widely apparent. However, a systematic review quantifying the
frequency of use of available outcome measures across ALS RCTs has yet to be
completed.
Various reviews have documented the use of primary and, less commonly,
secondary outcome measures across only select ALS clinical trials.3, 9, 21, 22 A systematic
review of ALS RCTs was conducted by Beghi et al. (2011)23, reporting on various
aspects of trial design and conduct, but without reporting on the use of outcome
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measures. Lastly, a systematic review of ALS RCTs by de Carvalho et al. (2005)12 with
highly selective inclusion criteria chose to focus on the sensitivity to change of various
primary outcome measures, but not on their frequency of use.
A systematic, quantitative synthesis of the literature would allow for identification
of all of the outcome measures that have been used in ALS clinical trials to date and
serve to pinpoint the most commonly used as well as underutilized outcome measures.
This would act as a resource to facilitate discussion regarding the selection of outcome
measures for future ALS clinical trials; a critical component of trial design impacting
largely on their potential for success.
Thus, the objectives of this systematic review were to quantify the frequency of
use of outcome measures as primary and secondary endpoints in ALS RCTs published
since 1990, classifying these outcome measures according to the previously mentioned
categories common in the ALS literature. A secondary objective was to briefly review
the advantages and disadvantages of select outcome measures identified by the review.
2.1 METHODS
Relevant studies were identified through a literature search encompassing the time
period from January 1990 to July 2011. The following databases were searched:
MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials. Search terms
varied slightly across databases and are listed in Box 2.1.
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Box 2.1 Search terms
amyotrophic lateral sclerosis OR ALS OR MND OR motor neuron disease OR
(MEDLINE only) motor neurone disease OR (MEDLINE only) motoneuron disease
OR motoneurone disease OR Lou Gehrig's disease OR Charcot's disease
AND
placebo OR placebos
AND
double blind OR double blinded OR double-blind*
AND
randomized controlled trial OR randomized controlled trials OR randomize* OR
randomization OR controlled clinical trial OR controlled clinical trials OR
(MEDLINE only) clinical trial, phase III
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2.1.1 Inclusion criteria
Studies were included if they: i) purported to assess an intervention for
efficacy/effectiveness solely in patients with ALS, regardless of phase (i.e. phase II trials
including assessments of efficacy were included); ii) compared subjects receiving the
intervention to a control group receiving placebo (in any form, frequency, dosage or in
combination with other products); and were iii) randomized or quasi-randomized (i.e.
alternate allocation); iv) double-blind; and v) prospective clinical trials. There were no
restrictions made with respect to study design (e.g. parallel group, cross-over), and
studies with multiple intervention and/or control groups were included.
2.1.2 Exclusion criteria
Review articles, editorials and other non-clinical trials were excluded, as were
abstracts that were published subsequently as full studies. Abstracts which lacked
sufficient reporting detail and abstracts/full-text articles that were unobtainable were also
excluded. Additionally, studies pertaining to symptomatic therapies for ALS (e.g. for
pseudobulbar affect, sialorrhoea, muscle cramps), ongoing studies, and non-English
studies were excluded.
Review of all search results and data extraction was performed by one author
(CI). First, titles and abstracts identified by the literature search were screened for
eligibility. For all retained abstracts (including all those for which eligibility remained in
question) an attempt was made to obtain the full-text articles and either the full-text
article or abstract (when the full-text was unavailable) was reviewed in detail to
determine eligibility. Upon determination of the eligible studies to be included in the
review, specific data were extracted from the methods section: the intervention, first
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author, year of publication, sample size (n), trial duration, and primary and secondary
outcome measures. The methodological quality of the studies was not assessed, as it was
not relevant to the assessment of outcome measure selection. If the study did not clearly
identify which outcome measures were primary and which were secondary, or listed
more than one endpoint as the primary outcome measure, the variable for which the study
was powered statistically (where identified) was considered to be the primary outcome
measure.
Each identified outcome measure was classified into one of the following
common categories of outcome measures used in ALS clinical trials: survival, muscle
strength, pulmonary function, functional rating scales/timed functional tests,
electrophysiological indices, biomarkers, imaging, or QoL.2, 6
2.2 RESULTS
2.2.1 Literature search results
The results of the literature search and the reasons for exclusion are presented in
Figure 2.1. From a total of 1127 titles and abstracts identified by the search strategy, 85
potentially relevant papers were identified from the initial screening and subsequently
reviewed in detail. Fifty-seven of these papers were ultimately determined to be eligible
for inclusion in the review. One of these papers reported the results of 2 RCTs24 and
thus, 58 clinical trials were identified in total. A summary of all of the included clinical
trials is presented in Appendix A. The trials were published from 1992 to 2011. The
average sample size of these trials was 207 ± 278 participants (median: 99), ranging from
1025 to 1210 participants,24 with trial durations ranging from 72 hr26 to 24 months.27, 28
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With the exception of 5 studies,28-32 all trials were assessments of pharmaceutical
compounds.
2.2.2 Primary outcome measures
The primary outcome measure was clearly stated in 45 (78%) of the clinical trials,
and these trials were incorporated into the descriptive analysis in Box 2.2. From these
clinical trials, 13 different primary outcome measures were identified. Twenty trials
(44%) utilized a primary outcome measure falling under the functional rating
scales/timed functional tests classification, 13 trials (29%) used survival, and 10 trials
(22%) used an outcome measure that assessed muscle strength. None of the trials in the
review utilized a primary outcome measure that evaluated pulmonary function, an
electrophysiological index, a biomarker, or QoL. Examining the most frequently used
individual outcome measures within these categories, survival was the most often used
primary outcome measure overall (13 trials; 29%), followed by MVIC – upper extremity
(UE) and the ALSFRS-R in 6 trials (13%) each. A megascore that incorporated more
than one outcome measure was used as the primary endpoint in 2 trials.33, 34
2.2.3 Secondary outcome measures
Forty-eight trials (83%) made it clear which endpoints (if any) were used as
secondary outcome measures, and these trials were incorporated into the descriptive
analysis in Box 2.3. On average, these trials utilized 4 ± 3 (median: 4) secondary
outcome measures, ranging from 034-37 to 10 outcome measures.38
Sixty different secondary outcome measures were identified across these 48 trials.
Measures classified as functional rating scales/timed functional tests were used most
frequently (73 times), followed by measures of muscle strength (35 times), pulmonary
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function (34 times), and QoL (16 times). Imaging was not used as a secondary outcome
in any of the trials. Examining the most frequently used individual outcome measures
within these categories, FVC was the most often used secondary outcome measure
overall, employed in 21 trials (44%), followed by MMT in 19 trials (40%), MVIC and
survival in 13 trials (27%), respectively, patient visual analogue scales and the ALSFRSR in 9 trials (19%), respectively, Amyotrophic Lateral Sclerosis Functional Rating Scale
(ALSFRS) in 8 trials (17%), and the Sickness Impact Profile in 6 trials (13%). The
modified Norris score, Norris score, Global Clinical Impression of Change scale, and
vital capacity were used in 5 trials (10%) each, while the SF-36 and MUNE were used in
4 trials (8%) each.

33

Titles and abstracts screened
(n = 1127)

Papers excluded after screening titles/abstracts
(n = 1042)
 Duplicates (n = 285)
 Non-ALS study (n = 551)
 Non-clinical trial (n = 94)
 Ancillary study to clinical trial (n = 29)
 Symptomatic therapy (n = 14)
 Included participants without ALS (n = 5)
 Not a randomized, double-blind, placebocontrolled trial (n = 41)
 Abstract subsequently published as full
study (n = 14)
 Non-English (n = 6)
 Unobtainable paper (n = 2)
 Ongoing study (n = 1)

Potentially relevant papers for which
full-text retrieved or abstract evaluated
in detail (n = 85)

Papers excluded after detailed evaluation
(n = 28)







Non-clinical trial (n = 2)
Included participants without ALS (n = 1)
Not a randomized, double-blind, placebocontrolled trial (n = 21)
Abstract subsequently published as full study
(n = 2)
Unable to obtain full-text for abstract lacking
sufficient detail (n = 1)
Ongoing study (n = 1)

Papers included in review (n = 57)
Number of clinical trials reported in
these papers (n = 58)

Figure 2.1 Flow of studies through the systematic review
Abbreviation: ALS, amyotrophic lateral sclerosis.
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Box 2.2 Frequency of use of primary outcome measures reported in ALS RCTs*
Survival (13)
Muscle strength (10)
- MVIC39, 40
o MVIC – UE (6)
o MVIC – UE and lower extremity (1)
- MMT41 (2)
- Tufts Quantitative Neuromuscular Exam
o Tufts Quantitative Neuromuscular Exam – arm strength megascore40, 42 (1)
Functional rating scales/timed functional tests (20)
- ALSFRS-R (6)
- Appel ALS Rating Scale43 (4)
- ALSFRS44 (2)
- Modified Norris score45
o Modified Norris score (2)
o Modified Norris score – limb scale45 (1)
- Number of patients becoming non-self-supporting, based on subset of Norris score (1)
- Decrease ≥ 6 points on ALSFRS-R or death (1)
- Summated megascore: Body weight, Norris score, Jamar grip strength, % FVC, %
maximum voluntary ventilation (1)
- Tufts Quantitative Neuromuscular Exam40 (1)
- Modification of Tufts Quantitative Neuromuscular Exam46 (1)
Imaging (1)
- N-acetylaspartate/(creatine + choline) ratio in motor cortex assessed by magnetic
resonance spectroscopy (1)
Other (1)
- MVIC and FVC combination megascore (1)
*

Based on 45 trials for which primary outcome measure clearly stated.
Outcome measures that are bolded and italicized were used most frequently within category.
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS, Amyotrophic Lateral Sclerosis
Functional Rating Scale; ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional
Rating Scale; FVC, forced vital capacity; MMT, manual muscle testing; MVIC, maximal
voluntary isometric contraction; RCT, randomized controlled trial; UE, upper extremity.

35

Box 2.3 Frequency of use of secondary outcome measures reported in ALS RCTs*
Survival (13)
Muscle strength (35)
- MMT 41 (19)
- MVIC (13)
- Muscle fatigue (1)
- Semiquantitative estimation of bulbar function (1)
- Tufts Quantitative Neuromuscular Exam
o Tufts Quantitative Neuromuscular Exam – leg strength megascore40, 42 (1)
Pulmonary function (34)
- FVC (21)
- Vital capacity (5)
- Slow vital capacity (3)
- Vital capacity ratio (1)
- Forced expiratory volume (1)
- Incidence of select respiratory events (1)
- Peak inspiratory flow (1)
- Ventilatory function (1)
Electrophysiological indices (13)
- MUNE (4)
- Neurophysiological index (3)
- Compound muscle action potential (CMAP)
o CMAP amplitude (2)
o CMAP latency, amplitude and duration (1)
- Spontaneous activity (1)
- Fiber density (1)
- Cortical threshold and motor evoked potential/CMAP ratios to magnetic stimulation (1)
Biomarkers (3)
- Cerebrospinal fluid prostaglandin E2 levels (1)
- Cerebrospinal fluid levels of amino acids (1)
- Various serum levels/blood markers of oxidative damage (1)
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS, Amyotrophic Lateral Sclerosis
Functional Rating Scale; ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional
Rating Scale; CMAP, compound muscle action potential; FVC, forced vital capacity; MMT,
manual muscle testing; MUNE, motor unit number estimation; MVIC, maximal voluntary
isometric contraction; QoL, quality of life; RCT, randomized controlled trial; SF-12, 12-item
Short-Form survey; SF-36, 36-item Short-Form survey.
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Box 2.3 continued. Frequency of use of secondary outcome measures reported in ALS RCTs*
Functional rating scales/timed functional tests (73)
- Patient visual analogue scales45 (9)
- ALSFRS-R47 (9)
- ALSFRS44 (8)
- Modified Norris score (5)
- Norris score48
o Norris score (5)
o Norris score – bulbar scale48 (1)
- Global Clinical Impression of Change scale44 (5)
- Spasticity scale (3)
- Time to walk 15 ft (3)
- Syllable repetition (PATA)/oral-labial-lingual dexterity (2)
- Frenchay Dysarthria Assessment (modification)49 (1)
- Ashworth scale50 (1)
- Modified clinical global impression scale (1)
- Spinal and bulbar score51 (1)
- Medical visual analogue scale (1)
- 16-item Quick Inventory of Depressive Symptomatology – Self-Report52 (1)
- Addenbrooke’s Cognitive Examination53 (1)
- Rankin scale54 (1)
- Barthel Index55 (1)
- Appel ALS Rating Scale43 (1)
- Modified Appel ALS Rating Scale
o Modified Appel ALS Rating Scale – bulbar section (1)
- Sickness Impact Profile
o Sickness Impact Profile – Physical Dimension Score56 (1)
- Modified Schwab and England Scale57 (1)
- ALS Severity Scale58 (1)
- ALS Health State Scale59 (1)
- Activities of daily living scores60 (1)
- Clinical deficit scores (1)
- Time to dial phone no. (1)
- No. rotations of pencil in 30 s (1)
- 6-minute walk test61 (1)
- Timed rapid alternating movement task (1)
- Rapid foot taps (1)
- Purdue pegboard test (1)
QoL (16)
- Sickness Impact Profile56 (6)
- SF-3618 (4)
- 12-item Short-Form survey (SF-12)62 (2)
- McGill single item QoL score63 (2)
- Sickness Impact Profile/ALS-1919 (1)
- ALS-Specific Quality of Life Instrument64 (1)
*

Based on 48 trials for which secondary outcome measures clearly stated.
Outcome measures that are bolded and italicized were used most frequently within category.
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2.3 DISCUSSION
Widely apparent from this review was the vast array of outcome measures that
have been employed in ALS RCTs. It was the aim of this study to quantify the frequency
of use of these outcome measures as either primary or secondary endpoints. However, a
number of trials did not clearly define their outcome measures as primary or secondary
endpoints and, therefore, were not able to be included in the analysis. This deficiency
points to the potential need for clearer reporting of outcome measure classification
(primary vs. secondary) in ALS RCTs.
2.3.1 Primary outcome measures
Of the 45 clinical trials that clearly specified a single primary outcome measure,
43 utilized either a functional rating scale/timed functional test, survival, or a measure of
muscle strength. Within these classifications, the selection of primary outcome measures
was relatively homogeneous, with the majority of trials choosing to employ either
survival, MVIC – UE, or the ALSFRS-R. These findings demonstrate alignment with
ALS clinical trial design guidelines which recommend the use of survival,9, 20 the
ALSFRS-R,9 or muscle strength20 as primary outcome measures.
2.3.1.1 Survival
As mentioned, survival was found to be the most frequently used primary
endpoint. Survival is certainly a clinically relevant endpoint given the fatal nature of the
disease. Use of survival also acts as a definitive measure that reduces missing data.65
However, as previously mentioned, its use typically requires trials of long duration with
large sample sizes.4 Further complicating the use of survival as a primary endpoint is the
fact that clinical practice associated with potentially confounding factors may vary across
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sites in a multicenter trial.3, 9 Survival is known to be affected by non-invasive
ventilation,66 and may be extended by other confounding variables such as care in a
multidisciplinary clinic67 and enteral tube feeding.68 Furthermore, whether prolonged
survival is clinically meaningful is questionable if, for example, it is realized in the
presence of QoL deterioration, or if prolongation is observed only during the advanced
stages of the disease.9 In the face of the disadvantages associated with the use of
survival, other endpoints are being utilized increasingly.6
2.3.1.2 Revised Amyotrophic Lateral Sclerosis Functional Rating Scale
The ALSFRS-R is a disease-specific functional rating scale that assesses activities
of daily living, consisting of 12 items rated from 0 to 4 for a total possible score ranging
from 0 (unable to attempt any task) to 48 (normal function). Four domains are assessed:
bulbar, fine motor, gross motor, and respiratory function, with each domain containing 3
items. The ALSFRS-R improves upon the disproportionate weighting given to
assessments of limb and bulbar function in the original ALSFRS with the inclusion of
additional items assessing respiratory function.47 The validity, strong internal
consistency, and excellent inter- and intra-rater reliability of this scale have been
established.47, 69 It has also been shown to predict survival, and to be more sensitive to
change than the original ALSFRS.47 In addition to being inexpensive and not requiring
any specialized equipment, the ALSFRS-R is simple and efficient to administer
independent of disease status,2 potentially reducing the amount of missing data/subject
dropout compared to other outcome measures. The scale can be administered through the
caregiver if the subject is unable to communicate, and/or over the telephone if the subject
is unable to attend a study visit.69, 70
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2.3.1.3 Maximal voluntary isometric contraction
Another measure commonly employed as a primary outcome was MVIC of the
UE. This quantitative assessment of muscle strength involves the use of an examination
table with vertical metal bars and adjustable rings. A strap positioned on the limb being
tested is connected to an electronic strain-gauge tensiometer, which is attached to a ring
on the fixed bars. The force measured by the strain gauge during a test is recorded on a
computer system.39, 40 For an assessment of MVIC in the UE, bilateral shoulder and
elbow flexion and extension are tested and, as was the case for some of the trials in this
review, bilateral grip strength with a Jamar dynamometer may be assessed as well.39 The
validity of this method has been established, in addition to its reliability with rigorous
training and monitoring of the clinical evaluators.40, 71 However, in addition to requiring
specialized, technically complex, expensive equipment, MVIC is time-consuming and
fatiguing for the patient, limiting the number of muscle groups that can be tested.
Inclusion of MVIC as a clinical trial outcome measure has been associated with missing
data and subject dropout related to the patient’s inability to perform the protocol as a
result of disease progression.2-4, 9
2.3.2 Secondary outcome measures
The review demonstrated the striking heterogeneity across ALS RCTs in the
selection of secondary outcome measures. This lack of consensus was also apparent in
the choice of how many secondary outcome measures to employ. Heterogeneity in the
selection of endpoints certainly adds difficulty to the potential for comparisons of results
between trials.72
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Measures from each of the previously outlined categories were represented, with
the exception of imaging. The most frequently used categories were functional rating
scales/timed functional tests, followed by muscle strength and pulmonary function.
While trials consistently selected from a small number of outcome measures in the latter
two categories, there were a remarkable assortment of outcome measures utilized from
the functional rating scales/timed functional tests category, with trials frequently utilizing
more than one of these measures. Perhaps, given that they are in the early stages of
development, it is not surprising that imaging endpoints were not used.
2.3.2.1 Forced vital capacity
Overall, the most commonly used secondary outcome measure was FVC, which
was incorporated into 44% of trials. Defined as the volume of air exhaled from total lung
capacity,8 FVC is a non-invasive measure assessed using a portable, relatively
inexpensive standard spirometer. FVC has been shown to be a reliable measure with
specialized evaluator training,73 in addition to being a good predictor of disease
progression and survival.74, 75 However, the presence of bulbar or facial weakness may
prevent a subject from performing the proper maneuver or forming a tight lip seal around
the mouthpiece. This may lead to increased variability of the measurement, an
underestimation of the subject’s true values, and the required use of a facemask or
alternate mouthpiece.4, 8
2.3.2.2 Manual muscle testing
Following FVC, the next most commonly used secondary outcome measure was
MMT. This assessment of muscle strength uses the standardized Medical Research
Council grading scale, which subjectively grades strength according to the patient’s
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ability to move against gravity and contract against the examiner’s manual resistance.41
MMT is a quick, inexpensive technique that doesn’t require any specialized equipment.
However, inherent to the ordinal nature of this scale, the difference between grades is not
linear. To illustrate, for the original 5-point version of the Medical Research Council
grading scale (0 representing no muscle movement, 5 representing normal strength),
grades 4 and 5 cover much larger ranges of muscle strength as measured by percentage
predicted MVIC than grades 0-3, diminishing the scale’s sensitivity to early change in
strength.76, 77
2.3.2.3 Maximal voluntary isometric contraction and survival
In addition to their frequent use as primary outcome measures, MVIC and
survival were commonly employed as secondary endpoints. While neither set of ALS
clinical trial guidelines makes many specific suggestions for the selection of secondary
endpoints, the use of these measures is not surprising, given that the World Federation of
Neurology guidelines suggest quantitative myometry and time to death are included in
every trial.20
2.3.2.4 Functional rating scales/timed functional tests
Functional rating scales/timed functional tests was the category from which
secondary outcome measures were most commonly pulled. Within this category, the
most frequently used outcome measures were patient visual analogue scales, the
ALSFRS-R (previously described) and the original ALSFRS. Patient visual analogue
scales are subjective self-evaluations of various symptoms on a 100 mm horizontal line
flanked by descriptors at each end.45 The subject places a mark on the line that represents
their perception of their symptoms and the distance to that mark is measured to derive a
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score. The majority of studies employing these scales in this review assessed each of the
following symptoms: fasciculations, cramps, fatigue/tiredness/sleeping, and stiffness.
These scales are quick to complete, generally simple for participants to understand, and
capable of capturing aspects of the disease that are difficult to measure otherwise.
However, a disadvantage of being self-administered is that these scales may become
difficult to complete for patients who experience UE weakness or cognitive dysfunction.
2.3.2.5 Quality of life
One specific guideline that was made pertaining to the use of secondary outcome
measures in ALS clinical trials is the inclusion of a disease-specific QoL measure along
with the SF-36.9, 20 While four trials in this review employed the SF-36, none of these
four trials included a disease-specific measure of QoL. Used more commonly than any
other measure of QoL was the Sickness Impact Profile, which is a generic QoL
questionnaire with 136 items in 12 subscales. While the validity, reliability and internal
consistency of this scale have been demonstrated,56 its length may make it burdensome
for the participant to fill out.9
2.3.2.6 Motor unit number estimation
As mentioned, measures from each of the outlined categories were represented,
with the exception of assessments using imaging. Used relatively infrequently, however,
were biomarkers and electrophysiological indices.
With the exception of one measure involving transcranial magnetic stimulation,
each of the electrophysiological indices identified were assessments of LMN
involvement. Unlike any other available electrophysiological measures of the LMN
component of the disease, MUNE is capable of directly quantifying the number of
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functioning motor units (MUs) within a muscle or group of muscles.78 This
quantification is invaluable, given that MU loss is a fundamental component of the
disease process, at which interventions are often aimed at slowing or stopping.79
Measures of muscle strength, pulmonary function, and activities of daily living
are affected by the compensatory process of collateral reinnervation, which may allow
these measures to remain relatively stable until the loss of MUs surpasses a critical
threshold.11 In contrast, collateral reinnervation is taken into account by MUNE,
allowing for the monitoring of the underlying progression of the disease and any response
to treatment.80
2.3.2.7 Use of motor unit number estimation in ALS clinical trials
What follows is a brief description of each trial identified by this review that
employed MUNE as an outcome measure. For each of these trials, MUNE was
incorporated as a secondary endpoint and there were no significant beneficial effects of
treatment found for any outcome measure.
Not included in the analysis in Box 2.3, as the trial failed to differentiate between
which measures were used as primary vs. secondary endpoints, a single-center, crossover trial of dextromethorphan was the earliest RCT identified that included MUNE as an
outcome measure.81 The trial applied a PC-based modification of manual incremental
stimulation to the abductor digiti minimi muscle and found a decline of 22% in the
treatment group, but an increase of 21% in the placebo group when MUNE was measured
at baseline and 3 month time points. Nevertheless, this difference was not statistically
significant, with the authors acknowledging a high degree of intra-individual variability
associated with their use of the technique.
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A 2-center, 3-arm trial of amino acid therapy was the next to incorporate MUNE,
in this case applying spike-triggered averaging to the biceps brachialis muscle at baseline
and 6 month time points.38, 82 Combining data across trial arms, MUNE was found to
decline over the duration of the trial. However, this decline was not significant, with the
authors citing trial duration and the examination of a potentially slowly-progressing
proximal muscle as possible contributing factors.82
A modification of statistical MUNE was included as an outcome measure in a 14center trial of creatine monohydrate, which involved monthly assessments (7 evaluations
in total) of 1 of 4 intrinsic hand muscles.83, 84 Combining data from both groups, MUNE
was shown to decline over 6 months by 23%, which was more than MVIC (20%) and the
ALSFRS-R (12%). While MUNE demonstrated good reproducibility, technical problems
as a result of MU instability were encountered. Surface-detected motor unit potential
instability resulted in the overrepresentation of small units in response to the repeated
stimuli required for this technique over the course of the trial. These issues were
corrected for partially with post-study data censuring, and the authors proposed
modifications for the technique prior to use in future trials.
A trial of celecoxib implemented this newly modified version of statistical MUNE
at 16 of 27 sites, evaluating the same intrinsic hand muscles as the previous study at 7
time points over 12 months.85, 86 Combining data across all subjects demonstrated a
decline in MUNE of 49% over 12 months. However, the same technical issues persisted,
necessitating the conclusion that statistical MUNE is unsuitable for use as a measurement
technique in any disease associated with MU instability.
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Finally, a recent single-center trial of memantine employed manual incremental
stimulation at baseline, 6, and 12 month time points, choosing to take the average value
calculated across both abductor digiti minimi for each subject.87 MUNE was found to be
the most sensitive out of all of the outcome measures, declining by 5.17%/month in the
treatment group and 5.85%/month in the placebo group.
As the review demonstrates, the use of MUNE in clinical trials to date has been
infrequent. This may stem in part from the lack of consensus surrounding which is the
most optimal technique.88 Focused efforts to improve one or two techniques may
accelerate more widespread incorporation of MUNE into clinical trials.89
Decomposition-enhanced spike-triggered averaging MUNE offers a number of
advantages over other available MUNE techniques, making it potentially valuable in this
regard.90
2.3.3 Limitations and future study
Potential limitations of this systematic review include that we did not search for
unpublished studies, nor hand search the reference lists of included studies, which may
have recovered more RCTs for inclusion in the analysis. Additionally, the
methodological quality of the included studies was not assessed; the results may have
differed had only RCTs of high internal validity been included. Improvement to the
number of trials included in the data analysis may have been possible had the authors
been contacted for the manuscripts in which a clear discernment between primary and
secondary outcome measures was not made. Lastly, decisions surrounding study
eligibility and data extraction were made by a single author. However, from the
perspective of this author, such decisions were highly straightforward.

46
Future reviews in this area focusing on the appropriateness of the measures
reported herein for use in an ALS population (i.e. disease-specific validity, reliability)
would be highly useful. This suggestion stems from the observation that many studies
failed to make reference to a source of rationale behind their use of an outcome measure
in an ALS population. This was particularly the case for many functional rating
scales/timed functional tests. In addition, a future quantitative review should focus on the
various outcome assessment methodologies used to collect and analyze data for any given
outcome measure (e.g. training of assessors, timing of assessment, use of megascores).
Such a review may promote discussion aimed at reducing heterogeneity in these areas,
facilitating the comparison of results across future studies.
2.3.4 Summary
In summary, this review demonstrates the wide array of outcome measures that
have been used in ALS RCTs, each with various advantages and limitations. In
particular, striking heterogeneity between trials was observed in the selection of
secondary outcome measures. Offering unique information concerning the underlying
disease process, there is room for the increased integration of MUNE into future clinical
trials. As the first review to quantify the frequency of use of outcome measures across
ALS RCTs systematically, this synthesis highlights the need for a clear consensus
regarding the most optimal primary and secondary outcome measures to include in the
design of future clinical trials.

47
2.4 REFERENCES

1. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral
sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007.
2. Gordon PH. Clinical trial methodology. In: Mitsumoto H, Przedborski S, Gordon PH,
editors. Amyotrophic lateral sclerosis. Taylor & Francis: New York; 2006. 583-604 p.
3. Gordon PH. Advances in clinical trials for amyotrophic lateral sclerosis. Curr Neurol
Neurosci Rep 2005; 5:48-54.
4. Shefner JM. Designing clinical trials in amyotrophic lateral sclerosis. Phys Med
Rehabil Clin N Am 2008; 19:495-508.
5. Gooch CL, Doherty TJ. The equations of life and death: Tales told by motor unit
number estimation. Neurology 2011; 77:208-209.
6. Miller RG. Classical and emergent measures for clinical trials in ALS. Amyotroph
Lateral Scler Other Motor Neuron Disord 2002; 3:1-2.
7. Miller RG. Measurement of strength: Summary. Amyotroph Lateral Scler Other Motor
Neuron Disord 2002; 3:S51-S54.
8. Lechtzin N, Rothstein J, Clawson L, Diette GB, Wiener CM. Amyotrophic lateral
sclerosis: Evaluation and treatment of respiratory impairment. Amyotroph Lateral Scler
Other Motor Neuron Disord 2002; 3:5-13.
9. Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meininger V, Miller RG, et al.
Amyotrophic lateral sclerosis: A consensus viewpoint on designing and implementing a
clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5:84-98.
10. Brooks BR. Functional scales: Summary. Amyotroph Lateral Scler Other Motor
Neuron Disord 2002; 3:13-18.
11. McComas AJ, Sica RE, Campbell MJ, Upton AR. Functional compensation in
partially denervated muscles. J Neurol Neurosurg Psychiatry 1971; 34:453-460.
12. de Carvalho M, Costa J, Swash M. Clinical trials in ALS: A review of the role of
clinical and neurophysiological measurements. Amyotroph Lateral Scler Other Motor
Neuron Disord 2005; 6:202-212.
13. de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M.
Neurophysiological measures in amyotrophic lateral sclerosis: Markers of progression in
clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6:17-28.

48
14. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral
sclerosis. Lancet Neurol 2009; 8:94-109.
15. Rothstein J. Biochemical markers: Pro. Amyotroph Lateral Scler Other Motor Neuron
Disord 2002; 3:81-81.
16. Leigh PN, Simmons A, Williams S, Williams V, Turner M, Brooks D. Imaging:
MRS/MRI/PET/SPECT: Summary. Amyotroph Lateral Scler Other Motor Neuron
Disord 2002; 3:75-80.
17. Epton J, Harris R, Jenkinson C. Quality of life in amyotrophic lateral sclerosis/motor
neuron disease: A structured review. Amyotroph Lateral Scler 2009; 10:15-26.
18. Ware Jr. JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
Conceptual framework and item selection. Med Care 1992; 30:473-483.
19. McGuire D, Garrison L, Armon C, Barohn RJ, Bryan WW, Miller R, et al. A brief
quality-of-life measure for ALS clinical trials based on a subset of items from the
sickness impact profile. J Neurol Sci 1997; 152:S18-S22.
20. Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design
and implementation of clinical trials in ALS. J Neurol Sci 1999; 169:2-12.
21. Bhatt JM, Gordon PH. Current clinical trials in amyotrophic lateral sclerosis. Expert
Opin Investig Drugs 2007; 16:1197-1207.
22. Lanka V, Cudkowicz M. Therapy development for ALS: Lessons learned and path
forward. Amyotroph Lateral Scler 2008; 9:131-140.
23. Beghi E, Chiò A, Couratier P, Esteban J, Hardiman O, Logroscino G, et al. The
epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and
critical appraisal of therapeutic trials. Amyotroph Lateral Scler 2011; 12:1-10.
24. Meininger V, Bensimon G, Bradley WR, Brooks B, Douillet P, Eisen AA, et al.
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase
III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5:107-117.
25. Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE, Aquilonius SM. Double blind
cross over trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm Suppl
1994; 41:237-241.
26. Berto MC, Filha SC, Camelier A, Rosa FW, de Souza BO, Jardim JR. Acute action of
aminophylline in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2007;
115:301-305.

49
27. Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al.
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008; 71:17701775.
28. Drachman DB, Chaudhry V, Cornblath D, Kuncl RW, Pestronk A, Clawson L, et al.
Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid
irradiation. Ann Neurol 1994; 35:142-150.
29. Cheah BC, Boland RA, Brodaty NE, Zoing MC, Jeffery SE, McKenzie DK, et al.
INSPIRATIonAL-INSPIRAtory muscle training in amyotrophic lateral sclerosis.
Amyotroph Lateral Scler 2009; 10:384-392.
30. Silva LB, Mourao LF, Silva AA, Lima NM, Almeida SR, Franca Jr MC, et al. Effect
of nutritional supplementation with milk whey proteins in amyotrophic lateral sclerosis
patients. Arq Neuropsiquiatr 2010; 68:263-268.
31. Di Lazzaro V, Dileone M, Pilato F, Profice P, Ranieri F, Musumeci G, et al.
Repetitive transcranial magnetic stimulation for ALS. A preliminary controlled study.
Neurosci Lett 2006; 408:135-140.
32. Di Lazzaro V, Pilato F, Profice P, Ranieri F, Musumeci G, Florio L, et al. Motor
cortex stimulation for ALS: A double blind placebo-controlled study. Neurosci Lett 2009;
464:18-21.
33. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, et al. A
placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in
amyotrophic lateral sclerosis. Ann Neurol 1996; 39:256-260.
34. Norris FH, Tan Y, Fallat RJ, Elias L. Trial of oral physostigmine in amyotrophic
lateral sclerosis. Clin Pharmacol Ther 1993; 54:680-682.
35. Munsat TL, Taft J, Jackson IM, Andres PL, Hollander D, Skerry L, et al. Intrathecal
thyrotropin-releasing hormone does not alter the progressive course of ALS: Experience
with an intrathecal drug delivery system. Neurology 1992; 42:1049-1053.
36. Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, et al. Selegiline
is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of
amyotrophic lateral sclerosis. Arch Neurol 1998; 55:93-96.
37. Miller RG, Shepherd R, Dao H, Khramstov A, Mendoza M, Graves J, et al.
Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord
1996; 6:101-104.
38. Tandan R, Bromberg MB, Forshew D, Fries TJ, Badger GJ, Carpenter J, et al. A
controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical,
functional, and maximum isometric torque data. Neurology 1996; 47:1220-1226.

50
39. Andres PL, Thibodeau LM, Finison LJ, Munsat TL. Quantitative assessment of
neuromuscular deficit in ALS. Neurol Clin 1987; 5:125-141.
40. Andres PL, Hedlund W, Finison L. Quantitative motor assessment in amyotrophic
lateral sclerosis. Neurology 1986; 36:937-941.
41. Aids to the investigation of peripheral nerve injuries. Her Majesty's Stationary Office:
London; 1943.
42. Andres PL, Finison LJ, Conlon T, Thibodeau LM, Munsat TL. Use of composite
scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 1988;
38:405-408.
43. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral
sclerosis: Description and preliminary experience. Ann Neurol 1987; 22:328-333.
44. Cedarbaum JM. The amyotrophic lateral sclerosis functional rating scale: Assessment
of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol
1996; 53:141-147.
45. Lacomblez L, Bouche P, Bensimon G, Meininger V. A double-blind, placebocontrolled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology
1989; 39:1635-1637.
46. Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, et al. The
natural history of amyotrophic lateral sclerosis. Neurology 1993; 43:1316-1322.
47. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The
ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of
respiratory function. J Neurol Sci 1999; 169:13-21.
48. Norris Jr. FH, Calanchini PR, Fallat RJ. The administration of guanidine in
amyotrophic lateral sclerosis. Neurology 1974; 24:721-728.
49. Enderby PM. Frenchay dysarthria assessment. College-Hill Press: San Diego; 1983.
50. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;
192:540-542.
51. Plaitakis A, Smith J, Mandeli J, Yahr MD. Pilot trial of branched-chain aminoacids in
amyotrophic lateral sclerosis. Lancet 1988; 1:1015-1018.
52. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C),
and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major
depression. Biol Psychiatry 2003; 54:573-583.

51
53. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive
test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology
2000; 55:1613-1620.
54. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, Van Gijn J. Interobserver
agreement for the assessment of handicap in stroke patients. Stroke 1988; 19:604-607.
55. Mahoney FI, Barthel DW. Functional evaluation: The barthel index. Md State Med J
1965; 14:61-65.
56. Bergner M, Bobbitt RA. The sickness impact profile: Development and final revision
of a health status measure. Med Care 1981; 19:787-805.
57. Schwab R, England A. Projection technique for evaluating surgery in Parkinson's
disease. In: Gillingham J, Donaldson I, editors. Third symposium on Parkinson's disease.
E & S Livingstone: Edinburgh; 1969. 152-157 p.
58. Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N.
Amyotrophic lateral sclerosis severity scale. Neuroepidemiology 1989; 8:142-150.
59. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in
patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998;
55:526-528.
60. Fillyaw MJ, Badger GJ, Bradley WG, Tandan R, Blair CJ, Fries TJ, et al.
Quantitative measures of neurological function in chronic neuromuscular diseases and
ataxia. J Neurol Sci 1989; 92:17-36.
61. Butland RJA, Pang J, Gross ER. Two-, six-, and 12-minute walking tests in
respiratory disease. BMJ 1982; 284:1607-1608.
62. Ware Jr. JE, Kosinski M, Keller SD. A 12-item short-form health survey:
Construction of scales and preliminary tests of reliability and validity. Med Care 1996;
34:220-233.
63. Robbins RA, Simmons Z, Bremer BA, Walsh SM, Fischer S. Quality of life in ALS is
maintained as physical function declines. Neurology 2001; 56:442-444.
64. Simmons Z, Felgoise SH, Bremer BA, Walsh SM, Hufford DJ, Bromberg MB, et al.
The ALSSQOL: Balancing physical and nonphysical factors in assessing quality of life in
ALS. Neurology 2006; 67:1659-1664.
65. Bensimon G. Survival endpoint: Pro. Amyotroph Lateral Scler Other Motor Neuron
Disord 2002; 3:35-36.

52
66. Radunovic A, Annane D, Jewitt K, Mustfa N. Mechanical ventilation for amyotrophic
lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2009.
67. Ng L, Khan F, Mathers S. Multidisciplinary care for adults with amyotrophic lateral
sclerosis or motor neuron disease. Cochrane Database Syst Rev 2009.
68. Katzberg Hans D, Benatar M. Enteral tube feeding for amyotrophic lateral
sclerosis/motor neuron disease. Cochrane Database Syst Rev 2011.
69. Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf A, Battista V, et al.
Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R
in a multicenter clinical trial. Amyotroph Lateral Scler 2007; 8:42-46.
70. Kasarskis EJ, Dempsey-Hall L, Malley Thompson M, Chi Luu L, Mendiondo M,
Kryscio R. Rating the severity of ALS by caregivers over the telephone using the
ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6:50-54.
71. Hoagland RJ, Mendoza M, Armon C, Barohn RJ, Bryan WW, Goodpasture JC, et al.
Reliability of maximal voluntary isometric contraction testing in a multicenter study of
patients with amyotrophic lateral sclerosis. Muscle Nerve 1997; 20:691-695.
72. Kaufmann P. ALS pharmacotherapy: Riluzole and clinical trials. In: Mitsumoto H,
Przedborski S, Gordon PH, editors. Amyotrophic lateral sclerosis. Taylor & Francis: New
York; 2006. 665-690 p.
73. Fallat RJ. Vital capacity as an efficacy measure: Pro. Amyotroph Lateral Scler Other
Motor Neuron Disord 2002; 3:S55-S57.
74. Fallat RJ, Jewitt B, Bass M. Spirometry in amyotrophic lateral sclerosis. Arch Neurol
1979; 36:74-80.
75. Schiffman PL, Belsh JM. Pulmonary function at diagnosis of amyotrophic lateral
sclerosis: Rate of deterioration. Chest 1993; 103:508-513.
76. Andres PL, Skerry LM, Thornell B, Portney LG, Finison LJ, Munsat TL. A
comparison of three measures of disease progression in ALS. J Neurol Sci 1996; 139:6470.
77. Sanjak M. Measurement of strength: Pro. Amyotroph Lateral Scler Other Motor
Neuron Disord 2002; 3:45-47.
78. McComas AJ, Fawcett PR, Campbell MJ, Sica RE. Electrophysiological estimation
of the number of motor units within a human muscle. J Neurol Neurosurg Psychiatry
1971; 34:121-131.

53
79. Olney RK. Motor unit number estimation (MUNE): Pro. Amyotroph Lateral Scler
Other Motor Neuron Disord 2002; 3:S91-S92.
80. Bromberg MB, Brownell AA. Motor unit number estimation in the assessment of
performance and function in motor neuron disease. Phys Med Rehabil Clin N Am 2008;
19:509-532.
81. Askmark H, Aquilonius SM, Gillberg PG, Liedholm LJ, Stalberg E, Wuopio R. A
pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg
Psychiatry 1993; 56:197-200.
82. Bromberg MB, Fries TJ, Forshew DA, Tandan R. Electrophysiologic endpoint
measures in a multicenter ALS drug trial. J Neurol Sci 2001; 184:51-55.
83. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. A
clinical trial of creatine in ALS. Neurology 2004; 63:1656-1661.
84. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D. The use of
statistical mune in a multicenter clinical trial. Muscle Nerve 2004; 30:463-469.
85. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein
JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006; 60:22-31.
86. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D. Revised statistical
motor unit number estimation in the celecoxib/ALS trial. Muscle Nerve 2007; 35:228234.
87. de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A. A randomized,
placebo-controlled trial of memantine for functional disability in amyotrophic lateral
sclerosis. Amyotroph Lateral Scler 2010; 11:456-460.
88. Rashidipour O, Chan KM. Motor unit number estimation in neuromuscular disease.
Can J Neurol Sci 2008; 35:153-159.
89. Bromberg MB. Updating motor unit number estimation (MUNE). Clin Neurophysiol
2007; 118:1-8.
90. Boe SG, Stashuk DW, Doherty TJ. Motor unit number estimation by decompositionenhanced spike-triggered averaging: Control data, test-retest reliability, and contractile
level effects. Muscle Nerve 2004; 29:693-699.

54
CHAPTER 3
RELIABILITY OF DECOMPOSITION-ENHANCED SPIKE-TRIGGERED
AVERAGING MOTOR UNIT NUMBER ESTIMATION IN THE UPPER
TRAPEZIUS IN CONTROL SUBJECTS1
3.0 INTRODUCTION
Degeneration of lower motor neurons and, subsequently, a decrease in the number
of functioning motor units (MUs) of a given muscle, occurs in aging, and a variety of
neuromuscular diseases such as amyotrophic lateral sclerosis (ALS).1 Highly relevant for
application to the study of these processes, motor unit number estimation (MUNE) is able
to estimate the number of functioning MUs within a muscle or group of muscles.2
ALS clinical trials aimed at finding treatments to alter the natural history of the
disease frequently employ outcome measures that assess function and muscle strength
(Chapter 2). However, as a result of collateral reinnervation, these measures may remain
relatively stable until MU loss has surpassed a critical threshold. In contrast, MUNE
takes into account the effects of collateral reinnervation.3 The subsequent ability of
MUNE to quantify underlying disease progression makes it a potentially valuable
outcome measure for use in ALS clinical trials.4, 5
First described as a MUNE method by Boe et al. (2004),6 a key advantage of
decomposition-enhanced spike-triggered averaging (DE-STA) over many other MUNE
techniques is its ability to study proximal muscle groups. It also improves upon other
techniques in its collection of not only surface, but also intramuscular electromyographic

1

A version of this chapter has been published.
Ives CT, Doherty TJ. Intra- and inter-rater reliability of motor unit number estimation and
quantitative motor unit analysis in the upper trapezius. Clin Neurophysiol 2012; 123:200-205.
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(EMG) data, allowing for quantitative motor unit potential (MUP) analysis.7
Incorporation of a series of computer-based algorithms for intramuscular EMG signal
decomposition (termed decomposition-based quantitative electromyography [DQEMG])8
gives DE-STA MUNE a number of specific advantages over conventional spike-triggered
averaging MUNE, which have been previously described (Chapter 1).7, 9
In evaluating the potential utility of DE-STA MUNE as an outcome measure in
ALS clinical trials, the role of the upper trapezius (UT) as an accessory muscle of
respiration10 may make it a particularly relevant muscle to study. Beginning an
evaluation of the technique, its results must be shown to be reproducible, both in the
hands of the same evaluator at two or more points in time (intra-rater reliability) and of
different evaluators (inter-rater reliability).11
The intra-rater reliability of DE-STA MUNE has been established in the thenar,6
first dorsal interosseous and biceps brachii (BB)12 muscles, and the inter-rater reliability
in the tibialis anterior of control subjects.13 However, reliability of the technique as
applied to the UT remains to be examined. Thus, the purpose of this study was to assess
the intra- and inter-rater reliability of DE-STA MUNE and quantitative MUP analysis in
the UT of control subjects.
3.1 METHODS
3.1.1 Subjects
Individuals between the ages of 40-65 (in order to allow for future comparison to
data from subjects with ALS) with no known neuromuscular or musculoskeletal disease
were eligible to participate in this study (n = 10). All subjects gave written, informed
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consent in accordance with The University of Western Ontario Health Sciences Research
Ethics Board, which approved this study.
3.1.2 Electromyographic data collection protocol
EMG signals were acquired using DQEMG (version 3.2) and Acquire EMG
software on a Neuroscan Comperio (Neuroscan Medical Systems, El Paso, TX). Selfadhering Silver Mactrode® electrodes (GE Medical Systems, Milwaukee, WI) were used
to detect surface signals, and 25 mm x 30 gauge TECA™ elite Disposable Concentric
Needle Electrodes (CareFusion, Middleton, WI) were used to detect intramuscular
signals, with bandpass settings of 5 Hz to 5 kHz and 10 Hz to 10 kHz, respectively.6, 9
The right UT was tested for each subject and subjects were seated upright in a
straight back chair with their feet on the floor. Surface electrodes were cut in strips (1 cm
x 3.5 cm) for use as the active and reference electrodes, with a full-sized electrode
serving as a ground. The skin was cleansed with isopropyl alcohol and surface electrodes
positioned appropriately. The active electrode was positioned transversely over the belly
of the muscle, approximately midway between the acromion process and C7 spinous
process, with the reference electrode placed over the acromion process, and the ground
electrode over the deltoid.14
A handheld bipolar stimulator was used in order to elicit a maximum compound
muscle action potential (CMAP), with the spinal accessory nerve stimulated posterior to
the sternocleidomastoid.14 If necessary, the active electrode was moved in small
increments to a position where the CMAP negative peak amplitude was maximized and
the rise time minimized. Following optimal positioning of the active electrode, the
surface electrode positions were reinforced with surgical tape to ensure that no movement
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occurred during the study. Gradually, the stimulation intensity was increased until the
CMAP negative peak amplitude reached a plateau. Automatically positioned markers
indicating onset, negative peak, positive peak, and end of the maximum CMAP were
reviewed and manually adjusted if necessary. Subsequently, size-related parameters of
the maximum CMAP including negative peak amplitude were calculated automatically.
Subjects then performed a 3-4 s voluntary contraction by way of scapular
elevation against resistance provided by the evaluator. Subjects were encouraged to
produce their maximal effort, and visual and auditory feedback was provided by the
surface EMG signal. The maximal root mean square value of the EMG signal over a 1 s
interval was calculated automatically and the intensity of subsequent sub-maximal
contractions was described as a percentage of this maximal voluntary contraction-root
mean square (% MVC-RMS).
Next, the concentric needle electrode was inserted into the UT, approximately 210 mm proximal or distal to the active surface electrode. Subjects were asked to perform
minimal isometric contractions while an optimal needle position was located that
minimized the rise times of the MUPs of the first two to three recruited MUs. With the
needle manually maintained in this position by the evaluator, the subject was instructed to
increase the contraction force to approximately 10-20% of the MVC-RMS. Each submaximal isometric contraction was maintained for 30 s, during which the subject
received visual and auditory feedback from the EMG signal and % MVC-RMS
information displayed on the screen to assist in the maintenance of a stable contraction.
Contractions were performed until a minimum of 20 MUP trains were collected, with
each contraction separated by a rest period of approximately 30-60 s, or as required by
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the subject. The needle position was adjusted between contractions to collect data from
different portions of the muscle, and, if necessary, inserted at a new site to complete the
collection of MUP trains.6, 9
3.1.3 Electromyographic signal decomposition and analysis
DQEMG and its associated algorithms have been described in detail previously
(Chapter 1).8, 9 Briefly, DQEMG decomposes the composite intramuscular EMG signal
into its constituent MUP trains. The individual MUP firings from each MUP train then
serve as triggers to isolate the time-locked surface-detected motor unit potentials (SMUPs) from the surface-recorded EMG signal. The S-MUPs associated with each MUP
firing are then ensemble-averaged to derive the S-MUP template associated with a given
MU.7, 15
During offline analysis, the acceptability of acquired MUP templates, S-MUP
templates, and MUP trains were reviewed based on specific criteria, with those failing to
meet the inclusion criteria excluded from further analysis.6, 16 Accepted MUP trains
demonstrated a consistent and physiological firing rate quantified by an interdischarge
interval histogram displaying a Gaussian-shaped main peak, a coefficient of variation <
0.3 for the interdischarge interval,8, 17 and by visual examination of the instantaneous
firing rate plot. Additionally, MUP trains were required to have MUP and S-MUP
templates derived from a minimum of 51 detected potentials each. When two MUP
trains within a contraction were identified by the software as ‘disparate’ (i.e. never firing
simultaneously and thus suspected to stem from the same MU), one of these MUP trains
was excluded following confirmation based on visual inspection of their raster plots. The
onset, positive peak, negative peak, and end markers of the MUP templates and the
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negative onset, negative peak, and positive peak markers of the S-MUP templates were
checked visually and repositioned if necessary. Finally, the onsets of the MUP and SMUP templates were required to occur within 10 ms of each other in order for the
corresponding MUP train to be accepted. MUP templates consistent with cannula
potentials (inverted MUPs as a result of a larger contribution from the cannula than from
the core detection surface of the concentric needle electrode) were excluded, as they
express different information than typical MUPs.18 However, their corresponding SMUP templates from the same MUP train were retained for further analysis, as the ability
of cannula potentials to serve as an accurate triggering source for spike-triggered
averaging is not compromised.
Descriptive statistics for various parameters were calculated automatically based
on all accepted MUPs, S-MUPs, and MUP trains. Additionally, the mean S-MUP was
calculated by way of data point-by-data point averaging of all accepted S-MUPs, aligned
based on their onsets. Lastly, the MUNE was calculated automatically through division
of the negative peak amplitude of this mean S-MUP into the negative peak amplitude of
the maximum CMAP previously obtained.6
3.1.4 Intra-rater reliability
The experimental protocol and subsequent review of the data was performed
twice on the same day by the same evaluator (C.I.; rater 1) for each subject. This
evaluator was a new user of DE-STA MUNE and had been trained with regard to data
collection and analysis by an individual experienced with the technique (T.D.).
Following completion of the first test (data reported under rater 1a), all electrodes were
removed and, with a minimum of 15 min between sessions, a new set of electrodes was
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applied for the repeat test (data reported under rater 1b). The electrode positions were not
marked during the first assessment. Data analysis was completed only following
collection of both sets of data so that the evaluator was blinded to the results of both
assessments until data collection was complete.6, 12
3.1.5 Inter-rater reliability
At a separate time point (ranging from 15 min to 76 days before/after rater 1), a
different evaluator (T.D.; rater 2) performed the experimental protocol and subsequent
review of the data on the same subject tested by C.I. The electrode positions were not
marked during the first assessment. Data analysis was performed independently by each
evaluator, with the exception of the repositioning of markers for MUP templates, which
was performed by rater 1 for rater 1 and 2 data due to issues of time. Evaluators
remained blind to the results of the other evaluator until the completion of data collection
for a given subject.13
3.1.6 Statistics
Mean values along with their standard deviations and ranges are presented
throughout. Relative intra-rater reliability was assessed using a Model 3 (two-way
mixed, consistency) single measure intraclass correlation coefficient (ICC) [ICC (3,1)],
and relative inter-rater reliability using a Model 2 (two-way random, absolute agreement)
single measure ICC [ICC (2,1)] (IBM® SPSS® Statistics 19, SPSS, Inc., Chicago, IL).
ICC point estimates <0.50 were considered poor, 0.50-0.75 considered moderate, and
>0.75 considered good reliability.11 Also, ICC point estimates > 0.90 were classified as
excellent reliability. If the F-test associated with between-subjects variance from the ICC
output was not significant, the corresponding ICC value was deemed potentially
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inaccurate. This conclusion was made because between-subject heterogeneity is a
necessary condition for reliability testing, without which the actual limits of the ICC may
deviate from the theoretical limits of 0.00-1.00.11
To augment the ICC, a standard error of measurement (SEM) was calculated as a
measure of absolute intra- and inter-rater reliability for maximum CMAP, mean S-MUP,
and MUNE values (Equation 1).19
3.1.6.1 Equation 1
SEM = sd/√2
Where SEM, standard error of measurement; sd, standard deviation of difference scores
between the two tests.
Lastly, a two-tailed, paired t-test was used to test for systematic biases between
tests for each parameter, with an a priori alpha level of 0.05 used to denote significance
(IBM® SPSS® Statistics 19, SPSS, Inc., Chicago, IL).
3.2 RESULTS
3.2.1 Subjects
Ten subjects (5 males, 5 females) aged 51 ± 7 years (40-62 years) participated in
this study. These subjects had an average height of 167 ± 5 cm (158-175 cm), and weight
of 76.3 ± 13.6 kg (61.3-99.0 kg).
3.2.2 Data collection results and S-MUP frequency distributions
On average, 28 ± 7, 27 ± 5, and 23 ± 6 acceptable S-MUPs were obtained (from
38 ± 9, 37 ± 7, and 28 ± 7 MUP trains collected in total) for each subject from 6 ± 1, 6 ±
2, and 5 ± 1 contractions for rater 1a, 1b, and 2, respectively. Thus, on average, 5 ± 2
acceptable S-MUPs per contraction were collected by each evaluator. Mean MU
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identification rates (percentage of expected firings detected) based on the samples of
accepted MUP trains were 59.5 ± 7.3% (rater 1a), 58.5 ± 8.3% (rater 1b), and 64.0 ±
7.0% (rater 2). The frequency distributions of S-MUP negative peak amplitudes, as a
percentage of maximum CMAP negative peak amplitudes for rater 1a (0.47 ± 0.23 %
maximum CMAP [0.06-1.51 % maximum CMAP]), rater 1b (0.52 ± 0.32 % maximum
CMAP [0.01-1.92 % maximum CMAP]), and rater 2 (0.52 ± 0.27 % maximum CMAP
[0.03-1.31 % maximum CMAP]) are illustrated in Figure 3.1.
3.2.3 Maximum CMAP, mean S-MUP, and MUNE
3.2.3.1 Intra-rater reliability
Analysis using the ICC revealed good intra-rater reliability for maximum CMAP
(ICC = 0.77) and moderate reliability for MUNE (ICC = 0.69). Insufficient betweensubject heterogeneity for mean S-MUP values resulted in a potentially inaccurate ICC
value.11 The SEMs for maximum CMAP, mean S-MUP, and MUNE were 0.9 mV, 11
µV, and 70 MUs, respectively. Using a paired t-test, there were no significant
differences between tests for maximum CMAP t(9) = -0.40, p = 0.70 (-1.13, 0.79), mean
S-MUP t(9) = -0.82, p = 0.43 (-14.65, 6.85), or MUNE t(9) = 0.59, p = 0.57 (-52.47,
89.67) (Table 3.1).
3.2.3.2 Inter-rater reliability
Consistent with the intra-rater reliability results, inter-rater reliability was found
to be good for maximum CMAP (ICC = 0.79) and moderate for MUNE (ICC = 0.73).
The ICC value for mean S-MUP (ICC = 0.42) indicated poor inter-rater reliability. The
SEMs for maximum CMAP, mean S-MUP, and MUNE were 1.1 mV, 9 µV, and 41
MUs, respectively. Using a paired t-test, there was no significant difference between
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tests for maximum CMAP t(9) = -0.43, p = 0.68 (-1.38, 0.93), while significant
differences between rater 1a and 2 were found for mean S-MUP t(9) = -3.06, p < 0.05 (20.36, -3.04) and MUNE t(9) = 4.19, p < 0.01 (35.36, 118.40) (Table 3.1).
3.2.4 Motor unit potential parameters
3.2.4.1 Intra-rater reliability
Analysis using the ICC revealed the highest level of intra-rater reliability for
mean firing rate (ICC = 0.87). Good reliability was also found for area-to-amplitude ratio
(AAR) (ICC = 0.79), with moderate reliability found for duration (ICC = 0.68) and area
(ICC = 0.53). Insufficient between-subject heterogeneity for peak-to-peak voltage,
phases, and turns resulted in potentially inaccurate ICC values.11 Using a paired t-test,
there were no significant differences between tests for any of the MUP parameters (Table
3.2).
3.2.4.2 Inter-rater reliability
Analysis using the ICC revealed moderate reliability for MUP mean firing rate
(ICC = 0.74). Insufficient between-subject heterogeneity for each of the other MUP
parameters resulted in potentially inaccurate ICC values.11 Consistent with the paired ttest results for intra-rater reliability, there were no significant differences between rater
1a and 2 for any of the MUP parameters (Table 3.2).
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Figure 3.1 Frequency distributions of S-MUP data from all subjects for rater 1a (closed
bars) (281 S-MUPs), rater 1b (open bars) (273 S-MUPs), and rater 2 (checkered bars)
(225 S-MUPs). The negative peak amplitudes of the S-MUPs have been normalized to
the negative peak amplitude of the maximum CMAP measured by each rater for each
subject. The y-axis represents the percentage of the total number of S-MUPs per rater.
Abbreviations: CMAP, compound muscle action potential; S-MUP, surface-detected
motor unit potential
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Table 3.1 Intra- and inter-rater reliability of maximum CMAP, mean S-MUP, and MUNE
Parameter

Rater 1a

Rater 1b

Rater 2

Intra-rater
Inter-rater
(1a vs. 1b)
(1a vs. 2)
ICC
SEM ICC SEM
8.5 ± 2.1
8.6 ± 1.9
8.7 ± 2.7
0.77
0.9 0.79
1.1
Maximum CMAP
(4.7-13.1)
neg. peak amp. (mV) (6.1-12.9) (5.8-13.0)
27 ± 7
31 ± 13
38 ± 17* -0.01†
11 0.42
9
Mean S-MUP
(16-38)
(17-58)
(11-67)
neg. peak amp. (µV)
339 ± 121 320 ± 131 262 ± 115*
0.69
70 0.73
41
MUNE (MUs)
(172-586) (153-590)
(135-466)
Values expressed as mean ± SD. Data in parentheses indicate range.
*
Significantly different from rater 1a (p < 0.05).
†
Insufficient between-subject heterogeneity, resulting in a potentially inaccurate ICC value.
Abbreviations: CMAP, compound muscle action potential; ICC, intraclass correlation coefficient; MU, motor unit; MUNE, motor
unit number estimation; neg. peak amp., negative peak amplitude; SEM, standard error of measurement; S-MUP, surface-detected
motor unit potential.

66

Table 3.2 Intra- and inter-rater reliability of MUP parameters
Parameter

Rater 1a

Rater 1b

Rater 2

Intra-rater Inter-rater
(1a vs. 1b) (1a vs. 2)
ICC
ICC
†
373.2 ± 72.5
382.4 ± 106.7
384.3 ± 96.7
0.44
0.13†
Peak-to-peak
(264.6-504.5)
(259.0-592.0) (201.4-545.6)
voltage (µV)
13.3 ± 2.5
13.2 ± 2.6
13.8 ± 1.7
0.68
-0.13†
Duration (ms)
(8.6-17.4)
(9.7-16.9)
(10.6-16.9)
688.0 ± 204.6
701.3 ± 206.9 643.2 ± 126.7
0.53
0.21†
Area (µVms)
(490.1-1073.2) (411.9-1055.5) (356.6-774.0)
1.9 ± 0.4
1.9 ± 0.3
1.8 ± 0.2
0.79
0.19†
AAR (ms)
(1.3-2.7)
(1.4-2.5)
(1.5-2.1)
2.7 ± 0.4
2.7 ± 0.4
2.6 ± 0.3
0.09†
0.10†
Phases
(2.2-3.3)
(2.0-3.5)
(2.0-3.1)
3.2 ± 0.6
3.3 ± 0.6
3.2 ± 0.4
0.12†
0.10†
Turns
(2.6-4.2)
(2.6-4.6)
(2.6-3.6)
11.0 ± 1.1
10.9 ± 1.1
10.8 ± 1.1
0.87
0.74
Mean firing
(9.1-13.1)
(9.8-13.0)
(8.9-13.2)
rate (Hz)
Values expressed as mean ± SD. Data in parentheses indicate range.
†
Insufficient between-subject heterogeneity, resulting in a potentially inaccurate ICC value.
Abbreviations: AAR, area-to-amplitude ratio; ICC, intraclass correlation coefficient; MUP, motor unit potential.
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3.3 DISCUSSION
This study has established a set of normative data pertaining to the
electrophysiological properties of MUs and the size of the MU pool in the UT using DESTA MUNE. While anatomical estimates of the number of MUs in the UT could not be
located in the literature for comparative purposes, average MUNE values in this study
(Table 3.1) are similar to a preliminary study of DE-STA MUNE in the UT, which found
an average peak-to-peak amplitude MUNE of 270 ± 19 MUs for control subjects (n =
3).14 In the current study, a great degree of variability between subjects was found for
MUNE values, ranging, for example, from 172 to 586 MUs for rater 1a. This is
consistent with the considerable between-subject variability reported for MUNE values
obtained using DE-STA in other muscles such as the BB (159-547 MUs)20 and tibialis
anterior (68-214 MUs)13 in control subjects.
Frequency distributions of S-MUP data revealed size distributions characterized
by large proportions of small S-MUPs (Figure 3.1). These results are similar to previous
studies in control subjects, including an evaluation of DE-STA MUNE in various
muscles of the hand,6 and studies using other types of MUNE in various muscles
groups.21-23
In order for DE-STA MUNE applied to the UT to be useful as an outcome
measure in ALS clinical trials, it is critical that the results it generates are reliable. Based
on the ICC, maximum CMAP and MUNE demonstrated good and moderate levels of
reliability, respectively, both when collected by the same evaluator at two different time
points and by two different evaluators. However, poor reliability and a systematic bias
for mean S-MUP results were found in the inter-rater reliability portion of the study,
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which carried over into the MUNE inter-rater reliability results. These results reflect
systematic difference(s) between evaluators with respect to the performance of the data
collection and analysis protocol.
The CMAP reliability results demonstrate the limited training required in order
for a less experienced evaluator to produce not only consistent results, but results that are
consistent with those of a highly experienced evaluator. The ease with which a
maximum CMAP can be elicited from the UT reflects the accessibility of its nerve
supply, and lies in contrast to the relative difficulty in obtaining a maximum CMAP from
more commonly studied muscles such as the BB.14
Variability in mean S-MUP results may stem from any of the numerous factors
involved in data collection (e.g. surface and needle electrode positions, contractile levels)
and analysis (e.g. inclusion/exclusion of S-MUPs, manual adjustment of markers) which
influence the sample of S-MUPs ultimately used to derive the mean. While variability
from test to test is inherent in the process of sampling, undesirably high levels may result
from failure to collect a representative sample of S-MUPs and point to opportunities to
better control for differences in the collection of S-MUPs. The ability to sample a wide
range and subsequently representative subset of S-MUPs may have been particularly
difficult in the UT muscle, given its depth and relatively large surface area. Rarely, less
than 20 acceptable S-MUPs were able to be collected for a given data collection session.
However, this was not clearly associated with higher levels of S-MUP variability.
Variability between tests may also result from inconsistent contractile levels
which, in a way, alter the pool from which S-MUPs are being sampled. Owing to the size
principle of MU recruitment,24 contraction intensity has been shown to influence the size
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of the S-MUPs sampled, and subsequently the mean S-MUP.16, 25 The importance of
contraction intensity may be magnified in a large, proximal muscle such as the UT, given
its likely reliance on recruitment over rate coding.26 While the protocol attempted to
control for levels of voluntary contraction, the calculation of referential MVC-RMS
values was unaided by a dynamometer for this proximal muscle. The use of such an
instrument may have decreased the variability in the results. It may also be useful in the
future to carefully instruct the subject to maintain a consistent arm/shoulder position in
order to ensure a contraction strategy throughout the series of sub-maximal contractions
that is comparable to their initial contraction used to calculate the MVC-RMS. Despite
any variability associated with the mean S-MUP results, MUNE, which is the primary
parameter of interest, demonstrated favorable levels of reliability.
As mentioned, the use of DE-STA MUNE offers the advantage over other
methods of MUNE of not only being able to study proximal muscles, but of the
performance of quantitative MUP analysis. Analysis of the reliability of the MUP
parameter values found high ICCs for mean firing rate (particularly for intra-rater
reliability). The limited between-subject heterogeneity found for many of the other
quantitative MUP parameters (resulting in artificially low and sometimes negative ICC
values) is likely an inherent property of these parameters, as similar results have been
encountered in reliability studies involving quantitative MUP data obtained using
DQEMG in other muscles in control subjects.13, 27
A potential limitation of this research was the inconsistent interval of time
separating inter-rater reliability tests. However, as this research involved control
subjects, it is unlikely that any important changes in MU numbers took place between
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tests. In addition, the current study was limited by a small sample size. However, the
majority of previous reliability studies utilizing DE-STA MUNE have also used 10 or
fewer subjects.12, 13
This study has been the first to establish normative data and assess the intra- and
inter-rater reliability of DE-STA MUNE and quantitative MUP analysis in the UT, which
may be a highly relevant muscle to study in patients with ALS. Thus, building on the
present study of control subjects, it is necessary to examine the intra-rater reliability of
the technique in this muscle group in subjects with ALS. Together, these studies are
essential to establishing DE-STA MUNE’s potential utility as an outcome measure for
use in ALS clinical trials.
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CHAPTER 4
EVALUATION OF DECOMPOSITION-ENHANCED SPIKE-TRIGGERED
AVERAGING MOTOR UNIT NUMBER ESTIMATION IN SUBJECTS WITH
AMYOTROPHIC LATERAL SCLEROSIS2
4.0 INTRODUCTION
The degeneration of lower motor neurons (LMNs) associated with amyotrophic
lateral sclerosis (ALS) results in denervation of skeletal muscle fibers and a
corresponding decline in the number of functioning motor units (MUs) within a given
muscle. Collateral reinnervation is eventually outpaced by MU loss, leading to
progressive muscle atrophy and weakness.1 Outcome measures assessing function and
muscle strength are used in ALS clinical trials commonly, but are influenced by collateral
reinnervation. In contrast, motor unit number estimation (MUNE) is able to detect the
underlying progression of the disease, and may thus be useful as an outcome measure in
ALS clinical trials.2, 3
As previously described, decomposition-enhanced spike-triggered averaging (DESTA) MUNE carries a number of advantages over other MUNE techniques, making it
valuable to evaluate further regarding its utility as an outcome measure (Chapter 1, 3). A
key advantage of DE-STA MUNE is that it can be applied to the study of proximal
muscles.4 One such muscle, the upper trapezius (UT) may be particularly relevant to
study in subjects with ALS, given its role as an accessory muscle of respiration.5 In
addition to the UT, the current study examined the biceps brachii (BB). Application of
the technique to multiple muscles representing different sources of innervation is relevant
2

A version of this chapter has been submitted for publication.
Ives CT, Doherty TJ. Intra-rater reliability of motor unit number estimation and quantitative motor
unit analysis in subjects with amyotrophic lateral sclerosis. Clin Neurophysiol; May, 2012.
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given the highly variable distribution and progression of muscle involvement associated
with the disease.2
In order for a measurement technique to be useful, its results must be reproducible
in the hands of the same evaluator at two or more points in time (intra-rater reliability).6
Among other muscle groups, the intra-rater reliability of DE-STA MUNE has been
studied in the BB7 and UT (Chapter 3) in control subjects. However, despite being
applied to the study of subjects with ALS in the BB,8-10 and to a single subject in the
UT,11 the intra-rater reliability of DE-STA MUNE has yet to be examined in these or any
other muscle groups in this patient population.
In addition to reliability, a critical property of any outcome measure is its validity.
In the absence of a gold standard technique, or normative anatomical data with which to
compare the results of DE-STA MUNE, the ability of the technique to detect the
underlying pathophysiology of the disease can be evaluated by comparing the results
between subjects with ALS and control subjects, as was done previously in the BB and
first dorsal interosseous.8
Thus, the objectives of this study were twofold. First, to assess the intra-rater
reliability of DE-STA MUNE and quantitative motor unit potential (MUP) analysis in the
UT and BB of subjects with ALS. Second, to compare the results of DE-STA MUNE
and quantitative MUP analysis in the UT of subjects with ALS to data obtained
previously in control subjects in the same muscle (Chapter 3).
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4.1 METHODS
4.1.1 Subjects
In total, 14 patients diagnosed with clinically probable or definite ALS as defined
by the revised El Escorial criteria12 were recruited from the Motor Neuron Diseases
Clinic at University Hospital, London Health Sciences Centre to participate in this study.
Patients were included if they were between the ages of 18-90, were within 10 years of
symptom onset, and were judged as having sufficient upper extremity (UE) strength to
perform the degree of scapular elevation and/or elbow flexion required for the MUNE
protocol. Patients were excluded if they had evidence of other neuromuscular or
musculoskeletal disease.
Each subject completed testing in one or both of the muscles of interest, with 10
subjects participating in the UT portion of the study and 9 subjects participating in the
BB portion of the study. All subjects gave written, informed consent in accordance with
The University of Western Ontario Health Sciences Research Ethics Board, which
approved this study.
4.1.2 Electromyographic data collection and analysis
Electromyographic (EMG) signals were acquired using decomposition-based
quantitative electromyography (DQEMG) (version 3.2) and Acquire EMG software on a
Neuroscan Comperio (Neuroscan Medical Systems, El Paso, TX). Self-adhering Silver
Mactrode® electrodes (GE Medical Systems, Milwaukee, WI) were used to detect surface
signals, and 25 mm x 30 gauge TECA™ elite Disposable Concentric Needle Electrodes
(CareFusion, Middleton, WI) were used to detect intramuscular signals, with bandpass
settings of 5 Hz to 5 kHz and 10 Hz to 10 kHz, respectively.13, 14
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Testing was conducted unilaterally on the arm identified by the subject as having
less weakness. If the patient was unable to determine which arm was stronger, the right
arm was selected. For the UT, subjects were seated upright in a straight back chair or
wheelchair, and for the BB, subjects were supine on an examination table or, if this was
not tolerated, positioned in a semi-reclined or seated position. For the BB, the arm being
tested was supported in partial abduction with the forearm supinated.
Surface electrodes were cut in strips (1 cm x 3.5 cm) for use as the active and
reference electrodes, with a full-sized electrode serving as a ground. For both muscle
groups, the skin was cleansed with isopropyl alcohol and surface electrodes positioned
appropriately. For the UT, the active electrode was positioned transversely over the belly
of the muscle, approximately midway between the acromion process and C7 spinous
process, with the reference electrode placed over the acromion process, and the ground
electrode over the deltoid.11 For the BB, the active electrode was again positioned
transversely over the belly of the muscle, with the reference electrode placed over the
tendon at the elbow and the ground electrode over the forearm just distal to the elbow
crease.7
A handheld bipolar stimulator was used in order to elicit a maximum compound
muscle action potential (CMAP), with the spinal accessory nerve stimulated posterior to
the sternocleidomastoid for the UT11 and the musculocutaneous nerve stimulated at the
axilla for the BB.7, 8 If necessary, the active electrode was moved in small increments to
a position where the CMAP negative peak amplitude was maximized and the rise time
minimized. Following optimal positioning of the active electrode, the surface electrode
positions were reinforced with surgical tape to ensure that no movement occurred during
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the study. Gradually, the stimulation intensity was increased until the CMAP negative
peak amplitude reached a plateau. Automatically positioned markers indicating onset,
negative peak, positive peak, and end of the maximum CMAP were reviewed and
manually adjusted if necessary. Subsequently, size-related parameters of the maximum
CMAP including negative peak amplitude were calculated automatically.
Subjects then performed a 3-4 s voluntary contraction by way of scapular
elevation (UT) or elbow flexion (BB) against resistance provided by the evaluator.
Subjects were encouraged to produce their maximal effort, and visual and auditory
feedback was provided by the surface EMG signal. The maximal root mean square value
of the EMG signal over a 1 s interval was calculated automatically and the intensity of
subsequent sub-maximal contractions was described as a percentage of this maximal
voluntary contraction-root mean square (% MVC-RMS).
Next, the concentric needle electrode was inserted into the UT or BB,
approximately 2-10 mm proximal or distal to the active surface electrode. Subjects were
asked to perform minimal isometric contractions while an optimal needle position was
located that minimized the rise times of the MUPs of the first two to three recruited MUs.
With the needle manually maintained in this position by the evaluator, the subject was
instructed to increase the contraction force to approximately 10-20% of the MVC-RMS.
Each sub-maximal isometric contraction was maintained for 30 s, during which the
subject received visual and auditory feedback from the EMG signal and % MVC-RMS
information displayed on the screen to assist in the maintenance of a stable contraction.
Contractions were performed until a minimum of 20 MUP trains were collected, with
each contraction separated by a rest period of approximately 30-60 s or as required by the
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subject. The needle position was adjusted between contractions to collect data from
different portions of the muscle, and, if necessary, inserted at a new site to complete the
collection of MUP trains.13, 14
Following EMG signal decomposition and the review of the acceptability of
acquired MUPs, surface-detected motor unit potentials (S-MUPs), and MUP trains, as has
been previously described (Chapters 1, 3), the onset, positive peak, negative peak, and
end markers of the MUP templates and the negative onset, negative peak, and positive
peak markers of the S-MUP templates were checked visually and repositioned if
necessary.
Descriptive statistics for various parameters were calculated automatically based
on all accepted MUPs, S-MUPs, and MUP trains. Additionally, the mean S-MUP was
calculated by way of data point-by-data point averaging of all accepted S-MUPs, aligned
based on their onsets. Lastly, the MUNE was calculated automatically through division
of the negative peak amplitude of this mean S-MUP into the negative peak amplitude of
the maximum CMAP previously obtained.13
4.1.3 Intra-rater reliability
The experimental protocol and subsequent review of the data was performed
twice by the same evaluator (C.I.) for each subject. Tests took place on the same day for
each subject, with the exception of a single subject, for whom the tests were performed
on consecutive days. Following completion of the first test (data reported under rater 1a),
all electrodes were removed and, with a minimum of 15 min between sessions, a new set
of electrodes was applied for the repeat test (data reported under rater 1b). The electrode
positions were not marked during the first assessment. Data analysis was completed only
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following collection of both sets of data so that the evaluator was blinded to the results of
both assessments until data collection was complete.7, 13
4.1.4 Statistics
Mean values along with their standard deviations and ranges are presented
throughout. Relative intra-rater reliability was assessed using a Model 3 (two-way
mixed, consistency) single measure intraclass correlation coefficient (ICC) [ICC (3,1)]
(IBM® SPSS® Statistics 19, SPSS, Inc., Chicago, IL). ICC point estimates <0.50 were
considered poor, 0.50-0.75 considered moderate, and >0.75 considered good reliability.6
Also, ICC point estimates > 0.90 were classified as excellent reliability. If the F-test
associated with between-subjects variance from the ICC output was not significant, the
corresponding ICC value was deemed potentially inaccurate. This conclusion was made
because between-subject heterogeneity is a necessary condition for reliability testing,
without which the actual limits of the ICC may deviate from the theoretical limits of
0.00-1.00.6
To augment the ICC, a standard error of measurement (SEM) was calculated as a
measure of absolute intra-rater reliability for maximum CMAP, mean S-MUP, and
MUNE values (Equation 1).15
4.1.4.1 Equation 1
SEM = sd/√2
Where SEM, standard error of measurement; sd, standard deviation of difference scores
between the two tests.
From the SEM, a margin of error (me) was calculated for MUNE based on a 95%
confidence level using Equation 2.
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4.1.4.2 Equation 2
me = 1.96 * SEM
Where me, margin of error; SEM, standard error of measurement.
Additionally, a minimal detectable difference (MDD) was calculated for MUNE
as an index of the smallest amount of change that can be considered to be above the
threshold of measurement error (Equation 3).6
4.1.4.3 Equation 3
MDD95 = 1.96 * SEM * √2
Where MDD95, minimal detectable difference based on a 95% confidence level; SEM,
standard error of measurement.
A two-tailed, paired t-test was used to test for systematic biases between tests for
each parameter, with an a priori alpha level of 0.05 used to denote significance (IBM®
SPSS® Statistics 19, SPSS, Inc., Chicago, IL).
Rater 1a parameter values from the UT were compared with rater 1a values from
a study of control subjects (Chapter 3) using two-tailed, unpaired t-tests, with an a priori
alpha level of 0.05 used to denote significance (IBM® SPSS® Statistics 19, SPSS, Inc.,
Chicago, IL). As the purposes of this study were exploratory in nature, Bonferroni
adjustments were not applied.
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4.2 RESULTS
4.2.1 Subjects
A summary of subject demographic and clinical characteristics is found in Table
4.1.
4.2.2 Data collection results and S-MUP frequency distributions
4.2.2.1 Upper trapezius
On average, 18 ± 5 and 16 ± 5 acceptable S-MUPs were obtained (from 33 ± 13
and 30 ± 13 MUP trains collected in total) for each subject from the first test (rater 1a)
and second test (rater 1b), respectively. For both tests, these S-MUPs were obtained from
6 ± 2 contractions. Thus, on average, 4 ± 2 and 3 ± 2 acceptable S-MUPs per contraction
were collected for rater 1a and 1b, respectively. The mean MU identification rate
(percentage of expected firings detected) based on the sample of accepted MUP trains
was 61 ± 10% for both tests. The frequency distributions of UT S-MUP negative peak
amplitudes, as a percentage of maximum CMAP negative peak amplitudes from rater 1a
(1.36 ± 1.59 % maximum CMAP [0.13-8.10 % maximum CMAP]) and rater 1b (0.99 ±
1.14 % maximum CMAP [0.08-6.18 % maximum CMAP]) are illustrated in Figure 4.1A.
4.2.2.2 Biceps brachii
On average, 13 ± 7 acceptable S-MUPs were obtained for both tests (from 34 ± 12
and 33 ± 16 MUP trains collected in total from the first test [rater 1a] and second test
[rater 1b], respectively) for each subject. The S-MUPs were obtained from 5 ± 2 and 6 ±
1 contractions for rater 1a and 1b, respectively. Thus, on average, 3 ± 2 acceptable SMUPs per contraction were collected for both tests. The mean MU identification rates
(percentage of expected firings detected) based on the samples of accepted MUP trains
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were 63 ± 12% and 59 ± 13% for rater 1a and 1b, respectively. The frequency
distributions of BB S-MUP negative peak amplitudes, as a percentage of maximum
CMAP negative peak amplitudes from rater 1a (2.29 ± 3.80 % maximum CMAP [0.2121.24 % maximum CMAP]), and rater 1b (2.10 ± 4.57 % maximum CMAP [0.14-26.33
% maximum CMAP]) are illustrated in Figure 4.1B.
4.2.3 Intra-rater reliability of maximum CMAP, mean S-MUP, and MUNE
4.2.3.1 Upper trapezius
Analysis using the ICC revealed good intra-rater reliability for maximum CMAP
(ICC = 0.88), mean S-MUP (ICC = 0.87), and MUNE (ICC = 0.88). The SEMs for
maximum CMAP, mean S-MUP, and MUNE were 0.7 mV, 19 µV, and 40 MUs,
respectively. For MUNE, the margin of error was ±79 MUs, and the MDD95 was 111
MUs. Using a paired t-test, there were no significant differences between tests for
maximum CMAP t(9) = -1.29, p = 0.23 (-1.16, 0.32) or mean S-MUP t(9) = 1.19, p =
0.26 (-8.87, 28.67), while a significant difference between tests was found for MUNE t(9)
= -2.83, p < 0.05 (-91.03, -10.17) (Table 4.2).
4.2.3.2 Biceps brachii
Analysis using the ICC revealed moderate intra-rater reliability for maximum
CMAP (ICC = 0.61), and excellent intra-rater reliability for mean S-MUP (ICC = 0.94),
and MUNE (ICC = 0.93). The SEMs for maximum CMAP, mean S-MUP, and MUNE
were 1.0 mV, 26 µV, and 30 MUs, respectively. For MUNE, the margin of error was ±
59 MUs, and the MDD95 was 83 MUs. Using a paired t-test, there were no significant
differences between tests for maximum CMAP t(8) = 1.29, p = 0.23 (-0.48, 1.71), mean
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S-MUP t(8) = 1.33, p = 0.22 (-12.17, 45.06) or MUNE t(8) = -1.11, p = 0.30 (-47.96,
16.85) (Table 4.3).
4.2.4 Intra-rater reliability of motor unit potential parameters
4.2.4.1 Upper trapezius
Analysis using the ICC revealed excellent levels of intra-rater reliability for area
(ICC = 0.96), and good levels for peak-to-peak voltage (ICC = 0.86), mean firing rate
(ICC = 0.84), duration (ICC = 0.81), and area-to-amplitude ratio (AAR) (ICC = 0.79).
Insufficient between-subject heterogeneity for phases and turns resulted in potentially
inaccurate ICC values.6 Using a paired t-test, there was a significant difference between
tests for phases (p = 0.04) (Table 4.4).
4.2.4.2 Biceps brachii
Analysis using the ICC revealed excellent levels of intra-rater reliability for mean
firing rate (ICC = 0.93), good intra-rater reliability for duration (ICC = 0.87), AAR (ICC
= 0.86), area (ICC = 0.80), and peak-to-peak voltage (ICC = 0.79), and moderate intrarater reliability for turns (ICC = 0.70). Insufficient between-subject heterogeneity for
phases resulted in a potentially inaccurate ICC value.6 Using a paired t-test, there were
no significant differences between tests for any of the parameters (Table 4.5).
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Table 4.1 Subject demographics and clinical summary
Variable
Age (years)
Sex
Height (cm)
Weight (kg)
Time from symptom
onset (months)
Area of onset

All subjects
(n = 14)
59 ± 11 (41-77)
5 male, 9 female
166 ± 10 (151-185)
70.9 ± 15.6
(37.5-108.0)
27 ± 14 (12-61)

UT subjects
(n = 10)
59 ± 11 (41-75)
3 male, 7 female
164 ± 10 (151-178)
71.1 ± 17.5
(37.5-108.0)
28 ± 15 (12-61)

BB subjects
(n = 9)
60 ± 13 (41-77)
4 male, 5 female
168 ± 10 (155-185)
71.4 ± 8.2
(54.4-81.9)
25 ± 11 (12-41)

2 bulbar, 12 limb
2 bulbar, 8 limb
1 bulbar, 8 limb
(11 UE, 1 LE)
(7 UE, 1 LE)
(7 UE, 1 LE)
13 sALS, 1 fALS
9 sALS, 1 fALS
9 sALS
ALS classification
2 left, 8 right
2 left, 7 right
Side of muscle testing 3 left, 11 right
Values expressed as mean ± SD. Data in parentheses indicate range.
Abbreviations: ALS, amyotrophic lateral sclerosis; BB, biceps brachii; fALS, familial
amyotrophic lateral sclerosis; LE, lower extremity; sALS, sporadic amyotrophic lateral
sclerosis; UE, upper extremity; UT, upper trapezius.
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Table 4.2 Intra-rater reliability of maximum CMAP, mean S-MUP, and MUNE in the
upper trapezius
Parameter
Rater 1a Rater 1b
ICC SEM
5.9 ± 1.7
6.4 ± 2.5 0.88
0.7
Maximum CMAP
neg. peak amp. (mV) (3.1-8.2) (2.8-10.0)
63 ± 54
53 ± 49 0.87
19
Mean S-MUP
(18-145)
neg. peak amp. (µV) (19-200)
145 ± 91 196 ± 131* 0.88
40
MUNE (MUs)
(27-294)
(37-373)
Values expressed as mean ± SD. Data in parentheses indicate range.
*
Significantly different from rater 1a (p < 0.05).
Abbreviations: CMAP, compound muscle action potential; ICC, intraclass correlation
coefficient; MU, motor unit; MUNE, motor unit number estimation; neg. peak amp.,
negative peak amplitude; SEM, standard error of measurement; S-MUP, surface-detected
motor unit potential
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Table 4.3 Intra-rater reliability of maximum CMAP, mean S-MUP, and MUNE in the
biceps brachii
Parameter
Rater 1a Rater 1b ICC SEM
4.9 ± 1.7 4.3 ± 1.5 0.61
1.0
Maximum CMAP
neg. peak amp. (mV) (2.9-8.7) (2.6-7.3)
104 ± 125
88 ± 97 0.94
26
Mean S-MUP
(11-417) (12-321)
neg. peak amp. (µV)
115 ± 104 130 ± 122 0.93
30
MUNE (MUs)
(12-319)
(8-324)
Values expressed as mean ± SD. Data in parentheses indicate range.
Abbreviations: CMAP, compound muscle action potential; ICC, intraclass correlation
coefficient; MU, motor unit; MUNE, motor unit number estimation; neg. peak amp.,
negative peak amplitude; SEM, standard error of measurement; S-MUP, surface-detected
motor unit potential
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Table 4.4 Intra-rater reliability of MUP parameters in the upper trapezius
Parameter
Rater 1a
Rater 1b
ICC
628.3 ± 346.6
610.5 ± 439.3
0.86
Peak-to-peak voltage (µV)
(291.1-1466.2) (304.3-1755.9)
16.7 ± 3.2
16.6 ± 4.3
0.81
Duration (ms)
(13.0-23.7)
(11.8-25.3)
1505.6 ± 1229.4 1385.1 ± 1304.8
0.96
Area (µVms)
(610.0-4648.3) (508.7-4760.4)
2.3 ± 0.6
2.2 ± 0.5
0.79
AAR (ms)
(1.6-3.4)
(1.6-3.1)
2.6 ± 0.4
3.0 ± 0.4* 0.13†
Phases
(1.9-3.0)
(2.4-3.8)
3.4 ± 1.0
3.5 ± 0.7 -0.23†
Turns
(2.0-5.6)
(2.8-5.1)
11.5 ± 2.3
11.1 ± 2.2
0.84
Mean firing rate (Hz)
(7.4-14.9)
(6.9-15.4)
Values expressed as mean ± SD. Data in parentheses indicate range.
*
Significantly different from rater 1a (p < 0.05).
†
Insufficient between-subject heterogeneity, resulting in a potentially inaccurate ICC
value.
Abbreviations: AAR, area-to-amplitude ratio; ICC, intraclass correlation coefficient;
MUP, motor unit potential.
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Table 4.5 Intra-rater reliability of MUP parameters in the biceps brachii
Parameter
Rater 1a
Rater 1b
ICC
765.0 ± 342.2
897.4 ± 558.5 0.79
Peak-to-peak voltage (µV)
(429.8-1446.8) (403.5-2221.0)
20.1 ± 7.1
22.5 ± 8.6 0.87
Duration (ms)
(9.2-34.5)
(12.3-38.5)
2272.6 ± 1788.0 3095.5 ± 3327.3 0.80
Area (µVms)
(687.2-6577.6) (808.8-11503.5)
2.7 ± 0.9
3.1 ± 1.2 0.86
AAR (ms)
(1.6-4.7)
(1.7-5.9)
2.8 ± 0.5
2.8 ± 0.4 0.28†
Phases
(2.0-3.5)
(2.0-3.4)
4.0 ± 1.3
3.9 ± 1.2 0.70
Turns
(2.0-6.1)
(2.0-5.6)
14.2 ± 5.1
14.9 ± 6.9 0.93
Mean firing rate (Hz)
(9.2-24.1)
(8.7-26.8)
Values expressed as mean ± SD. Data in parentheses indicate range.
†
Insufficient between-subject heterogeneity, resulting in a potentially inaccurate ICC
value.
Abbreviations: AAR, area-to-amplitude ratio; ICC, intraclass correlation coefficient;
MUP, motor unit potential.

90
4.2.5 Comparison of upper trapezius data between ALS and control subjects
Figure 4.1C depicts a comparison of frequency distributions of S-MUP negative
peak amplitudes, as a percentage of maximum CMAP negative peak amplitudes in the
UT between rater 1a in subjects with ALS (1.36 ± 1.59 % maximum CMAP [0.13-8.10 %
maximum CMAP]) and control subjects (data previously reported in Chapter 3) (0.47 ±
0.23 % maximum CMAP [0.06-1.51 % maximum CMAP]).
Comparison of UT data from subjects with ALS in the present study to control
subjects (5 females, 5 males) from a previous study of similar ages, ranging from 40-62
years (51 ± 7 years) (Chapter 3) found significant differences between groups for
maximum CMAP, mean S-MUP and MUNE values. Maximum CMAP values were
significantly lower in subjects with ALS (5.9 ± 1.7 mV [3.1-8.2 mV]) compared to
control subjects (8.5 ± 2.1 mV [6.1-12.9 mV]) t(18) = 3.00, p < 0.01 (0.75, 4.27), while
mean S-MUP values were significantly greater in the ALS group (63 ± 54 µV [19-200
µV]) compared to the control group (27 ± 7 µV [16-38 µV]) t(18) = -2.12, p < 0.05 (72.72, -0.28), and MUNE values were significantly lower in the ALS group (145 ± 91
MUs [27-294 MUs]) compared to the control group (339 ± 121 MUs [172-586 MUs])
t(18) = 4.05, p < 0.001 (93.19, 294.0) (Figure 4.2).
Comparison of MUP parameters between groups found significantly greater peakto-peak voltage (628.3 ± 346.6 µV [291.1-1466.2 µV] ALS; 373.2 ± 72.5 µV [264.6504.5 µV] control) (p = 0.035) and longer duration (16.7 ± 3.2 ms [13.0-23.7 ms] ALS;
13.3 ± 2.5 ms [8.6-17.4 ms] control) (p = 0.017) values for subjects with ALS. Although
not statistically significant, a trend was found in the direction of larger area (1505.6 ±
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1229.4 µVms [610.0-4648.3 µVms] ALS; 688.0 ± 204.6 µVms [490.1-1073.2 µVms]
control) (p = 0.053) for subjects with ALS.
AAR (2.3 ± 0.6 ms [1.6-3.4 ms] ALS; 1.9 ± 0.4 ms [1.3-2.7 ms] control), phases
(2.6 ± 0.4 [1.9-3.0] ALS; 2.7 ± 0.4 [2.2-3.3] control), turns (3.4 ± 1.0 [2.0-5.6] ALS; 3.2
± 0.6 [2.6-4.2] control), and mean firing rate (11.5 ± 2.3 Hz [7.4-14.9 Hz] ALS; 11.0 ±1.1
Hz [9.1-13.1 Hz] control) were not significantly different between groups.
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Figure 4.1 Frequency distributions of S-MUP data from all subjects for rater 1a (closed
bars) (183 S-MUPs) and rater 1b (open bars) (161 S-MUPs) for the UT (A) , for rater 1a
(closed bars) (120 S-MUPs) and rater 1b (open bars) (119 S-MUPs) for the BB (B), and
comparing rater 1a data from the UT between subjects with ALS (closed bars) (183 SMUPs) and control subjects (open bars) (281 S-MUPs) (data previously reported in
Chapter 3) (C). The negative peak amplitudes of the S-MUPs have been normalized to
the negative peak amplitude of the maximum CMAP for each subject. The y-axis
represents the percentage of the total number of S-MUPs per subject group.
Abbreviations: ALS, amyotrophic lateral sclerosis; BB, biceps brachii; CMAP,
compound muscle action potential; S-MUP, surface-detected motor unit potential; UT,
upper trapezius.
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Figure 4.2 Comparison of rater 1a data from the UT between control subjects from a
previous study (Chapter 3) and subjects with ALS in the present study. * indicates a
significant difference between groups. Maximum CMAP (p < 0.01) (A), mean S-MUP
(p < 0.05) (B), and MUNE (p < 0.001) (C). Note: Removing the 200 µV mean S-MUP
value from the ALS group, the significant difference is retained (p < 0.05) (B).
Abbreviations: ALS, amyotrophic lateral sclerosis; CMAP, compound muscle action
potential; MU, motor unit; MUNE, motor unit number estimation; neg. peak amp.,
negative peak amplitude; S-MUP, surface-detected motor unit potential; UT, upper
trapezius.
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4.3 DISCUSSION
This is the first study to assess the reliability of DE-STA MUNE and quantitative
MUP analysis in subjects with ALS. The results demonstrated the ability of the
technique to collect highly reliable data in two separate muscle groups. This study also
established the technique’s ability to detect the underlying pathophysiology of the disease
in a potentially clinically relevant muscle group not previously studied using MUNE.
4.3.1 Data collection and S-MUP frequency distributions
On average, less than the target of 20 acceptable S-MUPs for each subject were
collected for both muscle groups, reflective of the more challenging nature of the data
collection protocol as applied to subjects with ALS. The collection of fewer acceptable
S-MUPs was likely due in large part to the difficulty experienced by some subjects in
maintaining a series of sub-maximal contractions at consistent contraction intensities,
resulting in some cases in MUP trains with inconsistent firing patterns that did not meet
the inclusion criteria. Unfortunately, the performance of additional contractions in order
to obtain at least 20 acceptable S-MUPs was sometimes limited in this patient population
due to the energy expended for each contraction, and the underlying weakness and
fatigue associated with the disease. Nevertheless, the collection of less than 20
acceptable S-MUPs did not appear to influence the results greatly, as evidenced by the
high levels of reliability found for mean S-MUP and MUNE values in both muscle
groups. Despite the sampling of a smaller absolute number of S-MUPs, the MU loss
associated with the disease would have often resulted in the collection of S-MUPs from a
larger proportion of the total population of MUs, preserving the representativeness of the
sample.
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S-MUP frequency distributions were unimodal and positively skewed for both the
UT and BB data (Figures 4.1A, 4.1B). These distributions were similar between muscle
groups, with the exception of the finding that a number of S-MUPs collected from the BB
of a single subject were between 17.6% and 26.3% of the size of the maximum CMAP.
While enlarged S-MUPs are reflective of collateral reinnervation, none of the other SMUPs collected from either muscle group exceeded 9% of the size of the maximum
CMAP, indicating a unique degree of compensation in response to LMN degeneration for
the MUs of this one particular subject.
4.3.2 Intra-rater reliability
4.3.2.1 Upper trapezius
The levels of intra-rater reliability based on the ICC for UT MUNE and the
components of its equation were higher than results from a study of the technique in the
same muscle group performed in control subjects (Chapter 3). Similarly, the levels of
intra-rater reliability of each of the MUP parameters (all either good or excellent) were at
greater levels than the results from the study in control subjects (with the exception of
AAR and mean FR, which remained at similar levels) (Chapter 3). Similar findings of
enhanced reliability in subjects with ALS compared to control subjects have been
reported for other MUNE techniques in various muscle groups16, 17 and are likely as a
result of the smaller MU pool under study in these subjects. As mentioned previously,
the ability to collect a representative, and thus, reliable sample of MUPs and associated
S-MUPs is likely enhanced given that it is possible to collect potentials from a larger
proportion of the total number of MUs.17 Additionally, any wasting of the UT associated
with the disease process may have facilitated the sampling of a representative group of
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MUPs and associated S-MUPs from various positions in the muscle with the concentric
needle electrode, further enhancing the reliability of the technique.
An additional contributor to the higher ICCs found for subjects with ALS is likely
the positive impact that between-subject heterogeneity has on the coefficient.6 This was
especially apparent for mean S-MUP and peak-to-peak voltage values, for which accurate
ICCs could not be calculated for control subjects as a result of insufficient betweensubject heterogeneity (Chapter 3). Conversely, good levels of reliability were found for
the same parameters in subjects with ALS, for whom the heterogeneity was much greater.
Consistent with the previous study in control subjects (Chapter 3), insufficient
between-subject heterogeneity was found for the number of phases and turns for MUPs
from the UT, (also the case for phases for the BB), calling into question the validity of
the ICC values. This may be indicative of the between-subject homogeneity of these
indices of MUP complexity across health and disease.
Unlike the ICC, the SEM is unaffected by the heterogeneity of the data, and
serves as a measure of the amount of variation expected if one subject was tested
numerous times at a single testing session.15, 18 Based on the SEM and a 95% confidence
level, it was calculated that a subject’s observed MUNE could vary ± 79 MUs as a result
of measurement error. It follows that in constructing a confidence interval, we would be
95% confident that a subject with an observed MUNE of 200 MUs had a true value
between 121 MUs and 279 MUs.6 Similar estimations can be calculated for maximum
CMAP and mean S-MUP values based on their SEMs. The calculated MDD95 represents
the amount of change in MUNE that would be considered to represent a true change
between testing sessions, above and beyond measurement error, for 95% of patients with
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characteristics similar to those in the present study. The results found that a change ≥
111 MUs for the UT would be considered to exceed the threshold of measurement error.
Requiring such a threshold to detect change may hinder the technique in its ability to
follow progression in clinical trials and natural history studies of subjects with ALS.
However, it should be noted that a conservative 95% confidence level was chosen for the
calculation. For example, using an MDD80 (which would still apply to 80% of patients
with characteristics similar to those in the present study), a difference of 73 MUs would
be considered a true change. It should also be noted that, in general, the MDD is a very
conservative measure of change.6
Lastly, while significant differences were not found between tests for the
components of the MUNE equation, their dividend (MUNE) was found to be
significantly higher for rater 1b than for rater 1a (Table 4.2). Nevertheless, the 95%
confidence interval for the mean difference (-91.03, -10.17 MUs) encompassed values
that were less than the calculated MDD95 (111 MUs), and the other reliability statistics
calculated for MUNE and each of its components demonstrated the strong reliability of
the technique in this muscle group in subjects with ALS. Furthermore, no significant
differences were found between tests for any of these three parameters in a previous
study in this muscle group in control subjects (Chapter 3), nor in the present study in the
BB in subjects with ALS. The significant difference between tests for MUNE values
may have been avoided had the technique been examined with a larger sample size.
4.3.2.2 Biceps brachii
ICC levels representative of excellent intra-rater reliability were calculated for
mean S-MUP and MUNE for application of the technique to the BB (Table 4.3).

98
However, only moderate levels of reliability were found for maximum CMAP, likely
attributable in large part to the challenges associated with stimulation of the
musculocutaneous nerve. The relatively deep position of this nerve, in conjunction with
its close proximity at the axilla to the median and ulnar nerves made its isolated
stimulation difficult; issues which have been raised previously in the study of this muscle
group.11, 19, 20 While steps were taken to avoid activation of these nearby nerves, any
enduring volume conduction from their associated muscle groups would have certainly
impacted the reliability of the results. In addition, the high stimulation intensity and
repeated attempts required to activate the musculocutaneous nerve in isolation often
resulted in longer testing sessions involving more subject discomfort than for study of the
UT.
Based on the SEM and a 95% confidence level, it was calculated that a subject’s
observed MUNE could vary ± 59 MUs as a result of measurement error. It follows that
in constructing a confidence interval, we would be 95% confident that a subject with an
observed MUNE of 200 MUs had a true value between 141 MUs and 259 MUs.6 Similar
estimations can be calculated for maximum CMAP and mean S-MUP values based on
their SEMs. Also, a change ≥ 83 MUs for the BB was found to exceed the threshold of
measurement error. While this benchmark for the recognition of change over time was
more favorable than the MDD95 calculated for the UT, the practical challenges associated
with the collection of a reliable maximum CMAP from the BB likely outweigh this
benefit. Apart from the maximum CMAP, the reliability results were very similar for
application of the technique to the UT and BB. Thus, study of the UT seems to be more
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advantageous; while retaining the benefits associated with the study of a proximal muscle
group, it is innervated by a superficial, easily accessible nerve supply.
4.3.3 Comparison of upper trapezius data between ALS and control subjects
The comparison of data between subject groups revealed MUNE values that were
significantly lower in subjects with ALS. This ability of DE-STA MUNE to define the
underlying pathophysiology of the disease resulted from its detection of significant
differences from control subjects for each of the components of the equation (Figure 4.2).
Collateral reinnervation, and the associated increase in the innervation ratios of surviving
MUs,21 was reflected in the findings of significantly larger mean S-MUP values for
subjects with ALS (Figure 4.2B). Initially, this compensatory process is sufficient to
maintain maximum CMAP amplitude and clinical muscle strength at levels that are
normal or close to normal.1, 22, 23 However, with the eventual outpacing of reinnervation
by denervation, progressive muscular atrophy and weakness occur, associated with a
diminished maximum CMAP, as was seen in the results (Figure 4.2A).23, 24 These
findings of a reduced maximum CMAP, increased mean S-MUP and reduced MUNE in
the UT in subjects with ALS are consistent with results from previous studies using other
MUNE techniques in various muscle groups.16, 25, 26
The subjects in this study demonstrated varying levels of disease involvement for
both the UT and BB muscle groups. This was evident in the high degree of betweensubject variability for maximum CMAP, mean S-MUP and MUNE values for both
muscle groups (Tables 4.2, 4.3), and was in keeping with the findings of a previous study
of DE-STA MUNE in subjects with ALS.8 To illustrate using the present data from the
UT, some subjects demonstrated values for all three parameters that were within the
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range of control values previously reported (Chapter 3), while other subjects displayed
signs of effective collateral reinnervation, with an enlarged mean S-MUP size
maintaining a normal (or nearly normal) maximum CMAP level in the face of a
substantially reduced complement of MUs. For example, the mean S-MUP for one
subject was 200 µV, with an estimated 27 MUs producing a maximum CMAP of 5.5 mV
(lower limit for control subjects was 6.1 mV) (Chapter 3). The level of variability
between subjects with ALS was particularly high for mean S-MUP values, emphasizing
differing stages of the subjects’ MU pools in the dynamic process of collateral
reinnervation (Figure 4.2B).
While the frequency distribution of S-MUP sizes from the UT in subjects with
ALS was similar to that previously reported for control subjects (Chapter 3) in that both
were unimodal and positively skewed toward small S-MUPs, it differed from the control
distribution in that it revealed a much greater proportion of large S-MUPs (Figure 4.1C).
Consistent with the mean S-MUP results, this is once again reflective of collateral
reinnervation. These findings are consistent with numerous studies of MUNE techniques
comparing S-MUP frequency distributions between control subjects and subjects with
ALS in various muscle groups.1, 17, 23, 25, 27
As established electrophysiological signs of chronic denervation, increases in
MUP amplitude, duration and the number of polyphasic potentials are known to be
associated with ALS.12, 28 An additional sign of LMN loss in ALS is an increase in MU
discharge frequency.12 Comparing the results to control data (Chapter 3), such
neurogenic changes reflective of collateral reinnervation were identified with respect to
increased MUP peak-to-peak voltage and duration, and a statistical trend toward larger
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area (a measure related to these two parameters). While it was anticipated that subjects
with ALS would have exhibited a higher mean MU firing rate, the negative influence of
upper motor neuron loss on the descending drive necessary for rate coding may have
played a role in these non-significant findings.12, 29
The only other study to compare DE-STA MUNE results between subjects with
ALS and control subjects was applied to the BB and first dorsal interosseous.8 Consistent
with the present results, the study found significantly lower maximum CMAP and
MUNE values across both muscle groups for subjects with ALS. While they did not find
the same significant difference between groups for mean S-MUP values, they did also
report a higher proportion of large-amplitude S-MUPs for subjects with ALS. Consistent
with the literature28, 30 and the present results, their study found subjects with ALS to
have MUPs with significantly larger amplitudes and longer durations. However,
consistent with the present data, complexity and firing rate values were not significantly
different between groups. It may be of interest to compare each measure of MUP
morphology between groups in larger studies of the technique to determine whether these
findings are replicable or stem from an issue of sample size.
4.3.4 Limitations and future study
This study was limited in sample size to those patients who were well enough to
participate in a research study, and had sufficient remaining UE strength (although this
was less of an issue). Despite the challenges associated with recruitment in this disease
population, the sample size for each component of the study was similar to that of
previous studies of the technique in control subjects.7, 8 Given the multicenter nature of
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the majority of ALS clinical trials, future study should evaluate the inter-rater reliability
of the technique as applied to subjects with ALS.
4.3.5 Summary
The results of this study demonstrate that DE-STA MUNE and quantitative MUP
analysis is capable of producing reliable results in subjects with ALS and detecting the
underlying pathophysiology of the disease. Taken together with some advantages of DESTA MUNE over other available MUNE techniques, these results suggest promise for its
use an outcome measure.
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CHAPTER 5
SENSITIVITY TO CHANGE OF DECOMPOSITION-ENHANCED SPIKETRIGGERED AVERAGING MOTOR UNIT NUMBER ESTIMATION IN
SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
5.0 INTRODUCTION
Outcome measure selection is a critical component of amyotrophic lateral
sclerosis (ALS) clinical trial design. Motor unit number estimation (MUNE) is unique in
its ability to measure motor unit (MU) loss and the effects of collateral reinnervation
directly, making it an advantageous choice for use as an outcome measure in clinical
trials.1
Despite these advantages, the use of MUNE in ALS clinical trials has been
limited (Chapter 2). The trials that have incorporated MUNE have employed manual
incremental stimulation,2, 3 spike-triggered averaging,4 and modified versions of the
statistical method.5, 6 The use of the statistical method met with technical challenges as a
result of MU instability, prompting the conclusion that the technique was unsuitable for
application to this patient population.6 In selecting from the other available MUNE
techniques, decomposition-enhanced spike-triggered averaging (DE-STA) MUNE is a
relatively new method that offers a number of advantages (previously discussed in
Chapters 1, 3, 4), making it promising for use as an outcome measure.7, 8
An important property of any outcome measure is sensitivity to change, which is
the ability of an instrument to detect minimal change over time, and thus monitor the
potential efficacy of an intervention.9 Longitudinal studies of the sensitivity to change of
MUNE in comparison with various outcome measures have been conducted. These have
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involved evaluations of multiple point stimulation,10, 11 the statistical method,12 manual
incremental stimulation,13-15 and less common techniques such as the microstimulation
method16 and high-density MUNE.17
A cross-sectional study by Boe et al. (2009)18 compared DE-STA MUNE and
motor unit potential (MUP) peak-to-peak voltage results from the first dorsal interosseous
and biceps brachii, maximal voluntary isometric contractions (MVICs) for each of these
muscle groups, a modified form of the Tufts Quantitative Neuromuscular Exam, forced
vital capacity (FVC), and the Revised Amyotrophic Lateral Sclerosis Functional Rating
Scale (ALSFRS-R) in subjects with ALS to normative results for the same measures.
The study found DE-STA MUNE in both muscle groups to differ more from control
values than almost all of the clinical outcome measures, reflecting the ability of the
technique to detect underlying pathophysiological features of the disease despite betterpreserved functional performance. However, a longitudinal study allowing for a
comparison of the sensitivity to change between DE-STA MUNE and clinical outcome
measures in subjects with ALS has yet to be undertaken.
The study of any MUNE technique requires the selection of one or more muscle
groups for evaluation. Application of DE-STA MUNE to the upper trapezius (UT) is an
appealing choice given the potential clinical relevance of studying a muscle related to
respiratory function, and the practical nature of the data collection protocol (Chapters 3,
4).19 As a proximal muscle, its examination would also be novel, as each of the
previously mentioned longitudinal studies of MUNE utilized techniques that restricted
their evaluations to distal muscle groups of the hands and feet. Apart from the BB, the
UT is also the only muscle for which the intra-rater reliability of DE-STA MUNE has
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been established in subjects with ALS (Chapter 4). Additionally, the technique as
applied to the UT has been shown to detect the underlying pathophysiology of the disease
(Chapter 4).
In comparing the sensitivity to change of DE-STA MUNE in the UT with clinical
outcome measures, it would be valuable to select from measures of muscle strength,
measures of pulmonary function, and functional rating scales, which are the most
commonly used types of outcome measures in ALS clinical trials (Chapter 2).
Manual muscle testing (MMT) assesses muscle strength in terms of a patient’s
ability to move against gravity and contract against the evaluator’s manual resistance,20
and is one of the most commonly used secondary outcome measures in ALS clinical trials
(Chapter 2). Another technique for the assessment of muscle strength is hand-held
dynamometry (HHD), which involves the quantification of the force generated by an
MVIC against a portable electronic dynamometer held by the evaluator. Both MMT and
HHD are simple, inexpensive, and efficient measures of muscle strength21 that can be
used to assess the strength of scapular elevation, in which the UT is involved. It may be
useful to compare the sensitivity to change of DE-STA MUNE in the UT to that of the
strength of scapular elevation, in addition to other upper extremity (UE) muscle groups.
With respect to measures of pulmonary function, FVC assesses the volume of air
exhaled from total lung capacity using a portable, standard spirometer.22 FVC was found
to be the most frequently used secondary outcome measure in a review of ALS clinical
trials (Chapter 2). In contrast, sniff nasal inspiratory pressure (SNIP) is a relatively novel
measurement technique that assesses the pressure generated by a subject’s maximal short,
sharp, sniffing maneuver. SNIP avoids the challenges associated with the use of a
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mouthpiece related to bulbar or facial weakness, and has a protocol that is generally
natural and simple for subjects to perform.23, 24 Lastly, the ALSFRS-R is a diseasespecific functional rating scale that assesses activities of daily living25 and is used
frequently as a primary and secondary outcome measure in ALS clinical trials (Chapter
2).
The purpose of this study was to compare the sensitivity to change of DE-STA
MUNE and quantitative MUP analysis in the UT to that of various clinical outcome
measures in subjects with ALS. More specifically, to make comparisons with MMT in
five UE muscle groups, scapular elevation and elbow flexion peak force measured using
HHD, FVC, SNIP, and the ALSFRS-R.
5.1 METHODS
5.1.1 Subjects
Ten patients diagnosed with clinically probable or definite ALS as defined by the
revised El Escorial criteria26 were recruited from the Motor Neuron Diseases Clinic at
University Hospital, London Health Sciences Centre to participate in this study. Patients
were included if they were between the ages of 18-90, were within 10 years of symptom
onset, and were judged as having sufficient UE strength to perform the MUNE protocol.
Patients were excluded if they had evidence of other neuromuscular or musculoskeletal
disease. All subjects gave written, informed consent in accordance with The University
of Western Ontario Health Sciences Research Ethics Board, which approved this study.
5.1.2 Experimental protocol
Subjects were assessed at baseline (T0), 2 (T2), 4 (T4) and 6 (T6) month time
points. Expressed differently, they were assessed at baseline (T0), approximately 56 days
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(T2), 112 days (T4), and 168 days (T6). At each time point, subjects completed
assessments in the following sequence (with few exceptions): MMT, HHD, MUNE,
FVC, SNIP, and ALSFRS-R, and were given the opportunity to rest between tests.
Muscle strength and MUNE assessments were conducted unilaterally on the arm
identified by the subject at T0 as having less weakness in order to best facilitate
longitudinal evaluations.10, 11, 27 If the subject was unable to determine which arm was
stronger, the right arm was selected. Tests either required subjects to be seated upright in
a straight back chair or wheelchair or, for HHD and portions of MMT testing, supine on
an examination table with one pillow elevating their head. If subjects were unable to
tolerate the supine position, they were positioned in a semi-reclined position, or the test
was modified to be performed from a seated position.
5.1.2.1 Manual muscle testing
Muscle strength was assessed with MMT for five UE muscle groups. Scapular
elevation, shoulder abduction, elbow flexion, wrist extension and elbow extension were
tested. The muscle groups were graded from 0-5 using a modification of the Medical
Research Council grading scale,20 with 0 representing paralysis and 5 representing
normal strength (Appendix B). Previously standardized protocols were followed for each
muscle group28 with the exception of scapular elevation, for which a protocol was derived
with the assistance of the Motor Neuron Diseases Clinic physical therapist and ALS
clinical trials site evaluator.
Muscle groups were tested in a consistent sequence, with the number of required
position changes minimized by completing any testing requiring a seated position first,
followed by testing in the supine position. For each muscle group, the movement was
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demonstrated and the subject instructed to attempt the same movement through their full
range of motion, following which the evaluator applied force in the opposite direction. If
necessary, the muscle group was also tested in its alternate, gravity-eliminated position.
Next, for the purpose of calculating a final MMT score, the grade assigned to each
muscle group was converted to a 10-point version of the Medical Research Council
grading scale and these grades summed across muscle groups to yield a total value out of
50.
5.1.2.2 Hand-held dynamometry
Muscle strength was also measured quantitatively using a MicroFET 2™ HHD
(HOGGAN Health Industries, West Jordan, UT) to assess the peak force generated by
scapular elevation and elbow flexion. Prior to testing, the HHD was calibrated, and
subjects positioned supine with their arms at their sides on an examination table which
was elevated to the evaluator’s hip level. A curved transducer pad was utilized for both
muscle groups, and the HHD was set to ‘low’ threshold.
Scapular elevation was assessed first for each study visit, with the subject
instructed to elevate their shoulder partially, and the HHD held by the evaluator just
proximal to the acromioclavicular joint. To assess elbow flexion, the subject’s arm was
positioned in 90 degrees of elbow flexion, with the upper arm in contact with the
examination table and the forearm in neutral position. The transducer pad of the HHD
was held by the examiner on the radial surface of the forearm, just proximal to the radial
styloid process.
For both muscle groups, the subject was instructed to hold a maximal voluntary
contraction against the HHD, while the evaluator applied matching force in the opposite
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direction, simultaneously providing subject encouragement. After matching the subject’s
level of force for at least 2 s, the evaluator increased the force of resistance to attempt to
break the contraction. The resulting peak force value on the HHD in pounds was
recorded and note was made as to whether the contraction was broken. If it was
suspected that pain was an important contributing factor in breaking the contraction, this
was also noted. Following a brief rest period, the protocol was repeated. A third trial
was performed if the percentage difference between the first two tests was greater than
15% (Equation 1). Lastly, the maximum peak force value from the greatest two trials
demonstrating a percentage difference of less than 15% was recorded as the subject’s
result.29
5.1.2.3 Equation 1
% difference = ([maximum value – minimum value]/maximum value)*100
5.1.2.4 Motor unit number estimation
Electromyographic (EMG) signals were acquired using decomposition-based
quantitative electromyography (DQEMG) (version 3.2) and Acquire EMG software on a
Neuroscan Comperio (Neuroscan Medical Systems, El Paso, TX). Data collection was
performed by one evaluator (C.I.), with the exception of one subject at one time point, for
whom another evaluator (T.D.) completed the protocol. Self-adhering Silver Mactrode®
electrodes (GE Medical Systems, Milwaukee, WI) were used to detect surface signals,
and 25 mm x 30 gauge TECA™ elite Disposable Concentric Needle Electrodes
(CareFusion, Middleton, WI) were used to detect intramuscular signals, with bandpass
settings of 5 Hz to 5 kHz and 10 Hz to 10 kHz, respectively.7, 30
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Surface electrodes were cut in strips (1 cm x 3.5 cm) for use as the active and
reference electrodes, with a full-sized electrode serving as a ground. The skin was
cleansed with isopropyl alcohol and surface electrodes positioned appropriately. The
active electrode was positioned transversely over the belly of the muscle, approximately
midway between the acromion process and C7 spinous process, with the reference
electrode placed over the acromion process, and the ground electrode over the deltoid.19
A handheld bipolar stimulator was used in order to elicit a maximum compound
muscle action potential (CMAP), with the spinal accessory nerve stimulated posterior to
the sternocleidomastoid.19 If necessary, the active electrode was moved in small
increments to a position where the CMAP negative peak amplitude was maximized and
the rise time minimized. Following optimal positioning of the active electrode, the
surface electrode positions were reinforced with surgical tape to ensure that no movement
occurred during the study. Gradually, the stimulation intensity was increased until the
CMAP negative peak amplitude reached a plateau. Automatically positioned markers
indicating onset, negative peak, positive peak, and end of the maximum CMAP were
reviewed and manually adjusted if necessary. Subsequently, size-related parameters of
the maximum CMAP including negative peak amplitude were calculated automatically.
Following the determination of the maximal voluntary contraction-root mean
square (MVC-RMS) (described in Chapter 3), the concentric needle electrode was
inserted into the UT, approximately 2-10 mm proximal or distal to the active surface
electrode. Subjects were asked to perform minimal isometric contractions while an
optimal needle position was located that minimized the rise times of the MUPs of the first
two to three recruited MUs. With the needle manually maintained in this position by the
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evaluator, the subject was instructed to increase the contraction force to approximately
10-20% of the MVC-RMS. Each sub-maximal isometric contraction was maintained for
30 s, during which the subject received visual and auditory feedback from the EMG
signal and % MVC-RMS information displayed on the screen to assist in the maintenance
of a stable contraction. Contractions were performed until a minimum of 20 MUP trains
were collected, with each contraction separated by a rest period of approximately 30-60 s,
or as required by the subject. The needle position was adjusted between contractions to
collect data from different portions of the muscle, and, if necessary, inserted at a new site
to complete the collection of MUP trains.7, 30
Following EMG signal decomposition and the review of the acceptability of
acquired MUPs, surface-detected motor unit potentials (S-MUPs), and MUP trains, as has
been previously described (Chapters 1, 3), the onset, positive peak, negative peak, and
end markers of the MUP templates and the negative onset, negative peak, and positive
peak markers of the S-MUP templates were checked visually and repositioned if
necessary.
Descriptive statistics for various parameters were calculated automatically based
on all accepted MUPs, S-MUPs, and MUP trains. Additionally, the mean S-MUP was
calculated by way of data point-by-data point averaging all accepted S-MUPs, aligned
based on their onsets. Lastly, the MUNE was calculated automatically through division
of the negative peak amplitude of this mean S-MUP into the negative peak amplitude of
the maximum CMAP previously obtained (Equation 2).7 MUNE, maximum CMAP,
mean S-MUP, and MUP peak-to-peak voltage values were recorded for each subject.
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5.1.2.5 Equation 2
MUNE = maximum CMAP size
mean S-MUP size
Where MUNE, motor unit number estimate; CMAP, compound muscle action potential;
S-MUP, surface-detected motor unit potential.
5.1.2.6 Forced vital capacity
FVC was assessed using a Renaissance® II Spirometry System (Puritan
Bennett™, Boulder, CO), which was calibrated prior to each study visit. A disposable,
single-patient use FSII Flow Sensor pneumotach (Puritan Bennett™, Boulder, CO) was
attached, and a determination made prior to or during the initial trial as to whether the
subject was able to form a tight lip seal around the pneumotach or required an alternate
mouthpiece (VacuMed, Ventura, CA) attached with an adaptor. Having set up the
mouthpiece, the subject’s nose clip was positioned and the flow sensor zeroed.
The flow sensor was held by the evaluator or subject and, with a seal around the
mouthpiece, the subject was instructed to inhale maximally, subsequently exhaling
forcefully and fully by continuing for as long as possible. Encouragement was provided
to each subject during every trial. The result of the trial was recorded in liters and,
following a brief rest period, the protocol repeated. A minimum of three trials were
conducted for each subject, and if the percentage difference between the two highest
trials was greater than 10%, or one or more trials were considered unacceptable due to
deviations from the protocol, additional trials were performed up to a maximum of five
trials. Trial results were printed and the maximum value from the two highest acceptable
trials demonstrating a percentage difference of less than 10% was recorded as the
subject’s result. Both the raw value (L) and percentage of the subject’s predicted FVC
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based on height, age, and sex (calculated automatically) were documented for this final
value. If a mouthpiece attachment was employed, it was used at all future time points for
that subject.29
5.1.2.7 Sniff nasal inspiratory pressure
A pressure transducer was fashioned in line with the methods of previous
studies.23, 24 A silicone ear plug (PharmaSystems uSwim soft silicone Ear Plugs,
Toronto, ON) was formed around the tip of a 100 cm piece of polyethylene tubing (I.D.
1.14 mm [0.045”], O.D. 1.57 mm [0.062”]) (Intramedic™, Sparks, MD) which was
connected to a manometer (120 cm H2O maximum pressure). A new silicone plug was
used at each study visit, while the tubing was recycled for each subject. A small piece of
silicone was used to seal the point of entry of the tubing into the manometer. The
manometer was calibrated in our institution’s pulmonary function department prior to the
onset of this study.
The evaluator formed an appropriate amount of silicone around the tip of the
tubing for the subject’s nostril size, which was inserted into one nostril. The right nostril
or the nostril without obstruction (according to the subject) was tested, and the same
nostril tested at each time point. In order to check that a proper seal had been made, the
subject’s other nostril was closed manually and a sniff performed. If any air leakage was
noted, adjustments to the size of the plug were made. Finally, the manometer was
positioned flat on a table and its dial set to 0 cm H2O.
Subjects were instructed to perform 10 maximal short, sharp sniffing maneuvers
through their open nostril with their mouth closed, starting from the lung volume attained
following exhalation of a quiet breath with their mouth closed (functional residual
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capacity). Feedback was provided by the evaluator, and each sniff was separated by
approximately 5-30 s. If the 10th trial provided the highest value, additional trials were
performed until no further increase was noted. All maneuvers were recorded in cm H2O,
and the highest value was taken as the subject’s result.23, 24
5.1.2.8 Revised Amyotrophic Lateral Sclerosis Functional Rating Scale
Completion of the ALSFRS-R was performed according to standardized
guidelines.29, 31 The questionnaire was prefaced at each study visit by stating: “I am
going to ask you the questions on the ALS functional rating scale about how you are
currently functioning at home. The ALS functional rating scale compares how you are
doing today versus prior to having any signs or symptoms of ALS”. Questions were
asked of the subject, but if the subject was unable to communicate their response or
understand the question, an informant (spouse or other caregiver) was used for
assistance.32 Subject responses to each of the 12 questions were recorded to the closest
available score from 0-4, with each response clarified through further probing to ensure a
higher or lower score was not more appropriate. A total possible score ranging from 0
(unable to attempt any task) to 48 (normal function) was recorded (Appendix C).25
5.1.3 Evaluator training and reliability assessment
Each outcome measure was assessed by one evaluator (C.I.) trained in MMT,
HHD, FVC and ALSFRS-R evaluation by the Motor Neuron Diseases Clinic physical
therapist. Additional training in the performance of the ALSFRS-R was obtained through
a DVD of standard patient vignettes.31 The evaluator had been previously trained in data
collection and analysis for DE-STA MUNE by an individual experienced with the
technique (T.D.).
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To ensure that the evaluator was able to obtain reliable results in the performance
of these outcome measures, the study included a variety of assessments of intra- and
inter-rater reliability in control subjects prior to the beginning of the study, and in a
subset of subjects with ALS at T0. For each assessment, the protocols outlined above
were followed.
5.1.3.1 Manual muscle testing
An examination of the inter-rater reliability of MMT was performed in subjects
with ALS, with the clinic physical therapist acting as the second evaluator. For each
subject, grades were compared for each muscle group with the goal of achieving perfect
agreement between evaluators for at least four of the muscle groups, with a difference in
the summed total score (max. 50) of no greater than 2 points. If this level of agreement
was not attained, the experienced evaluator offered feedback, and additional subjects
were tested until acceptable results were obtained for two subjects.
5.1.3.2 Hand-held dynamometry
Intra-rater reliability of HHD was assessed and subsequently confirmed in two
control subjects and two subjects with ALS, with the protocol performed twice for both
scapular elevation and elbow flexion. Assessments were performed on the same day for
each subject and separated by a minimum of 1 hr. The accepted maximum peak force
values from each assessment were compared and the percentage difference was required
to fall below 15% for each muscle group.
5.1.3.3 Forced vital capacity and sniff nasal inspiratory pressure
Intra-rater reliability of FVC and SNIP was assessed and subsequently confirmed
in two control subjects each, with each protocol performed twice on the same day and
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separated by a minimum of 1 hr. The percentage difference between the accepted values
from each FVC assessment was required to fall below 10%, and SNIP below 15%.
5.1.3.4 Revised Amyotrophic Lateral Sclerosis Functional Rating Scale
The intra-rater reliability of assessments using the ALSFRS-R was established
through the comparison of initial scoring based on interviews conducted in two standard
patient vignettes with the re-scoring of these vignettes 1 month later.31 Inter-rater
reliability was established through comparison of the initial scoring with scoring of these
same vignettes by the clinic physical therapist. Acceptable reliability involved no more
than a 1 point difference on any single question, and no more than a 2 point difference in
the total score, which subsequently was achieved.29
5.1.4 Statistics
For each outcome measure, all statistical analyses were performed on the data of
those subjects who had complete T0 and T6 results. Descriptive statistics were also
calculated for each outcome measure based on the subjects who had complete data across
all time points. To facilitate statistical and graphical analyses, change scores (Equation
3) and percentage change values (Equation 4) were calculated for each subject with
complete T0 and T6 data for a given outcome measure. For each change score and
percentage change value, negative values denote decline in the outcome measure.
5.1.4.1 Equation 3
Change score = (T6 – T0)
5.1.4.2 Equation 4
Percentage change = ([T6 – T0]/T0) * 100
Where T6, 6 month value; T0, baseline value.
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To test for differences within each outcome measure from T0 to T6, a two-tailed,
paired t-test was used, with the exception of the ordinal variables (MMT and ALSFRSR), for which a two-tailed Wilcoxon signed-ranks test was performed.9 An a priori alpha
level of 0.05 was used to denote significance. As the purpose of this study was
exploratory in nature, a Bonferroni adjustment was not applied.
To facilitate an evaluation of the relative sensitivities to change of the outcome
measures under study, a unitless index was used. A standardized response mean (SRM)
was calculated for each outcome measure (Equation 5),33 with larger absolute values
representing a larger magnitude of change. Cohen’s criteria for effect sizes were used to
interpret the calculated SRMs: a value of 0.20 was considered small, 0.50 considered
moderate, and 0.80 considered large.33, 34
5.1.4.3 Equation 5
SRM =

change / schange

Where SRM, standardized response mean;

change,

mean change score; schange, standard

deviation of change scores.
All statistical analyses were performed using GraphPad Prism® 4.02 (GraphPad
Software, Inc., San Diego, CA), with the exception of the Wilcoxon signed-ranks test, for
which IBM® SPSS® Statistics 19 (SPSS, Inc., Chicago, IL) was used.
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5.2 RESULTS
5.2.1 Subjects
A summary of subject demographic and clinical characteristics is found in Table
5.1.
5.2.2 Missing data
Three subjects were lost to follow-up in this study. One subject died after their T2
study visit, one was not well enough to return for subsequent visits following their T2
study visit, and one subject was unable to attend their T6 study visit for reasons unrelated
to their health. The only other missing data point for the majority of outcome measures
was for one subject who was unable to attend their T2 study visit for reasons unrelated to
their health. Additional missing data was encountered for FVC and SNIP, related to the
inability of one subject with frontotemporal dementia to follow instructions for either
measure at all 4 time points, and for one subject with possible cognitive deficits to follow
the instructions to perform an FVC at their final study visit (T2).
Lastly, a single muscle group was not assessed for various reasons for three MMT
total scores. In these cases, the last observation for the muscle group was carried forward
as a conservative estimate of change, in order to avoid the loss of the entire MMT score.
5.2.3 Hand-held dynamometry data collection
For scapular elevation, the contraction was broken for only one subject at a single
time point (T0), and pain during the contraction was likely an important contributing
factor. For elbow flexion, six subjects’ contractions were broken at every time point that
they were assessed, two subjects that were able to maintain contractions at initial time
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point(s) had their contractions broken at later time point(s), and two subjects’
contractions were not broken at any time point that they were assessed.
With respect to deviations from the protocol, two subjects were unable to be
tested in a supine position at their final time point, and instead were assessed in a seated
position. For one subject at a single time point, the maximum peak force value recorded
for elbow flexion demonstrated a percentage difference greater than 15% (24%) from the
other trial performed (only two trials were conducted), in part contributed to by the small
absolute nature of the values (3.4 lb [trial 1], 2.6 lb [trial 2]). Lastly, for the assessment
of elbow flexion for one subject at T2, T4, and T6, the dynamometer was repositioned to
be in contact with the volar forearm, avoiding pain caused by positioning on the radial
surface of the forearm.
5.2.4 Results of data analysis
With respect to electrophysiological indices, no significant differences between T0
and T6 were found for MUNE t(6) = -1.66, p = 0.15 (-110.10, 21.28), maximum CMAP
t(6) = 0.43, p = 0.68 (-1.32, 1.90), mean S-MUP t(6) = 0.57, p = 0.59 (-51.05, 82.19), or
MUP peak-to-peak voltage t(6) = 1.81, p = 0.12 (-180.9, 1209) (Table 5.2, Figure 5.1).
Similarly, for measures of muscle strength, no significant differences between T0 and T6
were found for MMT (z = -1.70, p = 0.089), HHD – scapular elevation t(6) = -1.64, p =
0.15 (-14.26, 2.81), or HHD – elbow flexion t(6) = -2.11, p = 0.079 (-15.91, 1.16) (Table
5.2, Figure 5.2). Lastly, for measures of pulmonary function, no significant differences
between T0 and T6 were found for FVC t(5) = -1.94, p = 0.11 (-1.25, 0.18) or SNIP t(5) =
0.28, p = 0.79 (-16.24, 20.24) (Table 5.2, Figure 5.3). The only outcome measure for
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which there was a significant difference between T0 and T6 was ALSFRS-R, for which
there was a significant decrease over time (z = -2.12, p = 0.034) (Table 5.2, Figure 5.3C).
ALSFRS-R was found to have the largest absolute SRM, followed in decreasing
order by MMT, HHD – elbow flexion, and FVC, which each also had large SRMs.
Moderate SRMs (from highest to lowest) were found for MUP peak-to-peak voltage,
MUNE, and HHD – scapular elevation. Small SRMs (from highest to lowest) were
found for mean S-MUP, maximum CMAP, and SNIP. Positive SRMs were found for
MUP peak-to-peak voltage, mean S-MUP, SNIP, and maximum CMAP (indicative of an
increase from T0 to T6) and negative SRMs were found for each of the other outcome
measures (indicative of a decrease from T0 to T6) (Table 5.2).
The greatest absolute mean percentage change from T0 to T6 was found for MUP
peak-to-peak voltage, followed in decreasing order by mean S-MUP, SNIP, HHD –
elbow flexion, ALSFRS-R, MMT, FVC, MUNE, HHD – scapular elevation, and
maximum CMAP. Consistent with the SRM results, MUP peak-to-peak voltage, mean SMUP, SNIP, and maximum CMAP increased from T0 to T6 while each of the other
outcome measures decreased from T0 to T6 on average (Table 5.2).
On average, 18 ± 6 and 15 ± 6 acceptable S-MUPs were obtained (from 36 ± 14
and 45 ± 25 MUP trains collected in total) for each subject at T0 and T6, respectively.
These S-MUPs were obtained from 6 ± 2 contractions at T0 and 6 ± 1 contractions at T6.
Thus, on average, 3 ± 2 acceptable S-MUPs per contraction were collected at both time
points. The mean MU identification rates (percentage of expected firings detected) based
on the samples of accepted MUP trains were 58 ± 5% at T0 and 59 ± 11% at T6. The
frequency distributions of S-MUP negative peak amplitudes, as a percentage of

124
maximum CMAP negative peak amplitudes from T0 (1.88 ± 2.10 % maximum CMAP
[0.09-8.10 % maximum CMAP]) and T6 (2.06 ± 3.29 % maximum CMAP [0.16-16.14
maximum CMAP]) are illustrated in Figure 5.4.
Descriptive statistics for each outcome measure based on the subjects who had
complete data across all time points are found in Table 5.3. A consistent increase across
time points in the mean value of the outcome measure was seen for MUP peak-to-peak
voltage, and a consistent decrease across time points in the mean value of the outcome
measure was seen for MMT, HHD – elbow flexion, and the ALSFRS-R.

125

Table 5.1 Subject demographics and clinical summary at T0
Variable
Age (years)
Sex
Height (cm)
Weight (kg)
Time from symptom onset (months)
Area of onset
ALS classification
Side of muscle testing
Time from T0 (days)

All subjects (n = 10)
62 ± 7 (53-75)
7 male, 3 female
173 ± 9 (160-187)
86.8 ± 20.2 (59.4-124.0)
27 ± 18 (4-61)
1 bulbar, 9 limb (8 UE, 1 LE)
9 sALS, 1 fALS
4 left, 6 right
T2: 59 ± 3 (55-64)
T4: 109 ± 9 (98-129)
T6: 175 ± 10 (161-189)
Values expressed as mean ± SD. Data in parentheses indicate range.
Abbreviations: ALS, amyotrophic lateral sclerosis; fALS, familial amyotrophic lateral
sclerosis; LE, lower extremity; sALS, sporadic amyotrophic lateral sclerosis; T0,
baseline; T2, 2 month time point, T4, 4 month time point; T6, 6 month time point; UE,
upper extremity.
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Table 5.2 Longitudinal change in outcome measures for those subjects with complete T0
and T6 data
Outcome measure
MUNE (MUs)
Maximum CMAP
neg. peak amp. (mV)
Mean S-MUP
neg. peak amp. (µV)
MUP
peak-to-peak voltage
(µV)
MMT score
(max. 50)
HHD – Scapular
elevation
peak force (lb)
HHD – Elbow flexion
peak force (lb)
FVC (L)

n T0
T6
Mean % change SRM
7
159 ± 133
115 ± 81
-10.9 ± 57.9 -0.63
(19-387)
(13-228)
(-63.9 to 94.7)
7
5.9 ± 2.8
6.2 ± 2.6
7.6 ± 23.5
0.16
(3.1-11.2)
(2.9-9.5)
(-26.8 to 40.0)
7
68 ± 67
83 ± 61
55.2 ± 71.5
0.22
(29-214)
(36-211)
(-54.2 to 151.2)
7 575.4 ± 105.4 1089.2 ± 756.2
91.3 ± 139.1
0.68
(503.6-742.4) (528.6-2642.5)
(4.0 to 395.2)
7
7

7

35 ± 11
(22-47)
46.3 ± 8.9
(36.6-57.9)

30 ± 15
(11-46)
40.6 ± 5.0
(35.5-47.0)

-18.2 ± 21.4
(-56.0 to 2.6)
-9.8 ± 19.4
(-33.9 to 26.0)

-0.87
-0.62

27.1 ± 21.4
19.7 ± 14.6
-29.9 ± 39.3 -0.80
(2.8-59.2)
(0.0-35.5)
(-100.0 to 26.9)
6
3.32 ± 1.04
2.78 ± 0.47
-12.3 ± 17.9 -0.79
(2.09-5.08)
(2.41-3.67)
(-34.1 to 15.3)
6
37 ± 27
39 ± 16
40.7 ± 106.1
0.12
SNIP (cm H2O)
(11-85)
(13-59)
(-30.6 to 254.6)
7
32 ± 8
26 ± 10*
-20.6 ± 17.1 -1.11
ALSFRS-R score
(18-44)
(15-42)
(-41.2 to 5.6)
(max. 48)
Values expressed as mean ± SD. Data in parentheses indicate range.
Mean % change based on % change averaged across all subjects.
*
Significantly different from T0 (p < 0.05).
Abbreviations: ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating
Scale; CMAP, compound muscle action potential; FVC, forced vital capacity; HHD,
hand-held dynamometry; MMT, manual muscle testing; MU, motor unit; MUNE, motor
unit number estimation; MUP, motor unit potential; neg. peak amp., negative peak
amplitude; S-MUP, surface-detected motor unit potential; SNIP, sniff nasal inspiratory
pressure; SRM, standardized response mean; T0, baseline; T6, 6 month time point.
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Figure 5.1 Comparison between T0 and T6 for each electrophysiological outcome
measure. Data is presented for those subjects with complete T0 and T6 data (n = 7 for
each outcome measure). The x-axis for each graph represents the time point. MUNE (p
= 0.15) (A), maximum CMAP (p = 0.68) (B), mean S-MUP (p = 0.59) (C), and MUP
peak-to-peak voltage (p = 0.12) (D).
Abbreviations: CMAP, compound muscle action potential; MU, motor unit; MUNE,
motor unit number estimation; MUP, motor unit potential; neg. peak amp., negative peak
amplitude; ns, not significant; S-MUP, surface-detected motor unit potential; T0,
baseline; T6, 6 month time point.
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Figure 5.2 Comparison between T0 and T6 for each measure of muscle strength. Data is
presented for those subjects with complete T0 and T6 data (n = 7 for each outcome
measure). MMT (p = 0.089) (A), HHD – scapular elevation (p = 0.15) (B), and HHD –
elbow flexion (p = 0.079) (C).
Abbreviations: HHD, hand-held dynamometry; MMT, manual muscle testing; ns, not
significant; T0, baseline; T6, 6 month time point.
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Figure 5.3 Comparison between T0 and T6 for measures of pulmonary function and the
ALSFRS-R. Data is presented for those subjects with complete T0 and T6 data.
*
indicates a significant difference between T0 and T6. FVC (n = 6) (p = 0.11) (A), SNIP
(n = 6) (p = 0.79) (B), and ALSFRS-R (n = 7) (p < 0.05) (C).
Abbreviations: ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating
Scale; FVC, forced vital capacity; ns, not significant; SNIP, sniff nasal inspiratory
pressure; T0, baseline; T6, 6 month time point.
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Figure 5.4 Frequency distributions of S-MUP data comparing results between T0 (closed
bars) (124 S-MUPs) and T6 (open bars) (103 S-MUPs) for those subjects with complete
T0 and T6 data (n = 7, respectively). The negative peak amplitudes of the S-MUPs have
been normalized to the negative peak amplitude of the maximum CMAP for each subject
at each time point. The y-axis represents the percentage of the total number of S-MUPs
per time point.
Abbreviations: CMAP, compound muscle action potential; S-MUP, surface-detected
motor unit potential; T0, baseline; T6, 6 month time point.
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Table 5.3 Longitudinal change in outcome measures for those subjects with complete data across all time points
Outcome measure
MUNE (MUs)

n T0
T2
T4
T6
6
183 ± 130
159 ± 101
198 ± 172
128 ± 81
(36-387)
(18-274)
(26-489)
(13-228)
6
6.2 ± 3.0
6.6 ± 2.3
6.7 ± 2.8
6.6 ± 2.5
Maximum CMAP
(3.1-11.2)
(3.9-9.5)
(3.5-11.2)
(2.9-9.5)
neg. peak amp. (mV)
6
43 ± 21
69 ± 70
57 ± 42
81 ± 66
Mean S-MUP
(29-84)
(30-211)
(23-134)
(36-211)
neg. peak amp. (µV)
6 582.4 ± 113.7 652.8 ± 176.0
728.1 ± 365.7
830.3 ± 351.1
MUP peak-to-peak
(503.6-742.4) (502.2-987.7) (446.4-1440.9) (528.6-1508.9)
voltage (µV)
6
37 ± 11
36 ± 11
34 ± 12
32 ± 15
MMT score
(22-47)
(21-45)
(16-47)
(11-46)
(max. 50)
6
45.7 ± 9.6
39.9 ± 5.7
40.6 ± 7.4
40.1 ± 5.3
HHD – Scapular
(36.6-57.9)
(35.3-49.9)
(29.4-52.2)
(35.5-47.0)
elevation peak force (lb)
6
31.1 ± 20.2
29.5 ± 19.8
24.5 ± 16.7
23.0 ± 12.8
HHD – Elbow flexion
(6.7-59.2)
(6.7-57.1)
(6.4-50.5)
(6.7-35.5)
peak force (lb)
5
2.96 ± 0.65
3.01 ± 0.34
2.83 ± 0.40
2.60 ± 0.20
FVC (L)
(2.09-3.72)
(2.53-3.42)
(2.20-3.16)
(2.41-2.88)
5
27
±
14
29
±
12
38
±
14
35 ± 14
SNIP (cm H2O)
(11-40)
(16-39)
(17-56)
(13-46)
6
33 ± 9
30 ± 9
29 ± 10
26 ± 11
ALSFRS-R score
(18-44)
(20-42)
(17-43)
(15-42)
(max. 48)
Values expressed as mean ± SD. Data in parentheses indicate range.
Abbreviations: ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; CMAP, compound muscle action
potential; FVC, forced vital capacity; HHD, hand-held dynamometry; MMT, manual muscle testing; MU, motor unit; MUNE, motor
unit number estimation; MUP, motor unit potential; neg. peak amp., negative peak amplitude; S-MUP, surface-detected motor unit
potential; SNIP, sniff nasal inspiratory pressure; T0, baseline; T2, 2 month time point; T4, 4 month time point; T6, 6 month time point.
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5.3 DISCUSSION
5.3.1 Overall sensitivity to change results
The results of this study have established DE-STA MUNE as applied to the UT as
a practical technique for monitoring the progression of ALS in the context of a
longitudinal study. The results demonstrated a moderate degree of sensitivity to change
for MUNE. However, variability in maximum CMAP, mean S-MUP and, consequently,
MUNE values between time points indicated a need for future research regarding
potential sources of error associated with the technique.
The ALSFRS-R was the only outcome measure for which a significant change
was observed from T0 to T6. Correspondingly, this measure had the largest absolute
SRM of any of the outcome measures, indicating that it changed by the largest
magnitude, and thus was the most sensitive to change (Table 5.2).33 The magnitude of
the decline in this outcome measure (6.29 points over 6 months) was consistent with the
rate of change for the natural history of the disease of 0.9-1.0 points per month that has
been commonly reported.35 MMT and HHD – elbow flexion, which demonstrated trends
toward statistical significance (p < 0.10) for their changes over 6 months, were calculated
to have the second and third largest absolute SRMs, respectively. Alongside these
outcome measures, FVC was the only other measure classified as having a large SRM,
and was calculated to have a slightly higher p-value. Continuing along these lines,
placement of the remaining outcome measures in ascending order according to their pvalues resulted in their arrangement in descending order with respect to their SRMs,
owing to the similarity between the paired samples t-statistic and SRM calculations.33
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Although the differences were not statistically significant for the majority of
outcome measures, the directions of the mean changes from T0 to T6 were consistent with
what is known about the progression of the disease. Exceptions to this finding were the
mean increases observed for maximum CMAP and SNIP. However, these measures were
found to have the smallest SRMs of any of the outcome measures, indicating that their
changes from T0 to T6 were of very small magnitude (Table 5.2). Despite the minimal
mean change observed for maximum CMAP, variability at intermediate time points was
observed for individual subjects, as will be discussed shortly. The absence of the mean
decline anticipated for SNIP was likely related in part to measurement error associated
with the technique. The sensitivity to change of the results for this outcome measure may
have been improved through the use of a more standardized, commercially available
pressure transducer to minimize the effects of measurement error.
MUNE expressed a moderate magnitude of change (SRM, -0.63), with a mean
decline from T0 to T6. As anticipated, an overall decline in MUNE was seen for each
subject, with the exception of two subjects for whom an increase in MUNE was observed
(Figure 5.1A). Two subjects’ MUNE values declined more than the minimal detectable
difference (MDD95) of 111 MUs calculated previously (Chapter 4), while neither of the
subjects who demonstrated increases in MUNE changed more than the MDD95. Indeed,
the change score for one of the subjects who demonstrated an increase in MUNE (18
MUs, subject 5) was less than the absolute change score for any other subject. However,
owing to the low absolute MUNE values for this subject, this change translated into the
largest % change of any subject (approximately 95%), highlighting the caution that must
be exercised in interpreting % change results.
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5.3.2 Subjects
The demographic and clinical characteristics of the sample of patients under study
(middle-aged to older adults, a greater proportion of males, predominantly limb onset and
sporadic ALS) were consistent with the characteristics most common in the broader
disease population.36 There was a great deal of variability between subjects with respect
to symptom duration as of T0 (Table 5.1). This heterogeneity was further reflected in the
range of subject scores on the ALSFRS-R at T0, indicative of varying degrees of disease
progression (Table 5.2).
5.3.3 Hand-held dynamometry data collection
A limitation of the use of the HHD ‘break’ test to assess quantitative muscle
strength is that its ability to assess stronger muscles is dependent upon the strength of the
evaluator.37, 38 The inability of the evaluator to break the contraction of any subject at
any time point in the assessment of scapular elevation (with the exception of one subject
for whom pain during the contraction was likely an important contributing factor) speaks
to the strength of the proximal muscle groups, including the UT, that are involved in this
movement. The strength of these muscle groups limited the sensitivity to change of
HHD; any declines in peak force that may have been occurring were not detected, as
levels did not fall below the threshold set by the evaluator’s strength.37 Thus, changes
over time that yielded a moderate SRM for HHD as applied to scapular elevation were
not attributable to detected changes in the strength of the subjects. In contrast,
contractions were broken commonly in the assessment of elbow flexion, which involves
muscle groups with less force-producing capacity. This allowed for the more sensitive
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assessment of changes in strength over the course of the study, reflected by the large
SRM calculated for this outcome measure (Table 5.2).
Performance of HHD testing in an upright seated position for both muscle groups
would have avoided the need to alter the protocol for those subjects who were unable to
tolerate the supine position as a result of the progression of the disease. Although testing
in this position would have been more difficult to standardize, it may have increased the
number of contractions that were broken for scapular elevation, owing to the influence of
gravity, and the ability of the evaluator to exert greater levels of force.
5.3.4 Longitudinal variability in MUNE, maximum CMAP, and mean S-MUP
Inconsistent changes in MUNE were typically observed for individual subjects
when the intermediate 2 and 4 month time points were taken into consideration. These
fluctuations in MUNE values for individual subjects were reflected in the mean MUNE
values across time points (Table 5.3). While a similar study also observed inconsistent
changes in MUNE for individual subjects,27 consistent declines in mean MUNE values
were still observed, as was the case for other similar studies.10, 12, 15, 16
Fluctuations in MUNE values over time were as a result of inconsistent changes
in maximum CMAP and mean S-MUP values for these subjects. For example, one of the
subjects that declined more than the MDD95 overall demonstrated fluctuations in MUNE
at intermediate time points (e.g. T4 MUNE was larger than T0 MUNE). This inconsistent
pattern of change was driven by large oscillations in maximum CMAP values between
time points, while mean S-MUP values remained fairly constant. Similar results of an
inconsistent pattern of change were found for one of the subjects that demonstrated an
increase in MUNE from T0 to T6. In the face of a relatively consistent mean S-MUP size,
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this change was also driven by fluctuations in the maximum CMAP at each of the
intermediate time points, with an increase in the maximum CMAP of 2 mV (40%) from
T0 to T6.
We would have anticipated stable or, with the eventual outpacing of collateral
reinnervation by denervation, consistently declining maximum CMAP values for each
subject as was reflected in mean maximum CMAP values in previous longitudinal
studies.10, 12, 15, 16, 27 The fluctuations in maximum CMAP values that were observed
instead for a number of subjects likely stemmed from sources of error related to data
collection (e.g. failure to position the active electrode optimally over the motor point of
the muscle at each time point).
Mean S-MUP values also demonstrated inconsistent changes across time points
for a number of subjects, in contrast with the consistent increases in mean values
demonstrated previously in similar studies using various MUNE techniques.10, 12, 16 For
example, extensive fluctuations in mean S-MUP values across time points were observed
for one subject for whom MUNE changed more than the MDD95. Furthermore, while the
majority of subjects exhibited an increase in mean S-MUP size from T0 to T6, a consistent
decrease in this measure was observed for one subject (subject 5) (Figure 5.1C). This
decline was likely as a result of measurement error, as the maximum CMAP for this
subject remained relatively constant. Again, unanticipated changes in mean S-MUP size
for these subjects may have resulted from potential sources of error associated with the
data collection process.
Measurement error may have resulted from the failure to collect a representative
sample of S-MUPs, potentially related to the lack of a standardized protocol regarding the
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collection of data from various needle electrode depths in this large proximal muscle.
Another potential source of error relates to the influence of contractile intensity on the
pool of MUs from which S-MUPs are sampled. While we initially planned for each
subject to contract at 10-20% of their maximal voluntary contraction-root mean square
(MVC-RMS), this contractile level was often diverged from in order to improve the
complexity of the composite intramuscular EMG signal. Coupled with the variability
associated with calculating the referential MVC-RMS value without the aid of a
dynamometer, any inconsistencies in contractile intensity between time points for a given
subject may have added variability to the collection of the mean S-MUP. Further
discussion of these potential sources of variability has been presented in Chapter 3. An
additional potential source of variability relates to the upper motor neuron (UMN)
component of the disease. With the loss of UMNs, an impaired descending drive may
hamper a subject’s ability to recruit MUs from the pool under study.39 This may have
inhibited the collection of a representative sample of S-MUPs at a single time point, with
the progression of UMN loss for a given subject contributing variability to the
longitudinal study of the mean S-MUP.
DE-STA MUNE and each of the components of the equation as applied to the UT
have been shown to yield highly reliable results in subjects with ALS when tested twice
with a brief interval of time between tests (Chapter 4). Thus, the variability in the results
may point to the need for more stringent control and/or consideration of various sources
of error in the context of a longitudinal study involving disease progression.
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5.3.5 S-MUP and MUP data collection results
Measures of the MUNE data collection process yielded very similar results at T0
and T6, which were consistent with the study of the technique in the UT reported in
Chapter 4. On average, slightly less than the target of 20 acceptable S-MUPs were
obtained for the mean S-MUP calculation at both time points, reflecting the somewhat
more challenging nature of the data collection protocol in this disease population.
Despite the collection of fewer acceptable S-MUPs, the reliability of the technique has
been shown to be robust (Chapter 4).
Unimodal, positively skewed S-MUP frequency distributions were detected at
both T0 and T6 (Figure 5.4). On average, S-MUP size at T6 was found to be a larger
percentage of maximum CMAP size than at T0, indicative of collateral reinnervation.
These findings of collateral reinnervation were echoed in the mean S-MUP results, which
demonstrated a mean increase from T0 to T6 (Table 5.2). The largest absolute change
score was found for subject 1, amounting to an increase of approximately 151%. The
extensive degree of collateral reinnervation for this subject was also evident in the SMUP frequency distribution results. The individual S-MUPs making up the mean value
for this subject at T6 were 10.1-16.1% of the corresponding maximum CMAP size, while
the S-MUPs for each of the other subjects were less than or equal to 4.2% of the
maximum CMAP at this time point (Figure 5.4).
A moderate SRM was calculated for the change in MUP peak-to-peak voltage
over time, with each subject demonstrating an increase from T0 to T6 (Table 5.2, Figure
5.1D). While this parameter is influenced by differing factors during the data collection
process than S-MUP amplitude which make it less closely reflective of collateral

139
reinnervation,40 the demonstrated increases were concordant with the increases generally
found for the surface-detected signal.
5.3.6 Trends across outcome measures
Examining the results of individual subjects across outcome measures revealed
many clear trends in the data. For example, subjects 1 and 5 not only demonstrated the
largest mean S-MUP values at each time point but, along with subject 8, the smallest
maximum CMAP and MUNE values throughout the study. These three subjects also
consistently demonstrated markedly lower MMT and HHD – elbow flexion values than
each of the other subjects. Furthermore, the lowest ALSFRS-R scores at each study time
point were observed for subjects 1 and 8. In contrast, subject 10 demonstrated the largest
values for MUNE at every time point, corresponding with the smallest mean S-MUP
values, and one of the largest maximum CMAP values throughout the duration of the
study. The ALSFRS-R scores for this subject were also consistently larger than for each
of the other subjects. These parallel results across outcome measures reflect the ability of
each measure to consistently distinguish between subjects with differing levels of disease
severity in various UE muscle groups, be it at the electrophysiological or clinical (muscle
strength or functional) level.
5.3.7 Mean percentage change data
In order to take into account the variability between subjects associated with the
change in each outcome measure, conclusions regarding sensitivity to change were based
on statistical comparisons between T0 and T6, as well as SRM results. However, mean
percentage change values were calculated in addition for each outcome measure for the
purpose of comparing the present results to those of previous studies (Table 5.2).14, 27
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De Carvalho and Swash (2010)14 found that each clinical and lower motor neuron
neurophysiological measure assessed changed significantly over the 6 month duration of
the study. Based on mean % change results, MUNE was found to change by a similar
amount as the neurophysiological index,13 with these two measures changing more than
any other outcome measure. In contrast with the present study, which found MUNE to
decline by roughly 11%, their study found MUNE to decline by approximately 40% over
6 months in the abductor digiti minimi muscles. Similarly, van Dijk et al. (2010)27 found
MUNE to decline by approximately 49% over 8 months in the thenar muscles, which was
more than any other outcome measure. Discrepancies between the results of these
previous studies and the current findings may be as a result of different degrees of disease
involvement and rates of progression of small, distal muscle groups of the hand versus a
large proximal muscle group, or differences in levels of variability between MUNE
techniques.
5.3.8 Limitations and future study
While missing data was a limitation of this study, the reasons behind each of the
missed study visits were outside the control of the subjects and the evaluator, including
the loss to follow-up of three subjects. The opportunity for loss to follow-up of subjects
is a weakness of any study with a longitudinal design.9 This limitation was magnified in
the study of a progressive, fatal disease, although only two subjects were lost due to ill
health or death over the 6 month follow-up period.
The recruitment of subjects for this study was limited to those patients who were
well enough to participate, and for whom it was feasible to travel to the tertiary care
center for study visits. While similar studies have also used sample sizes of 10
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subjects,12, 16 the power of the study to detect significant changes in the outcome
measures over time would have been increased with a larger sample size. Specifically,
based on the present results, a sample size of approximately 20 subjects would have been
required to achieve power of 80% to detect a significant difference between T0 and T6 in
MUNE. A small number of similar studies were also 6 months in duration,12, 14 although
the majority of longitudinal studies of the sensitivity to change of MUNE techniques
have been 8-15 months in duration. The evaluation of a larger sample size over a longer
duration may have provided further information on the longitudinal performance of
MUNE in comparison with each of the other outcome measures.
Future study into the potential sources of error associated with DE-STA MUNE
as applied to the UT is warranted. In particular, the influence of needle electrode depth
on the results of the technique is an aspect of the data collection protocol that could be
readily assessed. It may also be necessary to evaluate the reliability of the technique
when performed on different days, separated by enough time to better reflect the
conditions of a longitudinal study, but not so much time as to allow for important MU
loss and/or collateral reinnervation.
5.3.9 Summary
This study has been the first to evaluate the sensitivity to change of DE-STA
MUNE and quantitative MUP data in comparison with clinical outcome measures in
subjects with ALS. While previous studies of the sensitivity to change of various MUNE
techniques were limited to the evaluation of distal muscle groups, the present study was
particularly novel in its application of MUNE to a proximal muscle group. The
feasibility of the longitudinal application of DE-STA MUNE to the UT was established,
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and the results demonstrated a moderate degree of sensitivity to change for MUNE over
the 6 month study period. Future investigation into potential sources of error associated
with the technique may aid in further establishing and optimizing DE-STA MUNE for
use as an outcome measure.
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CHAPTER 6
INFLUENCE OF NEEDLE ELECTRODE DEPTH ON DECOMPOSITIONENHANCED SPIKE-TRIGGERED AVERAGING MOTOR UNIT NUMBER
ESTIMATION IN THE UPPER TRAPEZIUS
6.0 INTRODUCTION
The sensitivity to change of decomposition-enhanced spike-triggered averaging
(DE-STA) motor unit number estimation (MUNE) was evaluated previously as applied to
the upper trapezius (UT) muscle in subjects with amyotrophic lateral sclerosis (ALS)
(Chapter 5). The study established the feasibility of longitudinal application of DE-STA
MUNE and quantitative motor unit potential (MUP) analysis to the UT. However, the
results also pointed to the need for additional study regarding potential sources of error
associated with the technique that may be better controlled.
One potential source of error associated with any MUNE technique is the failure
to collect a representative sample of surface-detected motor unit potentials (S-MUPs)
from which to calculate a mean S-MUP.1 DE-STA requires the collection of
intramuscularly-detected MUPs that serve as triggers to isolate corresponding S-MUPs.
Therefore, the sample of S-MUPs is completely dependent upon the sample of MUPs
collected. In order to sample from different MUPs, the data collection protocol involves
adjusting the position of the concentric needle electrode to different depths, angles, and,
in some instances, points of insertion between contractions, thereby sampling
corresponding S-MUPs from different areas of the muscle.2, 3 However, this sampling
procedure may require greater standardization in order to ensure that a representative
sample is collected; particularly when examining large muscles such as the UT.

148
It is well established that the characteristics of an electromyographic (EMG)
signal for a given motor unit (MU) are impacted in part by the position of the detecting
electrode relative to the muscle fibers of the MU.4 Numerous studies have demonstrated
that S-MUP size tends to be smaller for MUs located at greater intramuscular depths than
for MUs located more superficially, as a result of the larger distance between the surface
electrode and the MU.5-8 In calculating a MUNE, maximum compound muscle action
potential (CMAP) values are influenced similarly by the depths of contributing MUs.
Thus, it is important to collect a representative sample of S-MUPs as they originally
contributed to the maximum CMAP.
Barkhaus and Nandedkar (1994)5 examined the influence of needle electrode
depth on the MUNE results for the traditional spike-triggered averaging (STA) technique
in the biceps brachii (BB) of control subjects. In keeping with the principles described
above, MUNE values based on S-MUPs corresponding with deeper needle electrode
positions tended to be larger than MUNE values based on S-MUPs corresponding with
superficial needle electrode depths.
To date, however, the impact of the depth of the needle electrode on the results of
DE-STA MUNE, including the characteristics of quantitative MUP data, has yet to be
studied. Such an evaluation of the impact of this potential source of error may inform
efforts to improve the standardization of the data collection protocol, leading to the
further establishment and optimization of the utility of the technique as an outcome
measure.
Thus, the purpose of this study was to evaluate the influence of needle electrode
depth on the results of DE-STA MUNE and quantitative MUP analysis in the UT of
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control subjects by comparing the results obtained across superficial, intermediate and
deep needle electrode depths.
6.1 METHODS
6.1.1 Subjects
Individuals between the ages of 18-80 with no known neuromuscular or
musculoskeletal disease were eligible to participate in this study (n = 18). All subjects
gave written, informed consent in accordance with The University of Western Ontario
Health Sciences Research Ethics Board, which approved this study.
6.1.2 Electromyographic data collection and analysis
EMG signals were acquired using decomposition-based quantitative
electromyography (DQEMG) (version 3.2) and Acquire EMG software on a Neuroscan
Comperio (Neuroscan Medical Systems, El Paso, TX). Self-adhering Silver Mactrode®
electrodes (GE Medical Systems, Milwaukee, WI) were used to detect surface signals,
and 25 mm x 30 gauge TECA™ elite Disposable Concentric Needle Electrodes
(CareFusion, Middleton, WI) were used to detect intramuscular signals, with bandpass
settings of 5 Hz to 5 kHz and 10 Hz to 10 kHz, respectively.2, 3
The experimental protocol was performed three times for each subject, with the
needle electrode maintained as consistently as possible at one of three depths within the
muscle for each test. These depths of needle electrode insertion were referred to as
superficial, intermediate, and deep, and were judged relative to one another, thus varying
across subjects.6, 9 For each subject, the first test was completed at a superficial needle
electrode depth, chosen as a depth that went minimally into the muscle; just beyond the
skin and subcutaneous tissue. Subsequently, testing was completed at an intermediate

150
(approximately 2-6 mm deeper than the superficial position) and, lastly, deep
(approximately 2-6 mm deeper than the intermediate position) needle electrode depth.
The right UT was tested for each subject and subjects were seated upright in a
straight back chair with their feet on the floor. Surface electrodes were cut in strips (1 cm
x 3.5 cm) for use as the active and reference electrodes, with a full-sized electrode
serving as a ground. The skin was cleansed with isopropyl alcohol and surface electrodes
positioned appropriately. The active electrode was positioned transversely over the belly
of the muscle, approximately midway between the acromion process and C7 spinous
process, with the reference electrode placed over the acromion process, and the ground
electrode over the deltoid.10
A handheld bipolar stimulator was used in order to elicit a maximum CMAP, with
the spinal accessory nerve stimulated posterior to the sternocleidomastoid.10 If necessary,
the active electrode was moved in small increments to a position where the CMAP
negative peak amplitude was maximized and the rise time minimized. Following optimal
positioning of the active electrode, the surface electrode positions were reinforced with
surgical tape to ensure that no movement occurred during the study. Gradually, the
stimulation intensity was increased until the CMAP negative peak amplitude reached a
plateau. Automatically positioned markers indicating onset, negative peak, positive peak,
and end of the maximum CMAP were reviewed and manually adjusted if necessary.
Subsequently, size-related parameters of the maximum CMAP including negative peak
amplitude were calculated automatically.
Following the determination of the maximal voluntary contraction-root mean
square (MVC-RMS) (described in Chapter 3), the concentric needle electrode was

151
inserted into the UT, approximately 2-10 mm proximal or distal to the active surface
electrode. Subjects were asked to perform minimal isometric contractions while an
optimal needle position at the depth of interest was located that minimized the rise times
of the motor unit potentials (MUPs) of the first two to three recruited MUs. With the
needle manually maintained in this position by the evaluator, the subject was instructed to
increase the contraction force to approximately 10-20% of the MVC-RMS. Each submaximal isometric contraction was maintained for 30 s, during which the subject
received visual and auditory feedback from the EMG signal and % MVC-RMS
information displayed on the screen to assist in the maintenance of a stable contraction.
Contractions were performed until a minimum of 20 MUP trains were collected, with
each contraction separated by a rest period of approximately 30-60 s, or as required by
the subject. The angle of the needle position was adjusted between contractions to collect
data from different portions of the muscle, while maintaining the appropriate depth. If
necessary, the needle was inserted at a new site at approximately the same depth to
complete the collection of MUP trains.2, 3
Following EMG signal decomposition and the review of the acceptability of
acquired MUPs, S-MUPs, and MUP trains, as has been previously described (Chapters 1,
3), the onset, positive peak, negative peak, and end markers of the MUP templates, and
negative onset, negative peak, and positive peak markers of the S-MUP templates were
checked visually and repositioned if necessary.
Descriptive statistics for various parameters were calculated automatically based
on all accepted MUPs, S-MUPs, and MUP trains. Additionally, the mean S-MUP was
calculated by way of data point-by-data point averaging of all accepted S-MUPs, aligned

152
based on their onsets. Lastly, the MUNE was calculated automatically through division
of the negative peak amplitude of this mean S-MUP into the negative peak amplitude of
the maximum CMAP previously obtained.2
As mentioned, the experimental protocol and subsequent review of the data was
performed three times on the same day for each subject. Following the completion of
each test, all electrodes were removed and, with a minimum of 5 min between sessions, a
new set of electrodes applied. The electrode positions were not marked during any of the
tests. Data analysis was completed only following collection of all three sets of data for a
given subject so that the evaluator was blinded to the results of the assessments until data
collection was complete.
6.1.3 Statistics
Mean values along with their standard deviations and ranges are presented
throughout. A one-way repeated measures analysis of variance (ANOVA) was used to
compare the values of maximum CMAP, mean S-MUP, MUNE, and various MUP
parameters across needle electrode depths. The independent variable was needle
electrode depth, with three testing conditions: superficial, intermediate, and deep. An a
priori alpha level of 0.05 was used to denote significance. If Mauchly’s Test of
Sphericity was significant, a Greenhouse-Geisser correction was applied to the overall pvalue for the repeated measures ANOVA. If the overall p-value was found to be
significant, post hoc multiple comparison tests were performed. Two-tailed, paired t-tests
were used for pairwise comparisons, with a Bonferroni adjustment applied to an alpha
level of 0.05 (0.05/3 comparisons = 0.017).11 SPSS adjusted Bonferroni p-values are
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reported for each post hoc test. All statistical analyses were performed using IBM®
SPSS® Statistics 19 (SPSS, Inc., Chicago, IL).
6.2 RESULTS
6.2.1 Subjects
Eighteen subjects (8 males, 10 females) aged 32 ± 12 years (23-59 years)
participated in this study. These subjects had an average height of 172 ± 13 cm (147-191
cm), and weight of 72.1 ± 13.6 kg (53.4-93.0 kg).
6.2.2 Data collection results and S-MUP frequency distributions
On average, 21 ± 4, 21 ± 3, and 22 ± 4 acceptable S-MUPs were obtained (from
36 ± 9, 38 ± 10, and 39 ± 10 MUP trains collected in total) for each subject from
superficial, intermediate and deep needle electrode depths, respectively. These S-MUPs
were obtained from 6 ± 2 (superficial), 5 ± 2 (intermediate), and 5 ± 1 (deep)
contractions. Thus, on average, 4 ± 2 (superficial), and 5 ± 1 (intermediate, deep)
acceptable S-MUPs per contraction were collected. The mean MU identification rates
(percentage of expected firings detected) based on the samples of accepted MUP trains
were 62 ± 9% (superficial), 59 ± 7% (intermediate), and 57 ± 6% (deep). The frequency
distributions of S-MUP negative peak amplitudes, as a percentage of maximum CMAP
negative peak amplitudes from superficial (0.50 ± 0.40 % maximum CMAP [0.09-2.46 %
maximum CMAP]), intermediate (0.42 ± 0.39 % maximum CMAP [0.05-2.22 %
maximum CMAP]), and deep needle electrode depths (0.33 ± 0.35 % maximum CMAP
[0.02-2.43 % maximum CMAP]) are illustrated in Figure 6.1.
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Figure 6.1 Frequency distributions of S-MUP data from all subjects comparing results
between superficial (closed bars) (386 S-MUPs), intermediate (open bars) (386 S-MUPs),
and deep (checkered bars) (390 S-MUPs) needle electrode depths. The negative peak
amplitudes of the S-MUPs have been normalized to the negative peak amplitude of the
maximum CMAP for each subject at each needle electrode depth testing condition. The
y-axis represents the percentage of the total number of S-MUPs per needle electrode
depth.
Abbreviations: CMAP, compound muscle action potential; S-MUP, surface-detected
motor unit potential.
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6.2.3 Maximum CMAP, mean S-MUP, and MUNE: Needle electrode depth effects
Mean maximum CMAP values were 11.4 ± 2.1 (6.8-16.1) mV (superficial), 11.2
± 1.9 (7.4-14.9) mV (intermediate), and 11.0 ± 2.3 (7.0-15.8) mV (deep), with no
significant differences found among needle electrode depth testing conditions (p > 0.05)
(Figure 6.2A). On average, mean S-MUP values were 35 ± 18 (16-99) µV (superficial),
28 ± 21 (8-98) µV (intermediate), and 21 ± 16 (9-78) µV (deep). A significant difference
among needle electrode depths was found for this parameter, F(2, 34) = 19.82, p < 0.001.
Pairwise comparisons revealed that mean S-MUP was significantly smaller for
intermediate vs. superficial (p < 0.05), deep vs. superficial (p < 0.001), and deep vs.
intermediate (p < 0.05) needle electrode depths (Figure 6.2B). Mean MUNE values were
381 ± 157 (109-765) MUs (superficial), 563 ± 387 (111-1660) MUs (intermediate), and
711 ± 363 (131-1415) MUs (deep). There was also a significant difference among the
three needle electrode depths for this parameter, F(2, 34) = 13.82, p < 0.001. Pairwise
comparisons revealed that MUNE was significantly larger for deep vs. superficial needle
electrode depths (p < 0.001). While not statistically significant, the remaining pairwise
comparisons demonstrated trends toward larger MUNE values for intermediate vs.
superficial (p = 0.059), and deep vs. intermediate (p = 0.054) needle electrode depths
(Figure 6.2C).
6.2.4 Motor unit potential parameters: Needle electrode depth effects
Significant differences among needle electrode depths were also found for area,
F(2, 34) = 3.33, p < 0.05, and area-to-amplitude ratio (AAR), for which a GreenhouseGeisser correction was used, F(1.34, 22.81) = 4.05, p < 0.05. However, no significant
differences were found for any of the pairwise comparisons for either parameter (Table
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6.1). Lastly, no significant differences among needle electrode depths were found for
MUP peak-to-peak voltage, duration, phases, turns, or mean firing rate (p > 0.05) (Table
6.1).
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Figure 6.2 Maximum CMAP (A), mean S-MUP (B), and MUNE (C) across superficial,
intermediate, and deep needle electrode depth testing conditions. Error bars represent
SD. * indicates a significant difference from superficial needle electrode depth.
†
indicates a significant difference from intermediate needle electrode depth. Mean SMUP intermediate vs. superficial (p < 0.05), deep vs. superficial (p < 0.001), deep vs.
intermediate (p < 0.05), MUNE deep vs. superficial (p < 0.001). Results are based on
SPSS adjusted Bonferroni p-values.
Abbreviations: CMAP, compound muscle action potential; int., intermediate; MU, motor
unit; MUNE, motor unit number estimation; neg. peak amp., negative peak amplitude; SMUP, surface-detected motor unit potential; sup., superficial.
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Table 6.1 MUP parameters across superficial, intermediate, and deep needle electrode
depths
Parameter
Peak-to-peak voltage (µV)

Superficial
Intermediate
Deep
348.5 ± 82.7
372.8 ± 90.9
377.2 ± 96.0
(231.8-501.9) (243.7-602.2) (236.5-568.7)
13.3 ± 1.5
13.4 ± 1.6
13.4 ± 2.2
Duration (ms)
(9.4-16.2)
(10.0-16.2)
(9.9-19.0)
581.0 ± 166.4 657.8 ± 196.0 699.2 ± 218.6
Area (µVms)
(292.6-983.0) (372.5-1137.4) (403.9-1183.9)
1.7 ± 0.2
1.8 ± 0.2
1.9 ± 0.3
AAR (ms)
(1.3-1.9)
(1.4-2.1)
(1.5-2.7)
2.4 ± 0.4
2.5 ± 0.3
2.4 ± 0.4
Phases
(1.6-3.0)
(2.1-3.0)
(1.7-3.1)
3.0 ± 0.4
2.9 ± 0.3
3.1 ± 0.5
Turns
(2.2-3.6)
(2.3-3.5)
(2.2-3.9)
11.2 ± 1.4
11.2 ± 1.3
11.0 ± 1.4
Mean firing rate (Hz)
(7.9-13.1)
(8.6-14.3)
(8.1-14.4)
Values expressed as mean ± SD. Data in parentheses indicate range.
Abbreviations: AAR, area-to-amplitude ratio; MUP, motor unit potential.
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6.3 DISCUSSION
This has been the first study to evaluate the effect of needle electrode depth on the
results of DE-STA MUNE, including quantitative MUP data. In the face of consistent
maximum CMAP values, a significant decrease in mean S-MUP size with each increase
in needle electrode depth resulted in increases in MUNE values. This increase was
significant from superficial to deep needle electrode depths, and showed statistical trends
with increasing needle electrode depth for each of the other pairwise comparisons (Figure
6.2). The S-MUP frequency distribution results were consistent with these findings, with
S-MUP size found to represent a smaller percentage of maximum CMAP size, on
average, with increasing needle electrode depth (Figure 6.1).
The findings of attenuation of S-MUP amplitude are related to the increased
distance between the triggering MU (detected with the intramuscular electrode) and the
surface electrode, resulting in increased volume conduction as has been previously
demonstrated.5, 7, 8 The extent of this impact of MU-surface electrode distance on mean
S-MUP values resulted in an important influence on MUNE results. The present findings
for mean S-MUP and MUNE are consistent with those from the study of the influence of
needle electrode depth on the results of conventional STA MUNE in the BB.5
In the only other study to evaluate DE-STA MUNE in the UT of control subjects,
an assessment of the inter-rater reliability of the technique found mean S-MUP size to be
significantly smaller and MUNE values significantly larger for one rater than for the
other (Chapter 3). Based on the results of the current study, these systematic biases may
have resulted from a tendency toward the collection of data from deeper needle electrode
depths for this rater.
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No significant differences were found between needle electrode depths for any of
the MUP parameters (Table 6.1). Similarly, previous studies evaluating the influence of
various needle electrode depths in the BB on MUP parameters did not find significant
differences for amplitude,12, 13 duration,12 and phases.12, 13 However, comparing
superficial and deep needle electrode depths, the study by Falck et al. (1995)13 found
duration, area, thickness (AAR), and size index to be significantly smaller superficially.
Similarly, a study by Buchthal et al. (1954)9 that was also in the BB found peak-to-peak
amplitude and duration to be significantly smaller superficially. The latter two studies
attributed their results to the larger contribution of the cannula of the needle electrode to
MUPs acquired at superficial depths.9, 13 Discrepancies among the results of each of the
studies, including those found presently, may relate to the differences in the data
collection techniques used, the muscles groups under study, and the depths of needle
insertion that were evaluated.
While these MUP parameters do not influence the results of MUNE, owing to the
role of MUPs as simply triggers to isolate corresponding S-MUPs, they do offer insight
into the characteristics of the MUs at various needle electrode depths. The present
finding that there were no significant differences between depths for any of the MUP
parameters may indicate that the morphological and physiological features of MUs in the
UT do not vary systematically with respect to muscle depth.
The results of this study demonstrate the importance of collecting a sample of SMUPs from the UT corresponding with various needle electrode depths, not only to
collect a representative sample from different portions of the muscle, but also to
minimize any error related to the influence of needle electrode depth on S-MUP size.
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Needle electrode depth is certainly an important factor in the UT, which was found to
have an average depth of 6.2 ± 2.8 mm in a study of 18 subjects,14 and to be located 7.7
mm (4.6-10.2 mm) below the surface of the skin, on average, in a study of 9 female
subjects.15 While the current data collection protocol for the technique involves
adjustments to the position of the needle electrode between contractions,2, 3 more detailed
standardization of this aspect of the protocol may be required, particularly when
examining large muscles such as the UT. Such standardization may improve the
reliability of mean S-MUP and MUNE results, and prove particularly valuable in studies
of this muscle group involving multiple raters and/or a longitudinal study design.
In both types of studies, there may be an increased likelihood of inconsistencies
among data collection sessions in the adjustments made to the depth of the needle
electrode. As previously mentioned, this source of error may have played a role in the
systematic biases found in the assessment of the inter-rater reliability of the technique in
control subjects (Chapter 3). Should needle electrode depth have a similarly important
influence over the results of the technique in the UT in subjects with ALS, this factor
may have also contributed to the unanticipated fluctuations found for mean S-MUP and
MUNE values in the longitudinal study of the disease in this muscle group (Chapter 5).
In line with the findings of favorable levels of intra-rater reliability for maximum
CMAP values in control subjects (Chapter 3) and subjects with ALS (Chapter 4) in the
UT, no significant differences were found between testing conditions for this parameter
in the present study. These findings of consistent maximum CMAP values across tests
lie in contrast with the variability in maximum CMAP values observed between time
points in the longitudinal study of ALS in this muscle group (Chapter 5). Once again, the
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discrepancies among these results likely stem from the different testing conditions of the
studies, pointing to the need for better standardization of the protocol in studies involving
longer intervals of time between tests.
As significant differences were found between mean S-MUP values for each
pairwise comparison of needle electrode depths, standardization of the protocol should
involve the collection of data systematically from each of superficial, intermediate, and
deep sites within the UT. Roughly equivalent numbers of S-MUPs should be sampled
from each depth toward the collection of a minimum of 20 S-MUPs.6 At each depth, the
angle and, when necessary, insertion site of the needle electrode should continue to be
adjusted between contractions.
A limitation of this study was that the depths of needle electrode insertion were
determined based on rough approximations, instead of being based on consistently
measured depths for each data collection session. While the present approach would be
practical for application to study subjects in a clinical EMG setting, the optimal depths to
represent superficial, intermediate, and deep levels of insertion in the UT should be
determined and implemented in future studies of the influence of this variable. An
additional limitation of this study was that the order of testing of needle electrode depths
was not randomized. However, the assumption of sphericity (that the variances within
each set of difference scores will be relatively equal and correlated with each other)11 was
not violated for any of the parameters other than AAR and mean FR, to which
appropriate correction factors were subsequently applied.
Following the determination of standard distances that are optimal to represent
superficial, intermediate, and deep depths in the UT, research should begin by addressing
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whether modifications to the protocol involving the collection of data systematically from
each depth improves the intra- and inter-rater reliability of the technique in control
subjects. Furthermore, evaluation of the influence of needle electrode depth on the
results of the technique in other muscle groups to which it is commonly applied (e.g.
thenar muscles, first dorsal interosseous) would elucidate whether the present findings
may be more broadly applicable, or are important primarily in the UT. Should these
modifications to the protocol prove too technically challenging or fail to improve the
reliability of the technique in the UT, future study should address whether collecting data
solely from a superficial needle electrode depth improves reliability. While not allowing
for an accurate MUNE calculation, such a modification may be easier to standardize, and
still allow for the calculation of a reliable MUNE that enables an assessment of relative
longitudinal change.
In summary, this study has clearly demonstrated the important influence of needle
electrode depth on MUNE and mean S-MUP results obtained using DE-STA MUNE as
applied to the UT in control subjects. The results of the study point to opportunities for
better standardization of the data collection protocol in order to minimize this source of
error and further establish and optimize DE-STA MUNE for use as an outcome measure.
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CHAPTER 7
GENERAL DISCUSSION AND SUMMARY
7.0 GENERAL DISCUSSION
It was the overall objective of this thesis to review the use of outcome measures
systematically across amyotrophic lateral sclerosis (ALS) clinical trials, and to evaluate
the utility of decomposition-enhanced spike-triggered averaging (DE-STA) motor unit
number estimation (MUNE) as an outcome measure, with a particular focus on its
application to the upper trapezius (UT).
These objectives were achieved through a series of five studies. First, a
systematic review identified the vast array of outcome measures that have been used in
ALS randomized controlled trials, highlighting the particular heterogeneity in the
selection of secondary outcome measures and the need for a clearer consensus regarding
outcome measure selection (Chapter 2). In contrast to the frequently used measures of
function and muscle strength, MUNE has the advantage of being able to detect
underlying disease progression (motor unit loss as well as collateral reinnervation),1, 2 but
was found to be used infrequently in ALS clinical trials.
Until the ability of a MUNE technique to sensitively detect change is established
in the context of a positive clinical trial, it cannot yet be sufficiently ready for use as a
primary outcome measure.1, 3 However, the use of MUNE as such in clinical trials would
offer a number of benefits. The sensitivity to change of MUNE would allow for studies
with shorter durations and/or smaller sample sizes.2
Given the capacity of MUNE to quantify the underlying progression of the
disease, the use of a MUNE technique as a secondary outcome measure in a positive trial
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would also allow for valuable insights. Specifically, the technique could be used to
determine whether the intervention’s primary mechanism of action was to alter the rate of
denervation, or to enhance collateral reinnervation.4, 5
DE-STA MUNE shares advantages with conventional spike-triggered averaging
(STA) over other MUNE techniques of allowing for quantitative motor unit potential
analysis and the study of proximal muscles. Improving upon STA, the use of DE-STA
MUNE as an outcome measure would have the added benefit of more efficient data
collection from a potentially more representative sample of surface-detected motor unit
potentials (S-MUPs) through the use of decomposition-based quantitative
electromyography.6, 7 As an outcome measure, application of DE-STA MUNE to the UT
may be clinically relevant, given its role as an accessory respiratory muscle, and the
importance of respiratory failure as the typical cause of death in ALS.8
Normative data were collected from this muscle group, and the reliability of DESTA MUNE was evaluated in control subjects (Chapter 3) and subjects with ALS
(Chapter 4). Applied to the UT in control subjects, the technique was found to be simple
to perform, and MUNE results demonstrated moderate levels of intra- and inter-rater
reliability. However, inter-rater reliability was found to be poor for mean S-MUP results,
and systematic biases between raters were found for mean S-MUP and MUNE (Chapter
3).
The study reported in Chapter 4 marked the first evaluation of the reliability of
DE-STA MUNE in subjects with ALS. Although a significant difference between tests
was found for MUNE in the UT, application of the technique to the UT and biceps
brachii (BB) found consistently high levels of intra-rater reliability (Chapter 4). An

168
exception to this finding was the moderate level of reliability found for maximum
compound muscle action potential (CMAP) results in the BB, owing to technical
challenges associated with the stimulation of a relatively deep motor nerve. In addition
to finding the application of the technique to the UT to be highly practical and highly
reliable in the population of interest, an assessment of the validity of DE-STA MUNE as
applied to the UT established its ability to detect the underlying pathophysiology of the
disease (Chapter 4). Together, these results suggest promise for the utility of DE-STA
MUNE in the UT as an outcome measure in the study of ALS.
These studies led to an evaluation of the sensitivity to change of the technique in
the UT of subjects with ALS in comparison with that of clinical outcome measures
(Chapter 5). As the first study to evaluate the sensitivity to change of DE-STA MUNE,
the feasibility of its longitudinal application was established, and a moderate degree of
sensitivity to change was demonstrated for MUNE. However, variability in the results of
DE-STA MUNE also pointed to the need for future study regarding potential sources of
error associated with the data collection process. Subsequently, the influence of needle
electrode depth on the results of DE-STA MUNE in the UT was evaluated in control
subjects, identifying significantly smaller mean S-MUP and larger MUNE results with
increasing needle electrode depth (Chapter 6). Taking this important source of error into
account, the study made corresponding suggestions for improved standardization of the
protocol, involving the systematic sampling of data from various needle electrode depths.
This series of studies was novel in the evaluation of the proximal, potentially
clinically relevant UT muscle; the majority of previous studies using MUNE have
utilized techniques that limited their evaluations of the severity and progression of the
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disease to distal muscle groups. Each of the studies demonstrated the particularly
practical nature of the data collection process as applied to the UT, with its easily
accessible nerve supply. Implementation of the suggestions for improved standardization
of the DE-STA MUNE protocol in this muscle group may decrease variability in the
results, and be particularly valuable in applications involving multiple raters and/or
longitudinal study designs.
7.1 LIMITATIONS
Many of the present studies had relatively small sample sizes. The recruitment of
patients with ALS was particularly challenging, as it was limited to those who were well
enough overall to participate, and for whom it was feasible to travel to the tertiary care
center for study visits. The sample size in the cross-sectional evaluation of DE-STA
MUNE was sufficient to demonstrate the ability of the technique to detect lower motor
neuron involvement associated with the disease process (Chapter 4). However, the power
of the longitudinal study to detect significant changes in DE-STA MUNE and the other
outcome measures under evaluation would have been improved with a larger sample
(Chapter 5).
The present results can only be generalized to those with characteristics similar to
the samples under study. Specifically, the studies involving subjects with ALS were
confined to those patients receiving care through a tertiary care center who were well
enough to participate, and felt inclined to volunteer. These samples may not have been
representative of the population of those living with ALS, as care in a multidisciplinary
clinic may extend survival.9 In addition, those who were willing and able to participate
may have had higher functional levels than the broader population of people with ALS.
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A key limitation of the DE-STA MUNE technique itself is the invasiveness of the
data collection protocol. However, the use of the concentric needle electrode resulted in
only minimal subject discomfort, and did not lead to the discontinuation of participation
for subjects in any of the studies. The data collection protocol also requires subject
cooperation and effort in the maintenance of steady voluntary contractions (although to a
much lesser extent than STA).7 However, each subject (including one with
frontotemporal dementia) successfully performed this aspect of the protocol, even with
disease progression over the course of the longitudinal study.
7.2 FUTURE STUDIES
In order to establish the utility of DE-STA MUNE as applied to the UT further as
an outcome measure, a number of follow-up studies are warranted. Following the
determination of standard needle electrode depths to represent superficial, intermediate,
and deep locations in the UT, an evaluation should be conducted as to whether
systematically sampling data across each depth improves the intra- and inter-rater
reliability of the technique in control subjects.
Furthermore, while high levels of intra-rater reliability have been established for
the technique as applied to the UT in subjects with ALS, evaluations should be conducted
to build on these results. A study of intra-rater reliability with tests separated by longer
periods of time (e.g. performed on consecutive days) would better reflect the conditions
of a longitudinal study, but still avoid important progression of the disease between tests.
Additionally, an evaluation of the inter-rater reliability of the technique is necessary,
given the multicenter nature of the majority of ALS clinical trials. Both of these
evaluations should incorporate the present suggestions for improved standardization of
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the protocol, involving the systematic sampling of data from various needle electrode
depths.
Should these studies reveal favorable levels of reliability for the improved
standardization of the protocol, the logical progression would be to carry out a study of
the sensitivity to change of the technique in subjects with ALS similar to that reported in
Chapter 5, this time involving a larger sample size and extended study duration.
The simultaneous evaluation of a second muscle group in addition to the UT in
each of these proposed studies would be advantageous. The study reported in Chapter 4
demonstrated challenges associated with the collection of a maximum CMAP from the
BB that were encountered previously using other MUNE techniques.10-12 However, distal
upper extremity muscle groups such as the thenar muscles13 and first dorsal
interosseous14 have been shown to be assessed readily using DE-STA MUNE. An initial
assessment of whether needle electrode depth significantly influences the results of the
technique in one or more of these additional muscle groups would elucidate whether the
findings in the UT (Chapter 6) may be more broadly applicable. From here, the
simultaneous assessment of a proximal and distal muscle group would allow for a
comparative evaluation of the properties of DE-STA MUNE in muscles representing
different sources of innervation, and thus potentially differing degrees and rates of
disease progression.
7.3 SUMMARY
This series of studies has demonstrated the heterogeneity in the use of outcome
measures across ALS clinical trials, and found DE-STA MUNE to be promising for use
in such a role. These studies marked the first to evaluate the reliability and sensitivity to
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change of DE-STA MUNE as applied to subjects with ALS in any muscle group. In
particular, as a novel, potentially clinically relevant muscle group to study using MUNE,
application of the technique to the UT was found to be highly practical. As applied to
this muscle group in subjects with ALS, the technique also demonstrated high levels of
intra-rater reliability, the ability to detect the underlying pathophysiology of the disease,
and a moderate degree of sensitivity to change. Further evaluation found needle
electrode depth to exert an important influence over the results of DE-STA MUNE in the
UT, with corresponding suggestions being made for improved standardization of the data
collection protocol. Incorporation of these proposed improvements may aid in further
establishing and optimizing DE-STA MUNE for use in studies of ALS natural history
and severity, and as an outcome measure in ALS clinical trials.
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APPENDIX A
Summary of included clinical trials
Intervention

First author

Year

n

Duration

Outcome measures
Primary
survival

Acetylcysteine

Louwerse

1995

110

12 months

Amino acid therapy

Tandan

1996

95

6 months

MMT, max. isometric muscle
torque*

Aminophylline

Berto

2007

25

72 hr

Antioxidant therapy

Ellis

1997

10

12 months

FVC, PImax, PEmax, respiratory
muscle endurance, MVV,
MVIC – grip strength†
AALS

Recombinant
methionyl human
brain-derived
neurotrophic factor
(BDNF)
Branched-chain amino
acids (BCAA)

Bradley

1999

1135

9 months

FVC, survival*

Beghi

1993

126

12 months

Celecoxib

Cudkowicz

2006

300

12 months

survival, MMT, modified
Norris score‡, modified
AALS*
MVIC – UE

Secondary
MMT, MVIC (UE, LE and grip
strength), FVC, Barthel Index,
Rankin scale, Frenchay Dysarthria
Assessment (modification)
Norris score, semiquantitative
estimation of bulbar function,
ADL scores, time to dial phone
no., no. rotations of pencil in 30 s,
FVC, CMAP amplitude,
spontaneous activity, fiber density,
MUNE

blood markers of oxidative
damage
syllable repetition (PATA), time to
walk 15 ft., ALSFRS, incidence of
select respiratory events, FVC,
SIP-PDS, Ashworth scale

survival, CSF PGE2 levels, MVIC
– LE, MVIC – grip strength, VC,
ALSFRS-R, MUNE
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Recombinant human
ciliary neurotrophic
factor (rhCNTF)

Cedarbaum

1996

730

9 months

MVIC – UE and LE

rhCNTF

Miller

1996

570

6 months

Creatine monohydrate

Groeneveld

2003

175

16 months

MVIC (UE and LE) and FVC
combination megascore
survival

Creatine monohydrate

Shefner

2004

104

6 months

MVIC – UE

Creatine monohydrate

Rosenfeld

2008

107

9 months

MVIC – UE

Deprenyl

Jossan

1994

10

9 months

Dextromethorphan

Askmark

1993

14

7 months

Dextromethorphan

Blin

1996

49

12 months

Dextromethorphan
Gabapentin
Gabapentin

Gredal
Miller
Miller

1997
1996
2001

45
152
204

12 months
6 months
9 months

Norris score, spinal and
bulbar score†
Norris score, spinal and
bulbar score, MVIC, MUNE,
CMAP amplitude†
modified Norris score,
survival†
survival
MVIC – UE
MVIC – UE

Glatiramer acetate
Recombinant human
granulocyte-colony
stimulating factor
(G-CSF)
Recombinant growth
hormone

Meininger
Nefussy

2009
2010

366
39

52 weeks
12 months

ALSFRS-R
ALSFRS-R

Smith

1993

75

18 months

modification of TQNE, MMT,
various serum levels†

FVC, PIF, time to walk 15 ft.,
Purdue pegboard test, oral-labiallingual dexterity, ALSFRS,
modified Schwab and England
scale, GCIC scale
MVIC – UE, MVIC – LE, FVC,
SIP, survival
MVIC – UE, FVC, ALSFRS,
SF-36
MVIC – grip strength,
ALSFRS-R, MUNE
FVC, ALSFRS-R, SF-12, muscle
fatigue

FVC, ALS Severity Scale
FVC, MVIC – UE
MVIC – UE, FVC, survival,
ALSFRS, time to walk 15 ft., rapid
foot taps, SF-12, patient VASs
survival
FVC, MMT, CMAP amplitude,
NI, McGill single item QoL score,
survival
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Recombinant growth
hormone

Sacca

2011

40

12 months

NAA/Cre + Cho ratio in
motor cortex assessed by
MRS
ALSFRS
FVC, VC, lung volumes,
MIP, MEP, SNIP*
AALS

survival, ALSFRS-R

Indinavir
Inspiratory muscle
training
Recombinant human
insulin-like growth
factor-I (rhIGF-I)
rhIGF-I
rhIGF-I
Recombinant
interferon beta-1a
(IFNbeta)

Scelsa
Cheah

2005
2009

46
19

9 months
20 weeks

Lai

1997

266

9 months

Borasio
Sorenson
Beghi

1998
2008
2000

183
330
61

9 months
24 months
12 months

AALS
MMT
No. pts becoming non-selfsupporting

102
23

12 weeks
12 months

ALSFRS-R, VC†
modified Norris score

SIP
survival, ALSFRS-R
MMT, Norris score, modified
AALS bulbar section, FVC,
CMAP latency, amplitude, and
duration

KNS-760704
L-threonine

Bozik
Blin

2009
1992

Lamotrigine

Eisen

1993

67

18 months

survival

Lamotrigine

Ryberg

2003

39

38 weeks

Lithium

Aggarwal

2010

84

Memantine

de Carvalho

2010

63

5.4 months
(mean)
12 months

Norris score, spinal and
bulbar score*
decrease ≥ 6 points on
ALSFRS-R or death
ALSFRS

Methionine, vitamin
E, and selenium
Oral supplementation:
Milk whey proteins
and modified starch

Stevic

2001

28

12 months

survival

Silva

2010

16

4 months

anthropometric measures,
various serum levels,
ALSFRS-R†

MMT, FVC, SF-36
ALSFRS-R, SF-36, 6MWT,
MVIC – grip strength, NI
AALS, FVC, SIP

MMT, MVIC – grip strength,
patient VASs
clinical deficit scores, cortical
threshold and MEP/CMAP ratios
to magnetic stimulation
Norris score, spinal and bulbar
score, CSF levels of amino acids
ALSFRS-R, SVC, ALSSQoL,
QIDS-SR16, survival
FVC, MMT, patient VASs,
medical VAS, SF-36, MUNE, NI
modified Norris score, MMT
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Minocycline

Gordon

2007

412

9 months

ALSFRS-R

Nimodipine
Org 2766

Miller
Hesselmans

1996
1993

87
24

7 months
8 weeks

Pentoxifylline
Physostigmine
salicylate

Meininger
Norris

2006
1993

400
25

547 days
9 months

Riluzole

Bensimon

1994

155

Riluzole

Lacomblez

1996

959

573 days
(median)
18 months

modification of TQNE
sum score of manually and
functionally tested muscles,
MVIC – LE, jitter, fiber
density, macro MUP,
SEMAP†
survival
Summated megascore: Body
weight, Norris score, Jamar
grip strength, % FVC,
% MVV
survival‡, functional status,
modified Norris score*
survival

Riluzole

Bensimon

2002

168

18 months

survival

Selegiline
Talampanel

Lange
Pascuzzi

1998
2010

133
59

6 months
9 months

AALS
TQNE – arm strength
megascore

TCH346
Intrathecal
thyrotropin-releasing
hormone (TRH)
Topiramate

Miller
Munsat

2007
1992

553
36

24-44 weeks
13 months

ALSFRS-R
TQNE

Cudkowicz

2003

296

12 months

MVIC – UE

FVC, MMT, McGill single-item
QoL score, survival
None reported

ALSFRS-R, MMT
None reported

MMT, FVC, GCIC scale, patient
VASs
MMT, modified Norris score, VC,
GCIC scale, patient VASs
MMT, modified Norris score,
modified CGI scale, FEV, SVC,
VC ratio, patient VASs
None reported
VC, TQNE – leg strength
megascore, timed rapid alternating
movement task, ALSFRS, survival
survival, FVC, MMT, ACE
None reported
FVC, MVIC – grip strength,
ALSFRS, survival
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*

MVIC – LE and UE, MMT,
time to swallow 4 oz. water
using straw, time to walk 15
ft., time to walk 25 ft., timed
rise from 10 in. seat, activity
indexes, survival†
ALSFRS-R

MMT, MVIC – hand

ALSFRS-R
survival

MMT
ALSFRS-R

289

12 months
12 months
(mean)
12 months

modified Norris score – limb
scale

2005

160

18 months

survival

77

32 weeks

MMT

Meininger

2004
(study
2)
2004

survival, Norris score – bulbar
scale, MMT, patient VASs, SVC,
FVC, SIP, ALS Health State Scale
modified Norris score, MMT,
spasticity scale, ventilatory
function, SIP/ALS-19
modified Norris score, FVC

867

18 months

survival‡, time to VC < 50%*

Meininger

2004

1210

18 months

survival‡, time to VC < 50%*

Total lymphoid
irradiation (TLI)

Drachman

1994

61

24 months

Repetitive TMS
(rTMS)
rTMS
Valproic acid (VPA)

Di Lazzaro

2006

20

6 months

Di Lazzaro
Piepers

2009
2009

20
163

Vitamin E

Desnuelle

2001

Vitamin E

Graf

Xaliproden

Lacomblez

Xaliproden

Xaliproden

More than one primary outcome measure listed.
Differentiation between primary and secondary outcome measures unclear.
‡
Study was statistically powered for this variable (considered as primary outcome measure).
†

VC, MMT, ALSFRS, Norris score,
patient VASs, spasticity scale,
GCIC scale, SIP
VC, MMT, ALSFRS, Norris score,
patient VASs, spasticity scale,
GCIC scale, SIP
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Abbreviations: 6MWT, 6-minute walk test; AALS, Appel Amyotrophic Lateral Sclerosis Rating Scale; ACE, Addenbrooke’s
Cognitive Examination; ADL, activities of daily living scores; ALSFRS, Amyotrophic Lateral Sclerosis Functional Rating Scale;
ALSFRS-R, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; ALSSQoL, Amyotrophic Lateral Sclerosis-Specific
Quality of Life Instrument; CGI, clinical global impression scale; CMAP, compound muscle action potential; CSF, cerebrospinal
fluid; FEV, forced expiratory volume; FVC, forced vital capacity; GCIC, Global Clinical Impression of Change scale; LE, lower
extremity; MEP, motor evoked potential; MMT, manual muscle testing; MRS, magnetic resonance spectroscopy; MUNE, motor unit
number estimation; MUP, motor unit potential; MVIC, maximal voluntary isometric contraction; MVV, maximum voluntary
ventilation; NI, neurophysiological index; PEmax/MEP, maximal expiratory pressure; PGE2, prostaglandin E2; PIF, peak inspiratory
flow; PImax/MIP, maximal inspiratory pressure; QIDS-SR16, 16-item Quick Inventory of Depressive Symptomatology – Self-Report;
QoL, quality of life; SEMAP, supramaximal-evoked muscle action potential; SF-12, 12-item Short-Form survey; SF-36, 36-item
Short-Form survey; SIP, Sickness Impact Profile; SIP/ALS-19, Sickness Impact Profile/Amyotrophic Lateral Sclerosis-19; SIP-PDS,
Sickness Impact Profile – Physical Dimension Score; SNIP, sniff nasal inspiratory pressure; SVC, slow vital capacity; TQNE, Tufts
Quantitative Neuromuscular Exam; UE, upper extremity; VAS, visual analogue scale; VC, vital capacity.
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APPENDIX B
Manual muscle testing grading scale
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APPENDIX C
Revised Amyotrophic Lateral Sclerosis Functional Rating Scale
1. Speech
4 Normal speech processes
3 Detectable speech disturbance
2 Intelligible with repeating
1 Speech combined with nonvocal communication
0 Loss of useful speech
2. Salivation
4 Normal
3 Slight but definite excess of saliva in mouth; may have nighttime drooling
2 Moderately excessive saliva; may have minimal drooling
1 Marked excess of saliva with some drooling
0 Marked drooling; requires constant tissue or handkerchief
3. Swallowing
4 Normal eating habits
3 Early eating problems – occasional choking
2 Dietary consistency changes
1 Needs supplemental tube feeding
0 NPO (exclusively parenteral or enteral feeding)
4. Handwriting
4 Normal
3 Slow or sloppy: all words are legible
2 Not all words are legible
1 Able to grip pen but unable to write
0 Unable to grip pen
5a. Cutting food and handling utensils (patients without gastrostomy)
4 Normal
3 Somewhat slow and clumsy, but no help needed
2 Can cut most foods, although clumsy and slow; some help needed
1 Food must be cut by someone, but can still feed slowly
0 Needs to be fed
5b. Cutting food and handling utensils
(alternate scale for patients with gastrostomy)
4 Normal
3 Clumsy but able to perform all manipulations independently
2 Some help needed with closures and fasteners
1 Provides minimal assistance to caregiver
0 Unable to perform any aspect of task
6. Dressing and hygiene
4 Normal function
3 Independent and complete self-care with effort or decreased efficiency
2 Intermittent assistance or substitute methods
1 Needs attendant for self-care
0 Total dependence
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7. Turning in bed and adjusting bed clothes
4 Normal
3 Somewhat slow and clumsy, but no help needed
2 Can turn alone or adjust sheets, but with great difficulty
1 Can initiate, but not turn or adjust sheets alone
0 Helpless
8. Walking
4 Normal
3 Early ambulation difficulties
2 Walks with assistance
1 Nonambulatory functional movement
0 No purposeful leg movement
9. Climbing stairs
4 Normal
3 Slow
2 Mild unsteadiness or fatigue
1 Needs assistance
0 Cannot do
10. Dyspnea
4 None
3 Occurs when walking
2 Occurs with one or more of the following: eating, bathing, dressing (ADL)
1 Occurs at rest, difficulty breathing when either sitting or lying
0 Significant difficulty, considering using mechanical respiratory support
11. Orthopnea
4 None
3 Some difficulty sleeping at night due to shortness of breath,
does not routinely use more than two pillows
2 Needs extra pillows in order to sleep (more than two)
1 Can only sleep sitting up
0 Unable to sleep
12. Respiratory insufficiency
4 None
3 Intermittent use of BiPAP
2 Continuous use of BiPAP during the night
1 Continuous use of BiPAP during the night and day
0 Invasive mechanical ventilation by intubation or tracheostomy
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A
revised ALS functional rating scale that incorporates assessments of respiratory function. J
Neurol Sci 1999; 169:13-21.
Abbreviations: ADL, activities of daily living; BiPAP, bilevel positive airway pressure; NPO,
nothing by mouth.
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